[
  {
    "path":[
      907040000,
      802000000
    ],
    "contexts":[
      "and the medicine: (i) includes one or more active ingredients, the name of which includes descriptors (for example chemical salts or hydration states) that are not therapeutically relevant; and (ii) the name and quantity or proportion of each of those active ingredients is displayed in accordance with subsection 8(2), then the name of the therapeutically active moiety(ies) of the active ingredient may be displayed on the main label on the primary pack, instead of the name of the active",
      "and subsection 8(2) does not apply, then the names and the quantities or proportions of the active ingredients may be included on a side panel or side label or on a rear panel or rear label, when displayed in a text size of not less than 2.5 millimetres; or  (c) where the medicine contains four or more active ingredients and subsection 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) is not required; or  (d) if subsection 8(2) applies and the medicine: (i) includes one or more"
    ],
    "result_dict":{
      "QuestionAnswers":[
        {
          "Question":"Assuming a medicine contains three active ingredients and the name of one of the ingredients includes a descriptor that is not therapeutically relevant, can the name of the therapeutically active moiety of that ingredient be displayed on the main label instead of the full ingredient name, if the name and quantity or proportion of each active ingredient is displayed in accordance with subsection 8(2)?",
          "Answer":"Yes",
          "Answer Explanation":"According to the provided context, if a medicine includes one or more active ingredients whose names include descriptors that are not therapeutically relevant, and the name and quantity or proportion of each active ingredient is displayed in accordance with subsection 8(2), then the name of the therapeutically active moiety(ies) of the active ingredient may be displayed on the main label on the primary pack, instead of the full name of the active ingredient."
        },
        {
          "Question":"Assuming a medicine contains five active ingredients and subsection 8(2) does not apply, can the names and quantities or proportions of the active ingredients be included on a side or rear panel or label if displayed in a text size of 2.0 millimetres?",
          "Answer":"No",
          "Answer Explanation":"Based on the context provided, if a medicine contains four or more active ingredients and subsection 8(2) does not apply, the names and quantities or proportions of the active ingredients may be included on a side panel, side label, rear panel, or rear label, but only when displayed in a text size of not less than 2.5 millimetres. A text size of 2.0 millimetres would not meet this requirement."
        },
        {
          "Question":"Assuming a medicine contains six active ingredients and subsection 8(2) applies, is compliance with paragraphs 9(1)(b) and 9(1)(c) required?",
          "Answer":"No",
          "Answer Explanation":"The context states that if a medicine contains four or more active ingredients and subsection 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) is not required."
        },
        {
          "Question":"Assuming subsection 8(2) applies to a medicine that includes active ingredients with names containing therapeutically irrelevant descriptors, and the name and quantity or proportion of each active ingredient is displayed according to subsection 8(2), can the names of the therapeutically active moieties be displayed on the main label instead of the full ingredient names?",
          "Answer":"Yes",
          "Answer Explanation":"The context specifies that if subsection 8(2) applies and the medicine includes one or more active ingredients whose names contain descriptors that are not therapeutically relevant, and the name and quantity or proportion of each active ingredient is displayed in accordance with subsection 8(2), then the name of the therapeutically active moiety(ies) of the active ingredient may be displayed on the main label on the primary pack, instead of the full name of the active ingredient."
        }
      ]
    },
    "result_str":"{\"QuestionAnswers\": [{\"Question\": \"Assuming a medicine contains three active ingredients and the name of one of the ingredients includes a descriptor that is not therapeutically relevant, can the name of the therapeutically active moiety of that ingredient be displayed on the main label instead of the full ingredient name, if the name and quantity or proportion of each active ingredient is displayed in accordance with subsection 8(2)?\", \"Answer\": \"Yes\", \"Answer Explanation\": \"According to the provided context, if a medicine includes one or more active ingredients whose names include descriptors that are not therapeutically relevant, and the name and quantity or proportion of each active ingredient is displayed in accordance with subsection 8(2), then the name of the therapeutically active moiety(ies) of the active ingredient may be displayed on the main label on the primary pack, instead of the full name of the active ingredient.\"}, {\"Question\": \"Assuming a medicine contains five active ingredients and subsection 8(2) does not apply, can the names and quantities or proportions of the active ingredients be included on a side or rear panel or label if displayed in a text size of 2.0 millimetres?\", \"Answer\": \"No\", \"Answer Explanation\": \"Based on the context provided, if a medicine contains four or more active ingredients and subsection 8(2) does not apply, the names and quantities or proportions of the active ingredients may be included on a side panel, side label, rear panel, or rear label, but only when displayed in a text size of not less than 2.5 millimetres. A text size of 2.0 millimetres would not meet this requirement.\"}, {\"Question\": \"Assuming a medicine contains six active ingredients and subsection 8(2) applies, is compliance with paragraphs 9(1)(b) and 9(1)(c) required?\", \"Answer\": \"No\", \"Answer Explanation\": \"The context states that if a medicine contains four or more active ingredients and subsection 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) is not required.\"}, {\"Question\": \"Assuming subsection 8(2) applies to a medicine that includes active ingredients with names containing therapeutically irrelevant descriptors, and the name and quantity or proportion of each active ingredient is displayed according to subsection 8(2), can the names of the therapeutically active moieties be displayed on the main label instead of the full ingredient names?\", \"Answer\": \"Yes\", \"Answer Explanation\": \"The context specifies that if subsection 8(2) applies and the medicine includes one or more active ingredients whose names contain descriptors that are not therapeutically relevant, and the name and quantity or proportion of each active ingredient is displayed in accordance with subsection 8(2), then the name of the therapeutically active moiety(ies) of the active ingredient may be displayed on the main label on the primary pack, instead of the full name of the active ingredient.\"}]}",
    "misc_info":null
  },
  {
    "path":[
      908030000,
      907000000
    ],
    "contexts":[
      "number of active ingredients in the different formulations in the composite pack or medicine kit are to be counted; and (ii) if the same active ingredient is contained in two or more formulations in the composite pack or medicine kit, each of those active ingredients is to be counted separately, for the purposes of determining if paragraph 9(6)(b) applies to the composite pack or medicine kit, or which paragraph in subsection 9(7) applies to the composite pack or medicine kit; and  (d) the",
      "the composite pack or medicine kit; and  (d) the information required under either paragraph 9(6)(b) or subsection 9(7) must be provided separately in relation to each formulation of medicine in the composite pack or medicine kit.  (9) If the medicine is intended to be, or is, registered goods, and the name of an active ingredient included in the medicine comprises an ingredient name specified in Schedule 2 to this Order, either alone or in combination with any other descriptors, then the names"
    ],
    "result_dict":{
      "QuestionAnswers":[
        {
          "Question":"Assuming a composite pack contains two formulations, one with active ingredients A and B, and the other with active ingredient A only, how many active ingredients should be counted for the purposes of determining which labeling requirements in paragraph 9(6)(b) or subsection 9(7) apply?",
          "Answer":"3 active ingredients should be counted.",
          "Answer Explanation":"According to the context, if the same active ingredient is contained in two or more formulations in the composite pack, each of those active ingredients is to be counted separately for determining the applicable labeling requirements in 9(6)(b) or 9(7). Since active ingredient A is in both formulations, it is counted twice, plus active ingredient B, for a total of 3 active ingredients."
        },
        {
          "Question":"Given a medicine kit with 3 formulations containing a total of 5 unique active ingredients, and assuming the medicine is intended to be registered goods, how should the labeling requirements in 9(6)(b) or 9(7) be applied?",
          "Answer":"The labeling requirements in 9(6)(b) or 9(7) must be provided separately for each of the 3 formulations in the medicine kit.",
          "Answer Explanation":"The context states that the information required under either 9(6)(b) or 9(7) must be provided separately in relation to each formulation of medicine in the composite pack or medicine kit. Since there are 3 formulations, the requirements apply separately to each one."
        },
        {
          "Question":"Suppose a registered medicine contains an active ingredient whose name is specified in Schedule 2 of this Order, in combination with other descriptors. Assuming no other conditions override, what is required for labeling the active ingredient name?",
          "Answer":"The active ingredient name must be labeled using the ingredient name specified in Schedule 2 to this Order.",
          "Answer Explanation":"The context specifies that if a registered medicine contains an active ingredient name comprised of an ingredient name in Schedule 2, either alone or combined with other descriptors, then the Schedule 2 name must be used for labeling the active ingredient."
        },
        {
          "Question":"For a composite pack with formulations containing the same active ingredient, assuming the number of active ingredients determines whether 9(6)(b) or a paragraph in 9(7) applies, how should the duplicate active ingredients across formulations be handled?",
          "Answer":"Each instance of the duplicated active ingredient is counted separately to determine if 9(6)(b) or which paragraph in 9(7) applies to the composite pack labeling.",
          "Answer Explanation":"The context states that if the same active ingredient is in two or more formulations in the composite pack, each of those active ingredients is counted separately to determine the applicability of 9(6)(b) or 9(7) labeling requirements. The duplicate ingredients are not combined, but counted separately."
        }
      ]
    },
    "result_str":"{\"QuestionAnswers\": [{\"Question\": \"Assuming a composite pack contains two formulations, one with active ingredients A and B, and the other with active ingredient A only, how many active ingredients should be counted for the purposes of determining which labeling requirements in paragraph 9(6)(b) or subsection 9(7) apply?\", \"Answer\": \"3 active ingredients should be counted.\", \"Answer Explanation\": \"According to the context, if the same active ingredient is contained in two or more formulations in the composite pack, each of those active ingredients is to be counted separately for determining the applicable labeling requirements in 9(6)(b) or 9(7). Since active ingredient A is in both formulations, it is counted twice, plus active ingredient B, for a total of 3 active ingredients.\"}, {\"Question\": \"Given a medicine kit with 3 formulations containing a total of 5 unique active ingredients, and assuming the medicine is intended to be registered goods, how should the labeling requirements in 9(6)(b) or 9(7) be applied?\", \"Answer\": \"The labeling requirements in 9(6)(b) or 9(7) must be provided separately for each of the 3 formulations in the medicine kit.\", \"Answer Explanation\": \"The context states that the information required under either 9(6)(b) or 9(7) must be provided separately in relation to each formulation of medicine in the composite pack or medicine kit. Since there are 3 formulations, the requirements apply separately to each one.\"}, {\"Question\": \"Suppose a registered medicine contains an active ingredient whose name is specified in Schedule 2 of this Order, in combination with other descriptors. Assuming no other conditions override, what is required for labeling the active ingredient name?\", \"Answer\": \"The active ingredient name must be labeled using the ingredient name specified in Schedule 2 to this Order.\", \"Answer Explanation\": \"The context specifies that if a registered medicine contains an active ingredient name comprised of an ingredient name in Schedule 2, either alone or combined with other descriptors, then the Schedule 2 name must be used for labeling the active ingredient.\"}, {\"Question\": \"For a composite pack with formulations containing the same active ingredient, assuming the number of active ingredients determines whether 9(6)(b) or a paragraph in 9(7) applies, how should the duplicate active ingredients across formulations be handled?\", \"Answer\": \"Each instance of the duplicated active ingredient is counted separately to determine if 9(6)(b) or which paragraph in 9(7) applies to the composite pack labeling.\", \"Answer Explanation\": \"The context states that if the same active ingredient is in two or more formulations in the composite pack, each of those active ingredients is counted separately to determine the applicability of 9(6)(b) or 9(7) labeling requirements. The duplicate ingredients are not combined, but counted separately.\"}]}",
    "misc_info":null
  },
  {
    "path":[
      802060000,
      802050000
    ],
    "contexts":[
      "information other than: A. requirements relating to storage conditions B. information about package features to prevent tampering C. names of all excipients D. sponsor or distributor contact details.  (f) The presentation of the critical health information, and any information mentioned in paragraphs 8(2)(c), 8(2)(d) or 8(2)(e) that is included, must be presented in black or other dark coloured texts, using only one colour, on a white or other contrasting background.  (3) If the medicine is",
      "by this Order (such as allergen advice, caution, additional warning or advisory statements).  (e) If information other than the critical health information or information of a kind mentioned in subsections 8(2)(c) or 8(2)(d) is to be included, it must be placed under the \u2018Other information\u2019 heading or under another separate appropriate heading(s) that follow immediately below the headings mentioned in 8(2)(b) and must not contain any additional information other than: A. requirements relating"
    ],
    "result_dict":{
      "QuestionAnswers":[
        {
          "Question":"Assuming a non-prescription medicine label is required to present certain critical health information and additional information under specific headings, what color text and background must be used for this information?",
          "Answer":"Black or other dark colored text on a white or other contrasting background",
          "Answer Explanation":"Paragraph (f) states that the presentation of the critical health information and any additional information included under paragraphs 8(2)(c), 8(2)(d) or 8(2)(e) must be presented in black or other dark colored text, using only one color, on a white or other contrasting background."
        },
        {
          "Question":"Under the 'Other information' heading on a non-prescription medicine label, which of the following is NOT permitted to be included: storage conditions, tamper evident packaging features, excipient names, or sponsor contact details?",
          "Answer":"Sponsor contact details are not permitted under the 'Other information' heading",
          "Answer Explanation":"Paragraph (e) specifies that under the 'Other information' heading, the label must not contain any additional information other than requirements relating to storage conditions, information about package features to prevent tampering, and names of all excipients. Sponsor or distributor contact details are not included in this list of permitted information."
        },
        {
          "Question":"Assuming a non-prescription medicine label includes allergen advice, caution, additional warning or advisory statements required by the Order, where must this information be placed in relation to the critical health information?",
          "Answer":"Allergen advice, caution, additional warning or advisory statements must be placed immediately below the critical health information",
          "Answer Explanation":"The first context paragraph states that information such as allergen advice, caution, additional warning or advisory statements required by the Order must be placed immediately below the critical health information section of the label."
        },
        {
          "Question":"If a non-prescription medicine is presented in a small container where there is insufficient space for the required information on the main label, can the 'Other information' be omitted?",
          "Answer":"No, the 'Other information' cannot be omitted on a small container label",
          "Answer Explanation":"Paragraph (e) states that if information other than the critical health information or specific additional information is to be included, it must be placed under the 'Other information' heading or other appropriate headings immediately below the previously mentioned headings. There is no exception provided for small container labels to omit this 'Other information' section entirely."
        }
      ]
    },
    "result_str":"{\n  \"QuestionAnswers\": [\n    {\n      \"Question\": \"Assuming a non-prescription medicine label is required to present certain critical health information and additional information under specific headings, what color text and background must be used for this information?\",\n      \"Answer\": \"Black or other dark colored text on a white or other contrasting background\",\n      \"Answer Explanation\": \"Paragraph (f) states that the presentation of the critical health information and any additional information included under paragraphs 8(2)(c), 8(2)(d) or 8(2)(e) must be presented in black or other dark colored text, using only one color, on a white or other contrasting background.\"\n    },\n    {\n      \"Question\": \"Under the 'Other information' heading on a non-prescription medicine label, which of the following is NOT permitted to be included: storage conditions, tamper evident packaging features, excipient names, or sponsor contact details?\",\n      \"Answer\": \"Sponsor contact details are not permitted under the 'Other information' heading\",\n      \"Answer Explanation\": \"Paragraph (e) specifies that under the 'Other information' heading, the label must not contain any additional information other than requirements relating to storage conditions, information about package features to prevent tampering, and names of all excipients. Sponsor or distributor contact details are not included in this list of permitted information.\"\n    },\n    {\n      \"Question\": \"Assuming a non-prescription medicine label includes allergen advice, caution, additional warning or advisory statements required by the Order, where must this information be placed in relation to the critical health information?\",\n      \"Answer\": \"Allergen advice, caution, additional warning or advisory statements must be placed immediately below the critical health information\",\n      \"Answer Explanation\": \"The first context paragraph states that information such as allergen advice, caution, additional warning or advisory statements required by the Order must be placed immediately below the critical health information section of the label.\"\n    },\n    {\n      \"Question\": \"If a non-prescription medicine is presented in a small container where there is insufficient space for the required information on the main label, can the 'Other information' be omitted?\",\n      \"Answer\": \"No, the 'Other information' cannot be omitted on a small container label\",\n      \"Answer Explanation\": \"Paragraph (e) states that if information other than the critical health information or specific additional information is to be included, it must be placed under the 'Other information' heading or other appropriate headings immediately below the previously mentioned headings. There is no exception provided for small container labels to omit this 'Other information' section entirely.\"\n    }\n  ]\n}",
    "misc_info":null
  },
  {
    "path":[
      907030000,
      901030000
    ],
    "contexts":[
      "and subsection 8(2) does not apply, then the names and the quantities or proportions of the active ingredients may be included on a side panel or side label or on a rear panel or rear label, when displayed in a text size of not less than 2.5 millimetres; or  (c) where the medicine contains four or more active ingredients and subsection 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) is not required; or  (d) if subsection 8(2) applies and the medicine: (i) includes one or more",
      "number of active ingredients in the different formulations in the composite pack or medicine kit are to be counted; and (ii) if the same active ingredient is contained in two or more formulations in the composite pack or medicine kit, each of those active ingredients is to be counted separately, for the purposes of determining if paragraph 9(6)(b) applies to the composite pack or medicine kit, or which paragraph in subsection 9(7) applies to the composite pack or medicine kit; and  (d) the"
    ],
    "result_dict":{
      "QuestionAnswers":[
        {
          "Question":"Assuming a medicine contains four active ingredients and the names and quantities of these ingredients are not listed on the main or back panel, can the names and quantities be included on a side panel if the text size is at least 2.5 millimeters, given that subsection 8(2) does not apply?",
          "Answer":"Yes",
          "Answer Explanation":"According to the first context, if a medicine contains four or more active ingredients and subsection 8(2) does not apply, then the names and quantities or proportions of the active ingredients may be included on a side panel or side label or on a rear panel or rear label, when displayed in a text size of not less than 2.5 millimeters, as stated in paragraph (b)."
        },
        {
          "Question":"Assuming subsection 8(2) applies to a medicine with four or more active ingredients, is compliance with paragraphs 9(1)(b) and 9(1)(c) required?",
          "Answer":"No",
          "Answer Explanation":"The first context states in paragraph (c) that where the medicine contains four or more active ingredients and subsection 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) is not required."
        },
        {
          "Question":"When determining if paragraph 9(6)(b) or subsection 9(7) applies to a composite pack or medicine kit, how should the number of active ingredients be counted if the same active ingredient is contained in two or more formulations?",
          "Answer":"Each active ingredient should be counted separately",
          "Answer Explanation":"The second context states in subparagraph (c)(ii) that if the same active ingredient is contained in two or more formulations in the composite pack or medicine kit, each of those active ingredients is to be counted separately, for the purposes of determining if paragraph 9(6)(b) applies to the composite pack or medicine kit, or which paragraph in subsection 9(7) applies to the composite pack or medicine kit."
        },
        {
          "Question":"Assuming subsection 8(2) applies to a medicine that includes one or more unspecified additional criteria, what additional information is needed to determine the labeling requirements?",
          "Answer":"More information is needed",
          "Answer Explanation":"The first context mentions in paragraph (d) that if subsection 8(2) applies and the medicine includes one or more additional criteria, but does not specify what those criteria are. Therefore, more information is needed to determine the full labeling requirements in this case."
        }
      ]
    },
    "result_str":"{\"QuestionAnswers\": [{\"Question\": \"Assuming a medicine contains four active ingredients and the names and quantities of these ingredients are not listed on the main or back panel, can the names and quantities be included on a side panel if the text size is at least 2.5 millimeters, given that subsection 8(2) does not apply?\", \"Answer\": \"Yes\", \"Answer Explanation\": \"According to the first context, if a medicine contains four or more active ingredients and subsection 8(2) does not apply, then the names and quantities or proportions of the active ingredients may be included on a side panel or side label or on a rear panel or rear label, when displayed in a text size of not less than 2.5 millimeters, as stated in paragraph (b).\"}, {\"Question\": \"Assuming subsection 8(2) applies to a medicine with four or more active ingredients, is compliance with paragraphs 9(1)(b) and 9(1)(c) required?\", \"Answer\": \"No\", \"Answer Explanation\": \"The first context states in paragraph (c) that where the medicine contains four or more active ingredients and subsection 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) is not required.\"}, {\"Question\": \"When determining if paragraph 9(6)(b) or subsection 9(7) applies to a composite pack or medicine kit, how should the number of active ingredients be counted if the same active ingredient is contained in two or more formulations?\", \"Answer\": \"Each active ingredient should be counted separately\", \"Answer Explanation\": \"The second context states in subparagraph (c)(ii) that if the same active ingredient is contained in two or more formulations in the composite pack or medicine kit, each of those active ingredients is to be counted separately, for the purposes of determining if paragraph 9(6)(b) applies to the composite pack or medicine kit, or which paragraph in subsection 9(7) applies to the composite pack or medicine kit.\"}, {\"Question\": \"Assuming subsection 8(2) applies to a medicine that includes one or more unspecified additional criteria, what additional information is needed to determine the labeling requirements?\", \"Answer\": \"More information is needed\", \"Answer Explanation\": \"The first context mentions in paragraph (d) that if subsection 8(2) applies and the medicine includes one or more additional criteria, but does not specify what those criteria are. Therefore, more information is needed to determine the full labeling requirements in this case.\"}]}",
    "misc_info":null
  },
  {
    "path":[
      1009020000,
      900000000
    ],
    "contexts":[
      "and the medicine is intended to be, or is, registered goods; or (ii) two or more active ingredients in the medicine and the medicine is intended to be, or is, listed goods, then, in relation to compliance of the label on the strip, blister or dial dispenser pack with sections 8 and 9, it shall be sufficient if the following information is displayed: (iii) the name of the medicine; and (iv) the batch number of the medicine preceded by the batch number prefix; and (v) the expiry date of the",
      "of the label on each individual wrapper or blister with sections 8 and 9, it shall be sufficient if the following information is displayed: (v) the name of the medicine; and (vi) the name(s) of all active ingredients in the medicine; and (vii) the quantity or proportion of all active ingredients in the medicine; and (viii) the batch number of the medicine preceded by the batch number prefix; and (ix) the expiry date of the medicine preceded by the expiry date prefix; and (x) the name of the"
    ],
    "result_dict":{
      "QuestionAnswers":[
        {
          "Question":"Assuming a medicine containing two active ingredients is intended to be listed goods, and the medicine is packaged in a strip, blister or dial dispenser pack, what information must be displayed on the label of the pack in order to comply with sections 8 and 9 of the regulation?",
          "Answer":"The name of the medicine, the batch number preceded by the batch number prefix, and the expiry date of the medicine must be displayed on the label.",
          "Answer Explanation":"This is specified in context (i) and (ii), which state that for a medicine with two or more active ingredients intended to be listed goods, packaged in a strip, blister or dial dispenser pack, the label must display (iii) the name of the medicine, (iv) the batch number preceded by the batch number prefix, and (v) the expiry date of the medicine, in order to comply with sections 8 and 9."
        },
        {
          "Question":"Assuming a medicine is packaged with each dosage unit enclosed in an individual wrapper or blister, what information must be displayed on the label of each individual wrapper or blister in order to comply with sections 8 and 9 of the regulation?",
          "Answer":"The name of the medicine, the name(s) and quantity or proportion of all active ingredients, the batch number preceded by the batch number prefix, the expiry date preceded by the expiry date prefix, and the name of the sponsor of the medicine must be displayed on each individual wrapper or blister label.",
          "Answer Explanation":"Context paragraph beginning with '(v)' specifies that for a medicine packaged with each dosage unit in an individual wrapper or blister, the label on each wrapper\/blister must display (v) the name of the medicine, (vi) the name(s) of all active ingredients, (vii) the quantity or proportion of all active ingredients, (viii) the batch number preceded by the batch number prefix, (ix) the expiry date preceded by the expiry date prefix, and (x) the name of the sponsor, to comply with sections 8 and 9."
        },
        {
          "Question":"Assuming a medicine containing only one active ingredient is intended to be registered goods and is packaged in a strip, blister or dial dispenser pack, what information must be displayed on the label of the pack to comply with sections 8 and 9 of the regulation?",
          "Answer":"The name of the medicine, the batch number preceded by the batch number prefix, and the expiry date of the medicine must be displayed on the label of the pack.",
          "Answer Explanation":"Context paragraph (i) states that for a medicine containing only one active ingredient that is intended to be registered goods, if packaged in a strip, blister or dial pack, the label must display (iii) the name of the medicine, (iv) the batch number preceded by the batch number prefix, and (v) the expiry date of the medicine, in order to comply with sections 8 and 9 of the regulation."
        },
        {
          "Question":"Based on the given regulation sections, is the required labeling information different for medicines packaged in individual wrappers\/blisters compared to those packaged in strips, blisters or dial packs?",
          "Answer":"Yes, the required labeling information differs between the two packaging types.",
          "Answer Explanation":"For medicines with dosage units in individual wrappers or blisters, context paragraph (v) specifies that the name of the medicine, active ingredients and their quantity, batch number, expiry date, and sponsor name are required on each wrapper\/blister label. In contrast, for medicines in strip, blister or dial packs, context paragraphs (i) and (ii) state that only the medicine name, batch number and expiry date are required on the pack label, depending on if the medicine has one active ingredient and is registered, or has multiple active ingredients and is listed."
        }
      ]
    },
    "result_str":"{\"QuestionAnswers\": [{\"Question\": \"Assuming a medicine containing two active ingredients is intended to be listed goods, and the medicine is packaged in a strip, blister or dial dispenser pack, what information must be displayed on the label of the pack in order to comply with sections 8 and 9 of the regulation?\", \"Answer\": \"The name of the medicine, the batch number preceded by the batch number prefix, and the expiry date of the medicine must be displayed on the label.\", \"Answer Explanation\": \"This is specified in context (i) and (ii), which state that for a medicine with two or more active ingredients intended to be listed goods, packaged in a strip, blister or dial dispenser pack, the label must display (iii) the name of the medicine, (iv) the batch number preceded by the batch number prefix, and (v) the expiry date of the medicine, in order to comply with sections 8 and 9.\"}, {\"Question\": \"Assuming a medicine is packaged with each dosage unit enclosed in an individual wrapper or blister, what information must be displayed on the label of each individual wrapper or blister in order to comply with sections 8 and 9 of the regulation?\", \"Answer\": \"The name of the medicine, the name(s) and quantity or proportion of all active ingredients, the batch number preceded by the batch number prefix, the expiry date preceded by the expiry date prefix, and the name of the sponsor of the medicine must be displayed on each individual wrapper or blister label.\", \"Answer Explanation\": \"Context paragraph beginning with '(v)' specifies that for a medicine packaged with each dosage unit in an individual wrapper or blister, the label on each wrapper\/blister must display (v) the name of the medicine, (vi) the name(s) of all active ingredients, (vii) the quantity or proportion of all active ingredients, (viii) the batch number preceded by the batch number prefix, (ix) the expiry date preceded by the expiry date prefix, and (x) the name of the sponsor, to comply with sections 8 and 9.\"}, {\"Question\": \"Assuming a medicine containing only one active ingredient is intended to be registered goods and is packaged in a strip, blister or dial dispenser pack, what information must be displayed on the label of the pack to comply with sections 8 and 9 of the regulation?\", \"Answer\": \"The name of the medicine, the batch number preceded by the batch number prefix, and the expiry date of the medicine must be displayed on the label of the pack.\", \"Answer Explanation\": \"Context paragraph (i) states that for a medicine containing only one active ingredient that is intended to be registered goods, if packaged in a strip, blister or dial pack, the label must display (iii) the name of the medicine, (iv) the batch number preceded by the batch number prefix, and (v) the expiry date of the medicine, in order to comply with sections 8 and 9 of the regulation.\"}, {\"Question\": \"Based on the given regulation sections, is the required labeling information different for medicines packaged in individual wrappers\/blisters compared to those packaged in strips, blisters or dial packs?\", \"Answer\": \"Yes, the required labeling information differs between the two packaging types.\", \"Answer Explanation\": \"For medicines with dosage units in individual wrappers or blisters, context paragraph (v) specifies that the name of the medicine, active ingredients and their quantity, batch number, expiry date, and sponsor name are required on each wrapper\/blister label. In contrast, for medicines in strip, blister or dial packs, context paragraphs (i) and (ii) state that only the medicine name, batch number and expiry date are required on the pack label, depending on if the medicine has one active ingredient and is registered, or has multiple active ingredients and is listed.\"}]}",
    "misc_info":null
  },
  {
    "path":[
      1005000000,
      900000000
    ],
    "contexts":[
      "to the list of homoeopathic ingredients, or by prefacing the name of the homoeopathic active ingredient with the term \u2018homoeopathic\u2019.  (5) Sunscreen preparations If:  (a) the medicine is a sunscreen preparation; and  (b) is enclosed in a container with a capacity of not more than 25 millilitres, then, in relation to compliance with sections 8 and 9, it shall be sufficient if (i) the sun protection factor is displayed in a text size of not less than 1.5 millimetres; and (ii) all other",
      "on the delivery device and not the container.  9 Information to be included on the main label  (1) Subject to the qualifications and special requirements specified in this section and section 10 of this Order, the information on the main label of the medicine must include:  (a) the name of the medicine; and  (b) the name(s) of all active ingredients in the medicine; and  (c) the quantity or proportion of all active ingredients in the medicine; and  (d) the name of the dosage form; and  (e) the"
    ],
    "result_dict":{
      "QuestionAnswers":[
        {
          "Question":"Assuming a sunscreen preparation is in a container with a capacity of 10 millilitres, what is the minimum required text size for displaying the sun protection factor on the label to comply with sections 8 and 9 of the regulation?",
          "Answer":"1.5 millimetres",
          "Answer Explanation":"Section 8(5) states that for a sunscreen preparation in a container with a capacity of not more than 25 millilitres, to comply with sections 8 and 9, it is sufficient if (i) the sun protection factor is displayed in a text size of not less than 1.5 millimetres. Since the given container capacity is 10 millilitres, which is less than 25 millilitres, the minimum required text size for the sun protection factor is 1.5 millimetres."
        },
        {
          "Question":"Based on section 9(1), and assuming no other qualifications or special requirements apply, which of the following pieces of information must be included on the main label of a medicine: the name of the medicine, the quantity of active ingredients, or the dosage form name?",
          "Answer":"All of the above",
          "Answer Explanation":"Section 9(1) states that subject to qualifications and special requirements in sections 9 and 10, the information on the main label of the medicine must include: (a) the name of the medicine, (c) the quantity or proportion of all active ingredients in the medicine, and (d) the name of the dosage form. Therefore, all three pieces of information mentioned in the question must be included on the main label."
        },
        {
          "Question":"Assuming a medicine contains homoeopathic ingredients, what are the two ways the main label can indicate this as per section 8(4)?",
          "Answer":"By adding the word 'homoeopathic' to the list of homoeopathic ingredients, or by prefacing the name of the homoeopathic active ingredient with the term 'homoeopathic'",
          "Answer Explanation":"Section 8(4) states that if the medicine contains homoeopathic ingredients, this should be clearly indicated on the main label either by adding the word 'homoeopathic' to the list of homoeopathic ingredients, or by prefacing the name of the homoeopathic active ingredient with the term 'homoeopathic'."
        },
        {
          "Question":"Assuming a medicine is a sunscreen preparation in a 10 millilitre container, and section 8(5)(ii) applies, what information related to the sun protection factor must still be included on the main label as per section 9(1)?",
          "Answer":"The sun protection factor value itself",
          "Answer Explanation":"Section 8(5) provides an exception for sunscreen preparations in small containers, allowing the sun protection factor to be displayed in a smaller text size. However, section 9(1) still requires the information on the main label to include (c) the quantity or proportion of all active ingredients. The sun protection factor is a measure of the proportion of UV radiation blocked, so the SPF value itself must still be included on the main label even if the text size requirement is relaxed by section 8(5)."
        }
      ]
    },
    "result_str":"{\"QuestionAnswers\":[{\"Question\":\"Assuming a sunscreen preparation is in a container with a capacity of 10 millilitres, what is the minimum required text size for displaying the sun protection factor on the label to comply with sections 8 and 9 of the regulation?\",\"Answer\":\"1.5 millimetres\",\"Answer Explanation\":\"Section 8(5) states that for a sunscreen preparation in a container with a capacity of not more than 25 millilitres, to comply with sections 8 and 9, it is sufficient if (i) the sun protection factor is displayed in a text size of not less than 1.5 millimetres. Since the given container capacity is 10 millilitres, which is less than 25 millilitres, the minimum required text size for the sun protection factor is 1.5 millimetres.\"},{\"Question\":\"Based on section 9(1), and assuming no other qualifications or special requirements apply, which of the following pieces of information must be included on the main label of a medicine: the name of the medicine, the quantity of active ingredients, or the dosage form name?\",\"Answer\":\"All of the above\",\"Answer Explanation\":\"Section 9(1) states that subject to qualifications and special requirements in sections 9 and 10, the information on the main label of the medicine must include: (a) the name of the medicine, (c) the quantity or proportion of all active ingredients in the medicine, and (d) the name of the dosage form. Therefore, all three pieces of information mentioned in the question must be included on the main label.\"},{\"Question\":\"Assuming a medicine contains homoeopathic ingredients, what are the two ways the main label can indicate this as per section 8(4)?\",\"Answer\":\"By adding the word 'homoeopathic' to the list of homoeopathic ingredients, or by prefacing the name of the homoeopathic active ingredient with the term 'homoeopathic'\",\"Answer Explanation\":\"Section 8(4) states that if the medicine contains homoeopathic ingredients, this should be clearly indicated on the main label either by adding the word 'homoeopathic' to the list of homoeopathic ingredients, or by prefacing the name of the homoeopathic active ingredient with the term 'homoeopathic'.\"},{\"Question\":\"Assuming a medicine is a sunscreen preparation in a 10 millilitre container, and section 8(5)(ii) applies, what information related to the sun protection factor must still be included on the main label as per section 9(1)?\",\"Answer\":\"The sun protection factor value itself\",\"Answer Explanation\":\"Section 8(5) provides an exception for sunscreen preparations in small containers, allowing the sun protection factor to be displayed in a smaller text size. However, section 9(1) still requires the information on the main label to include (c) the quantity or proportion of all active ingredients. The sun protection factor is a measure of the proportion of UV radiation blocked, so the SPF value itself must still be included on the main label even if the text size requirement is relaxed by section 8(5).\"}]}",
    "misc_info":null
  },
  {
    "path":[
      907020000,
      802000000
    ],
    "contexts":[
      "and subsection 8(2) does not apply, then the names and the quantities or proportions of the active ingredients may be included on a side panel or side label or on a rear panel or rear label, when displayed in a text size of not less than 2.5 millimetres; or  (c) where the medicine contains four or more active ingredients and subsection 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) is not required; or  (d) if subsection 8(2) applies and the medicine: (i) includes one or more",
      "registered goods, and (i) subsection 8(2) does not apply, then the names, and quantities or proportions, of the active ingredients must be displayed on the side or rear panel or label in a text size of not less than 2.5 millimetres; or (ii) subsection 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) is not required.  (6) If the medicine is intended to be, or is, listed goods:  (a) if the medicine is a sunscreen preparation - the name of every active ingredient, together with"
    ],
    "result_dict":{
      "QuestionAnswers":[
        {
          "Question":"Assuming a medicine contains three active ingredients and subsection 8(2) does not apply, where must the names and quantities or proportions of the active ingredients be displayed, and what is the minimum required text size?",
          "Answer":"The names and quantities or proportions of the active ingredients must be displayed on a side panel, side label, rear panel, or rear label, with a minimum text size of 2.5 millimetres.",
          "Answer Explanation":"According to the context, if a medicine contains three active ingredients and subsection 8(2) does not apply, then paragraph 9(1)(b) states that the names and quantities or proportions of the active ingredients may be included on a side panel, side label, rear panel, or rear label, with a minimum text size of 2.5 millimetres."
        },
        {
          "Question":"Assuming a medicine contains five active ingredients and subsection 8(2) applies, are the requirements in paragraphs 9(1)(b) and 9(1)(c) still mandatory?",
          "Answer":"No, compliance with paragraphs 9(1)(b) and 9(1)(c) is not required in this case.",
          "Answer Explanation":"The context states in paragraph 9(1)(c) that if a medicine contains four or more active ingredients and subsection 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) is not required."
        },
        {
          "Question":"For listed goods that are sunscreen preparations, what information must be displayed together with the name of every active ingredient, and where should this information be displayed?",
          "Answer":"For listed goods that are sunscreen preparations, the quantity or proportion of every active ingredient must be displayed together with the name of every active ingredient, on a side panel, side label, rear panel, or rear label.",
          "Answer Explanation":"Paragraph 9(6)(a) states that if the medicine is a listed good and a sunscreen preparation, the name of every active ingredient, together with the quantity or proportion of every active ingredient, must be displayed on a side panel, side label, rear panel, or rear label."
        },
        {
          "Question":"Assuming a medicine is registered goods containing two active ingredients and subsection 8(2) does not apply, where must the names and quantities or proportions of the active ingredients be displayed, and what is the minimum required text size?",
          "Answer":"For registered goods containing two active ingredients where subsection 8(2) does not apply, the names and quantities or proportions of the active ingredients must be displayed on the side or rear panel or label, with a minimum text size of 2.5 millimetres.",
          "Answer Explanation":"Paragraph 9(5)(d)(i) states that for registered goods where subsection 8(2) does not apply, the names and quantities or proportions of the active ingredients must be displayed on the side or rear panel or label, with a minimum text size of 2.5 millimetres."
        }
      ]
    },
    "result_str":"{\n  \"QuestionAnswers\": [\n    {\n      \"Question\": \"Assuming a medicine contains three active ingredients and subsection 8(2) does not apply, where must the names and quantities or proportions of the active ingredients be displayed, and what is the minimum required text size?\",\n      \"Answer\": \"The names and quantities or proportions of the active ingredients must be displayed on a side panel, side label, rear panel, or rear label, with a minimum text size of 2.5 millimetres.\",\n      \"Answer Explanation\": \"According to the context, if a medicine contains three active ingredients and subsection 8(2) does not apply, then paragraph 9(1)(b) states that the names and quantities or proportions of the active ingredients may be included on a side panel, side label, rear panel, or rear label, with a minimum text size of 2.5 millimetres.\"\n    },\n    {\n      \"Question\": \"Assuming a medicine contains five active ingredients and subsection 8(2) applies, are the requirements in paragraphs 9(1)(b) and 9(1)(c) still mandatory?\",\n      \"Answer\": \"No, compliance with paragraphs 9(1)(b) and 9(1)(c) is not required in this case.\",\n      \"Answer Explanation\": \"The context states in paragraph 9(1)(c) that if a medicine contains four or more active ingredients and subsection 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) is not required.\"\n    },\n    {\n      \"Question\": \"For listed goods that are sunscreen preparations, what information must be displayed together with the name of every active ingredient, and where should this information be displayed?\",\n      \"Answer\": \"For listed goods that are sunscreen preparations, the quantity or proportion of every active ingredient must be displayed together with the name of every active ingredient, on a side panel, side label, rear panel, or rear label.\",\n      \"Answer Explanation\": \"Paragraph 9(6)(a) states that if the medicine is a listed good and a sunscreen preparation, the name of every active ingredient, together with the quantity or proportion of every active ingredient, must be displayed on a side panel, side label, rear panel, or rear label.\"\n    },\n    {\n      \"Question\": \"Assuming a medicine is registered goods containing two active ingredients and subsection 8(2) does not apply, where must the names and quantities or proportions of the active ingredients be displayed, and what is the minimum required text size?\",\n      \"Answer\": \"For registered goods containing two active ingredients where subsection 8(2) does not apply, the names and quantities or proportions of the active ingredients must be displayed on the side or rear panel or label, with a minimum text size of 2.5 millimetres.\",\n      \"Answer Explanation\": \"Paragraph 9(5)(d)(i) states that for registered goods where subsection 8(2) does not apply, the names and quantities or proportions of the active ingredients must be displayed on the side or rear panel or label, with a minimum text size of 2.5 millimetres.\"\n    }\n  ]\n}",
    "misc_info":null
  },
  {
    "path":[
      601150000,
      801030000
    ],
    "contexts":[
      "information\" means information required under paragraphs 8(1)(b), (c), (j), (k), (l) and (n) of this Order, that is critical for safe use of medicines that are self-selected by a consumer; \"delivered dose\" means, in relation to: (a) metered dose preparations - the dose delivered to the patient in a single actuation or delivery; and (b) powders for inhalation - the dose delivered from the inhaler in a single delivery; \"dial dispenser pack\" means a container that has the following",
      "such as \u2018inhalation\u2019, \u2018For oral use only\u2019 or other phrase, word or abbreviation denoting the approved route(s) of administration.  (2)  (a) Subject to paragraphs (b), (c) and (d), where the medicine is registered goods, the critical health information must be displayed on the label of the primary pack in a tabulated form.  (b) The critical health information must be presented under appropriate headings and in the following order: (i) Active ingredients (ii) Indications (iii) Warnings (iv)"
    ],
    "result_dict":{
      "QuestionAnswers":[
        {
          "Question":"Assuming a medicine is delivered via a metered dose inhaler and is registered goods, what form and order must the critical health information be displayed on the label of the primary pack?",
          "Answer":"The critical health information must be displayed in a tabulated form, under appropriate headings, and in the following order: (i) Active ingredients (ii) Indications (iii) Warnings (iv) Dosage and administration instructions.",
          "Answer Explanation":"Based on the information provided in the two context sections, we can determine that for a metered dose inhaler medicine that is registered goods, the critical health information as defined in 8(1)(b), (c), (j), (k), (l) and (n) must be displayed on the primary pack label in tabulated form, under headings, and in the specified order per section (2)(a) and (b)."
        },
        {
          "Question":"For an inhaled powder medicine delivered via an inhaler device, what specific phrase or abbreviation must be included on the label to denote the approved route of administration?",
          "Answer":"The label must include a phrase like 'For inhalation' or similar to denote the approved inhalation route of administration for a powder medicine delivered from an inhaler device.",
          "Answer Explanation":"The contexts define a 'delivered dose' for powders as the dose delivered from the inhaler in a single delivery. Section (1) states the label must include a phrase denoting the approved route like 'For inhalation' for the administration route. Combining these, for an inhaled powder, the label must specify 'For inhalation' or similar for the inhaled route of delivery from the device."
        },
        {
          "Question":"Assuming an oral liquid medicine is packaged in a dial dispenser pack, what features must the container have to meet the definition of a dial dispenser pack?",
          "Answer":"Insufficient information provided to determine the required features of a dial dispenser pack. The provided context cuts off mid-sentence when defining 'dial dispenser pack' and does not list the necessary container features.",
          "Answer Explanation":"The 'dial dispenser pack' definition begins stating it 'means a container that has the following' but then ends abruptly without specifying the required features. The information needed to answer the question about what features an oral liquid dial dispenser pack must have is not provided in the given context sections."
        },
        {
          "Question":"For a non-prescription registered medicine in a metered-dose inhaler, what information defined as critical health information in section 8(1) must be displayed on the label?",
          "Answer":"The critical health information that must be on the label for a non-prescription registered metered-dose inhaler medicine is the information required under paragraphs 8(1)(b), (c), (j), (k), (l) and (n) of the Order, as these sections are specified in the 'critical health information' definition provided.",
          "Answer Explanation":"The context defines 'critical health information' as the information required under 8(1)(b), (c), (j), (k), (l) and (n) that is critical for safe use of self-selected medicines. It also notes this must be displayed on the primary pack label for registered goods. Referencing both context sections, a non-prescription metered-dose inhaler that is registered goods must display the 8(1)(b), (c), (j), (k), (l) and (n) information on the label."
        }
      ]
    },
    "result_str":"{\"QuestionAnswers\": [\n  {\n    \"Question\": \"Assuming a medicine is delivered via a metered dose inhaler and is registered goods, what form and order must the critical health information be displayed on the label of the primary pack?\",\n    \"Answer\": \"The critical health information must be displayed in a tabulated form, under appropriate headings, and in the following order: (i) Active ingredients (ii) Indications (iii) Warnings (iv) Dosage and administration instructions.\",\n    \"Answer Explanation\": \"Based on the information provided in the two context sections, we can determine that for a metered dose inhaler medicine that is registered goods, the critical health information as defined in 8(1)(b), (c), (j), (k), (l) and (n) must be displayed on the primary pack label in tabulated form, under headings, and in the specified order per section (2)(a) and (b).\"\n  },\n  {\n    \"Question\": \"For an inhaled powder medicine delivered via an inhaler device, what specific phrase or abbreviation must be included on the label to denote the approved route of administration?\",\n    \"Answer\": \"The label must include a phrase like 'For inhalation' or similar to denote the approved inhalation route of administration for a powder medicine delivered from an inhaler device.\",\n    \"Answer Explanation\": \"The contexts define a 'delivered dose' for powders as the dose delivered from the inhaler in a single delivery. Section (1) states the label must include a phrase denoting the approved route like 'For inhalation' for the administration route. Combining these, for an inhaled powder, the label must specify 'For inhalation' or similar for the inhaled route of delivery from the device.\"\n  },\n  {\n    \"Question\": \"Assuming an oral liquid medicine is packaged in a dial dispenser pack, what features must the container have to meet the definition of a dial dispenser pack?\",\n    \"Answer\": \"Insufficient information provided to determine the required features of a dial dispenser pack. The provided context cuts off mid-sentence when defining 'dial dispenser pack' and does not list the necessary container features.\",\n    \"Answer Explanation\": \"The 'dial dispenser pack' definition begins stating it 'means a container that has the following' but then ends abruptly without specifying the required features. The information needed to answer the question about what features an oral liquid dial dispenser pack must have is not provided in the given context sections.\"\n  },\n  {\n    \"Question\": \"For a non-prescription registered medicine in a metered-dose inhaler, what information defined as critical health information in section 8(1) must be displayed on the label?\",\n    \"Answer\": \"The critical health information that must be on the label for a non-prescription registered metered-dose inhaler medicine is the information required under paragraphs 8(1)(b), (c), (j), (k), (l) and (n) of the Order, as these sections are specified in the 'critical health information' definition provided.\",\n    \"Answer Explanation\": \"The context defines 'critical health information' as the information required under 8(1)(b), (c), (j), (k), (l) and (n) that is critical for safe use of self-selected medicines. It also notes this must be displayed on the primary pack label for registered goods. Referencing both context sections, a non-prescription metered-dose inhaler that is registered goods must display the 8(1)(b), (c), (j), (k), (l) and (n) information on the label.\"\n  }\n]}",
    "misc_info":null
  },
  {
    "path":[
      1102070000,
      1102060000
    ],
    "contexts":[
      "metered dose products such as nasal sprays, the quantity of the active ingredient is: (i) the quantity delivered per actuation; or where the Secretary, when registering the medicine, has accepted that the dose of products containing those active ingredients was clinically established as the metered dose, then: (ii) the quantity metered per actuation;  (g) for preparations applied to the skin and mucous membranes, other than those covered by paragraph (f) - as a percentage expressed in terms of",
      "(ii) for any other medicines - as the weight or volume of active ingredient in a stated weight or volume of the medicine, after preparation in accordance with the instructions included in the label of the medicine;  (e) for a transdermal patch, as the total quantity of the active ingredient in each patch and the quantity of the active ingredient released in a stated time;  (f) for pressurised metered dose inhalers, dry powder inhalers and other metered dose products such as nasal sprays, the"
    ],
    "result_dict":{
      "QuestionAnswers":[
        {
          "Question":"Assuming a transdermal patch medicine label states it contains 10mg of the active ingredient per patch and releases 1mg per hour, what is the correct way to express the quantity of active ingredient for this product according to the regulation?",
          "Answer":"The quantity of active ingredient should be expressed as 10mg per patch and 1mg released per hour.",
          "Answer Explanation":"This is clearly stated in section (e) of the regulation: 'for a transdermal patch, as the total quantity of the active ingredient in each patch and the quantity of the active ingredient released in a stated time'."
        },
        {
          "Question":"For a nasal spray product where the dose was established as the metered dose during registration with the Secretary, and each actuation delivers 50mcg, how should the quantity of active ingredient be expressed on the label based on the regulation?",
          "Answer":"The quantity of active ingredient should be expressed as 50mcg metered per actuation.",
          "Answer Explanation":"Section (f) part (ii) states that 'where the Secretary, when registering the medicine, has accepted that the dose of products containing those active ingredients was clinically established as the metered dose, then: (ii) the quantity metered per actuation'. Since the dose was established as the metered dose during registration, this rule applies."
        },
        {
          "Question":"A topical cream medicine label expresses the quantity of active ingredient as 10mg per gram of cream. Assuming this is not a preparation applied to mucous membranes, is this compliant with the regulation?",
          "Answer":"No, this is not compliant with the regulation for topical creams not applied to mucous membranes.",
          "Answer Explanation":"Section (g) requires that 'for preparations applied to the skin and mucous membranes, other than those covered by paragraph (f) - as a percentage'. Therefore, expressing the quantity as 10mg per gram is not the correct format according to the regulation, it should be a percentage."
        },
        {
          "Question":"For an oral liquid medicine, the label states each 5mL contains 250mg of the active ingredient after preparation according to the label instructions. Does this expression of the quantity of active ingredient comply with the regulation?",
          "Answer":"Yes, this complies with the regulation for expressing the quantity of active ingredient in oral liquid medicines.",
          "Answer Explanation":"Section (d) part (ii) states that for medicines other than divided preparations, the quantity should be expressed 'as the weight or volume of active ingredient in a stated weight or volume of the medicine, after preparation in accordance with the instructions included in the label of the medicine'. The label follows this rule by stating the weight of active ingredient (250mg) per volume (5mL) of the medicine after preparation according to instructions."
        }
      ]
    },
    "result_str":"{\"QuestionAnswers\": [{\"Question\": \"Assuming a transdermal patch medicine label states it contains 10mg of the active ingredient per patch and releases 1mg per hour, what is the correct way to express the quantity of active ingredient for this product according to the regulation?\", \"Answer\": \"The quantity of active ingredient should be expressed as 10mg per patch and 1mg released per hour.\", \"Answer Explanation\": \"This is clearly stated in section (e) of the regulation: 'for a transdermal patch, as the total quantity of the active ingredient in each patch and the quantity of the active ingredient released in a stated time'.\"}, {\"Question\": \"For a nasal spray product where the dose was established as the metered dose during registration with the Secretary, and each actuation delivers 50mcg, how should the quantity of active ingredient be expressed on the label based on the regulation?\", \"Answer\": \"The quantity of active ingredient should be expressed as 50mcg metered per actuation.\", \"Answer Explanation\": \"Section (f) part (ii) states that 'where the Secretary, when registering the medicine, has accepted that the dose of products containing those active ingredients was clinically established as the metered dose, then: (ii) the quantity metered per actuation'. Since the dose was established as the metered dose during registration, this rule applies.\"}, {\"Question\": \"A topical cream medicine label expresses the quantity of active ingredient as 10mg per gram of cream. Assuming this is not a preparation applied to mucous membranes, is this compliant with the regulation?\", \"Answer\": \"No, this is not compliant with the regulation for topical creams not applied to mucous membranes.\", \"Answer Explanation\": \"Section (g) requires that 'for preparations applied to the skin and mucous membranes, other than those covered by paragraph (f) - as a percentage'. Therefore, expressing the quantity as 10mg per gram is not the correct format according to the regulation, it should be a percentage.\"}, {\"Question\": \"For an oral liquid medicine, the label states each 5mL contains 250mg of the active ingredient after preparation according to the label instructions. Does this expression of the quantity of active ingredient comply with the regulation?\", \"Answer\": \"Yes, this complies with the regulation for expressing the quantity of active ingredient in oral liquid medicines.\", \"Answer Explanation\": \"Section (d) part (ii) states that for medicines other than divided preparations, the quantity should be expressed 'as the weight or volume of active ingredient in a stated weight or volume of the medicine, after preparation in accordance with the instructions included in the label of the medicine'. The label follows this rule by stating the weight of active ingredient (250mg) per volume (5mL) of the medicine after preparation according to instructions.\"}]}",
    "misc_info":null
  },
  {
    "path":[
      805000000,
      801000000
    ],
    "contexts":[
      "to be included on the label  (1) Subject to the qualifications and requirements specified in subsections 8(2) and 8(3) and sections 9 and 10 below, the labels of a medicine must include:  (a) the name of the medicine; and  (b) the name(s) of all active ingredients in the medicine; and  (c) the quantity or proportion of all active ingredients in the medicine; and  (d) the name of the dosage form; and  (e) the quantity of the medicine; and  (f) the batch number of the medicine preceded by the",
      "on the delivery device and not the container.  9 Information to be included on the main label  (1) Subject to the qualifications and special requirements specified in this section and section 10 of this Order, the information on the main label of the medicine must include:  (a) the name of the medicine; and  (b) the name(s) of all active ingredients in the medicine; and  (c) the quantity or proportion of all active ingredients in the medicine; and  (d) the name of the dosage form; and  (e) the"
    ],
    "result_dict":{
      "QuestionAnswers":[
        {
          "Question":"Assuming that all the information required to be on the label of a medicine is present, and that the medicine is in a container with a delivery device, what specific information must be included on the main label of the container?",
          "Answer":"The name of the medicine, the name(s) of all active ingredients, the quantity or proportion of all active ingredients, the name of the dosage form, and the quantity of the medicine must be included on the main label of the container.",
          "Answer Explanation":"Section 8(1) lists the information that must be included on the labels of a medicine, subject to subsections 8(2) and 8(3) and sections 9 and 10. Section 8(3) allows certain information to be on the delivery device instead of the container. Section 9(1) then specifies that the main label of the medicine must include the name of the medicine, the name(s) of all active ingredients, the quantity or proportion of all active ingredients, the name of the dosage form, and the quantity of the medicine, subject to section 10."
        },
        {
          "Question":"Assuming a medicine comes in a container with a delivery device, the batch number is on the delivery device, and all other required label information is present, does the label meet the requirements?",
          "Answer":"Yes, the label meets the requirements in this scenario.",
          "Answer Explanation":"Section 8(1) requires the batch number to be on the labels of the medicine. However, section 8(3) provides an exception, allowing the batch number to be on the delivery device if the medicine has both a container and delivery device. Therefore, since the batch number is on the delivery device and all other required information is present, the labeling requirements are satisfied."
        },
        {
          "Question":"If a medicine has a container and a delivery device, and all required information except the batch number is on the main label, can the batch number be included on a label that is not the main label?",
          "Answer":"No, if the batch number is not on the main label, it must be on the delivery device, not a different label.",
          "Answer Explanation":"Section 8(1)(f) requires the batch number to be included on the labels of the medicine. Section 8(3) provides an exception, allowing the batch number to be on the delivery device instead of the container labels. Section 9(1) specifies the information that must be on the main label. These sections together indicate that the batch number must be either on the main label or the delivery device, not a different label."
        },
        {
          "Question":"Assuming a medicine does not have a delivery device and the quantity of the medicine is not on the label, but all other required information is present, does the label meet the requirements?",
          "Answer":"No, the label does not meet the requirements in this scenario.",
          "Answer Explanation":"Section 8(1)(e) states that the quantity of the medicine must be included on the labels. Section 9(1) further specifies that the quantity of the medicine must be on the main label, subject to section 10 (which does not provide an exception for quantity). Since the medicine has no delivery device, section 8(3) does not apply. Therefore, lacking the quantity on the label is a violation of the requirements."
        }
      ]
    },
    "result_str":"{\"QuestionAnswers\": [{\"Question\": \"Assuming that all the information required to be on the label of a medicine is present, and that the medicine is in a container with a delivery device, what specific information must be included on the main label of the container?\", \"Answer\": \"The name of the medicine, the name(s) of all active ingredients, the quantity or proportion of all active ingredients, the name of the dosage form, and the quantity of the medicine must be included on the main label of the container.\", \"Answer Explanation\": \"Section 8(1) lists the information that must be included on the labels of a medicine, subject to subsections 8(2) and 8(3) and sections 9 and 10. Section 8(3) allows certain information to be on the delivery device instead of the container. Section 9(1) then specifies that the main label of the medicine must include the name of the medicine, the name(s) of all active ingredients, the quantity or proportion of all active ingredients, the name of the dosage form, and the quantity of the medicine, subject to section 10.\"}, {\"Question\": \"Assuming a medicine comes in a container with a delivery device, the batch number is on the delivery device, and all other required label information is present, does the label meet the requirements?\", \"Answer\": \"Yes, the label meets the requirements in this scenario.\", \"Answer Explanation\": \"Section 8(1) requires the batch number to be on the labels of the medicine. However, section 8(3) provides an exception, allowing the batch number to be on the delivery device if the medicine has both a container and delivery device. Therefore, since the batch number is on the delivery device and all other required information is present, the labeling requirements are satisfied.\"}, {\"Question\": \"If a medicine has a container and a delivery device, and all required information except the batch number is on the main label, can the batch number be included on a label that is not the main label?\", \"Answer\": \"No, if the batch number is not on the main label, it must be on the delivery device, not a different label.\", \"Answer Explanation\": \"Section 8(1)(f) requires the batch number to be included on the labels of the medicine. Section 8(3) provides an exception, allowing the batch number to be on the delivery device instead of the container labels. Section 9(1) specifies the information that must be on the main label. These sections together indicate that the batch number must be either on the main label or the delivery device, not a different label.\"}, {\"Question\": \"Assuming a medicine does not have a delivery device and the quantity of the medicine is not on the label, but all other required information is present, does the label meet the requirements?\", \"Answer\": \"No, the label does not meet the requirements in this scenario.\", \"Answer Explanation\": \"Section 8(1)(e) states that the quantity of the medicine must be included on the labels. Section 9(1) further specifies that the quantity of the medicine must be on the main label, subject to section 10 (which does not provide an exception for quantity). Since the medicine has no delivery device, section 8(3) does not apply. Therefore, lacking the quantity on the label is a violation of the requirements.\"}]}",
    "misc_info":null
  },
  {
    "path":[
      1008030000,
      900000000
    ],
    "contexts":[
      "of the label for each individual wrapper with sections 8 and 9, it shall be sufficient if the name of the medicine is displayed.  (c) Where: (i) a medicine consists of dry herbs contained in individual bags and the bag is retained around the herbs during preparation; (ii) the bags are contained in a primary pack, the label of which complies with the requirements of this Order, then the individual bag need not be labelled with the information referred to in sections 8 and 9.  (9) Strip, blister",
      "is enclosed in a small container; and  (b) the container is enclosed in a primary pack, the label of which complies with sections 8 and 9 and subsection 10(1) (if applicable), then, in relation to compliance of the label on the container with sections 8 and 9 and subsection 10(1) (if applicable), it shall be sufficient if the following information is displayed in a text size of not less than 2 millimetres:  (c) the name of the medicine; and  (d) the name(s) of all active ingredients in the"
    ],
    "result_dict":{
      "QuestionAnswers":[
        {
          "Question":"Assuming a non-prescription medicine consists of dry herbs in individual bags within a primary pack that has a compliant label, and the bags are kept around the herbs during preparation, do the individual bags need to be labelled with the information from sections 8 and 9?",
          "Answer":"No",
          "Answer Explanation":"Based on the information provided in the first context paragraph, specifically part (c), if a medicine consists of dry herbs in individual bags retained around the herbs during preparation, and these bags are inside a primary pack with a label complying with sections 8 and 9, then the individual bags do not need to be labelled with the information from sections 8 and 9."
        },
        {
          "Question":"Given a non-prescription medicine in a small container within a primary pack that has a label complying with sections 8, 9 and 10(1) if applicable, what minimum information must be on the label of the small container in a text size of at least 2 millimetres to be considered sufficient?",
          "Answer":"The name of the medicine and the name(s) of all active ingredients",
          "Answer Explanation":"The second context paragraph states that if a medicine is in a small container within a primary pack having a label complying with sections 8, 9 and 10(1) if applicable, then for the small container label to sufficiently comply with those same sections, it must minimally display the name of the medicine and the name(s) of all active ingredients in a text size of not less than 2 millimetres."
        },
        {
          "Question":"Assuming a non-prescription medicine has individually wrapped portions inside a primary pack, what label information from sections 8 and 9 must be on each individual wrapper?",
          "Answer":"The name of the medicine",
          "Answer Explanation":"The first context paragraph, specifically part (b), indicates that for a non-prescription medicine with individually wrapped portions inside a primary pack, to comply with sections 8 and 9, it is sufficient if the name of the medicine is displayed on the label of each individual wrapper."
        },
        {
          "Question":"If a non-prescription medicine consists of dry herbs in individual bags within a labelled primary pack, and a small container of the medicine is also inside a labelled primary pack, are the labelling requirements the same for the individual herb bags and the small container?",
          "Answer":"No",
          "Answer Explanation":"Based on the two context paragraphs provided, the labelling requirements differ between the individual herb bags and the small container when each is inside a primary pack with a compliant label. The individual herb bags do not need to be labelled at all with the section 8 and 9 information, as stated in part (c) of the first paragraph. However, the small container label must display at minimum the medicine name and active ingredient name(s) in a 2mm or larger text size to sufficiently comply with sections 8, 9 and 10(1) if applicable, as described in the second paragraph."
        }
      ]
    },
    "result_str":"{\"QuestionAnswers\": [{\"Question\": \"Assuming a non-prescription medicine consists of dry herbs in individual bags within a primary pack that has a compliant label, and the bags are kept around the herbs during preparation, do the individual bags need to be labelled with the information from sections 8 and 9?\", \"Answer\": \"No\", \"Answer Explanation\": \"Based on the information provided in the first context paragraph, specifically part (c), if a medicine consists of dry herbs in individual bags retained around the herbs during preparation, and these bags are inside a primary pack with a label complying with sections 8 and 9, then the individual bags do not need to be labelled with the information from sections 8 and 9.\"}, {\"Question\": \"Given a non-prescription medicine in a small container within a primary pack that has a label complying with sections 8, 9 and 10(1) if applicable, what minimum information must be on the label of the small container in a text size of at least 2 millimetres to be considered sufficient?\", \"Answer\": \"The name of the medicine and the name(s) of all active ingredients\", \"Answer Explanation\": \"The second context paragraph states that if a medicine is in a small container within a primary pack having a label complying with sections 8, 9 and 10(1) if applicable, then for the small container label to sufficiently comply with those same sections, it must minimally display the name of the medicine and the name(s) of all active ingredients in a text size of not less than 2 millimetres.\"}, {\"Question\": \"Assuming a non-prescription medicine has individually wrapped portions inside a primary pack, what label information from sections 8 and 9 must be on each individual wrapper?\", \"Answer\": \"The name of the medicine\", \"Answer Explanation\": \"The first context paragraph, specifically part (b), indicates that for a non-prescription medicine with individually wrapped portions inside a primary pack, to comply with sections 8 and 9, it is sufficient if the name of the medicine is displayed on the label of each individual wrapper.\"}, {\"Question\": \"If a non-prescription medicine consists of dry herbs in individual bags within a labelled primary pack, and a small container of the medicine is also inside a labelled primary pack, are the labelling requirements the same for the individual herb bags and the small container?\", \"Answer\": \"No\", \"Answer Explanation\": \"Based on the two context paragraphs provided, the labelling requirements differ between the individual herb bags and the small container when each is inside a primary pack with a compliant label. The individual herb bags do not need to be labelled at all with the section 8 and 9 information, as stated in part (c) of the first paragraph. However, the small container label must display at minimum the medicine name and active ingredient name(s) in a 2mm or larger text size to sufficiently comply with sections 8, 9 and 10(1) if applicable, as described in the second paragraph.\"}]}",
    "misc_info":null
  },
  {
    "path":[
      905030000,
      901030000
    ],
    "contexts":[
      "and subsection 8(2) does not apply, then the names and the quantities or proportions of the active ingredients may be included on a side panel or side label or on a rear panel or rear label, when displayed in a text size of not less than 2.5 millimetres; or  (c) where the medicine contains four or more active ingredients and subsection 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) is not required; or  (d) if subsection 8(2) applies and the medicine: (i) includes one or more",
      "registered goods, and (i) subsection 8(2) does not apply, then the names, and quantities or proportions, of the active ingredients must be displayed on the side or rear panel or label in a text size of not less than 2.5 millimetres; or (ii) subsection 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) is not required.  (6) If the medicine is intended to be, or is, listed goods:  (a) if the medicine is a sunscreen preparation - the name of every active ingredient, together with"
    ],
    "result_dict":{
      "QuestionAnswers":[
        {
          "Question":"Assuming a non-prescription medicine contains 5 active ingredients and meets the conditions of subsection 8(2), what are the requirements for displaying the names and quantities\/proportions of the active ingredients on the label?",
          "Answer":"The medicine is not required to comply with paragraphs 9(1)(b) and 9(1)(c) for displaying names and quantities\/proportions of active ingredients.",
          "Answer Explanation":"According to 9(1)(c), if the medicine contains four or more active ingredients and subsection 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) is not required. Since the question states the medicine has 5 active ingredients and meets the conditions of 8(2), the specific labeling requirements in 9(1)(b) and 9(1)(c) do not apply."
        },
        {
          "Question":"For a non-prescription medicine that is registered goods, contains 3 active ingredients, and does not meet the conditions of subsection 8(2), what are the label display requirements for the names and quantities\/proportions of the active ingredients?",
          "Answer":"The names and quantities\/proportions of the active ingredients must be displayed on the side or rear panel or label in a text size of at least 2.5 millimeters.",
          "Answer Explanation":"9(1)(e)(i) states that for registered goods where subsection 8(2) does not apply, the names and quantities\/proportions of active ingredients must be displayed on the side or rear panel\/label with a minimum text size of 2.5 millimeters. The question specifies the medicine is registered goods with 3 active ingredients and does not meet 8(2) conditions, so this requirement applies."
        },
        {
          "Question":"Assuming a non-prescription medicine is listed goods and is a sunscreen preparation, what information about the active ingredients must be displayed on the label?",
          "Answer":"For a listed sunscreen preparation, the name of every active ingredient along with the quantity of each expressed as a percentage must be displayed on the label.",
          "Answer Explanation":"According to 9(6)(a), if the medicine is listed goods and is a sunscreen preparation, the label must display the name of every active ingredient together with the quantity of each expressed as a percentage. The question states these conditions, so this specific labeling requirement applies to the sunscreen preparation."
        },
        {
          "Question":"For a non-prescription medicine that is registered goods, contains 6 active ingredients, and meets the conditions of subsection 8(2), what options are available for displaying the names and quantities\/proportions of the active ingredients on the label?",
          "Answer":"The medicine has no required location or text size for displaying the active ingredient names and quantities\/proportions, as it is exempt from complying with paragraphs 9(1)(b) and 9(1)(c).",
          "Answer Explanation":"Based on 9(1)(c), a medicine with four or more active ingredients that meets subsection 8(2) conditions does not need to comply with 9(1)(b) and 9(1)(c) labeling requirements. Additionally, 9(1)(e)(ii) further specifies that registered goods meeting 8(2) conditions are exempt from 9(1)(b) and 9(1)(c). Since the medicine in question is registered goods with 6 active ingredients and meets 8(2), it has flexibility in how it displays that information on the label."
        }
      ]
    },
    "result_str":"{\"QuestionAnswers\": [\n  {\n    \"Question\": \"Assuming a non-prescription medicine contains 5 active ingredients and meets the conditions of subsection 8(2), what are the requirements for displaying the names and quantities\/proportions of the active ingredients on the label?\",\n    \"Answer\": \"The medicine is not required to comply with paragraphs 9(1)(b) and 9(1)(c) for displaying names and quantities\/proportions of active ingredients.\",\n    \"Answer Explanation\": \"According to 9(1)(c), if the medicine contains four or more active ingredients and subsection 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) is not required. Since the question states the medicine has 5 active ingredients and meets the conditions of 8(2), the specific labeling requirements in 9(1)(b) and 9(1)(c) do not apply.\"\n  },\n  {\n    \"Question\": \"For a non-prescription medicine that is registered goods, contains 3 active ingredients, and does not meet the conditions of subsection 8(2), what are the label display requirements for the names and quantities\/proportions of the active ingredients?\",\n    \"Answer\": \"The names and quantities\/proportions of the active ingredients must be displayed on the side or rear panel or label in a text size of at least 2.5 millimeters.\",\n    \"Answer Explanation\": \"9(1)(e)(i) states that for registered goods where subsection 8(2) does not apply, the names and quantities\/proportions of active ingredients must be displayed on the side or rear panel\/label with a minimum text size of 2.5 millimeters. The question specifies the medicine is registered goods with 3 active ingredients and does not meet 8(2) conditions, so this requirement applies.\"\n  },\n  {  \n    \"Question\": \"Assuming a non-prescription medicine is listed goods and is a sunscreen preparation, what information about the active ingredients must be displayed on the label?\",\n    \"Answer\": \"For a listed sunscreen preparation, the name of every active ingredient along with the quantity of each expressed as a percentage must be displayed on the label.\",\n    \"Answer Explanation\": \"According to 9(6)(a), if the medicine is listed goods and is a sunscreen preparation, the label must display the name of every active ingredient together with the quantity of each expressed as a percentage. The question states these conditions, so this specific labeling requirement applies to the sunscreen preparation.\"\n  },\n  {\n    \"Question\": \"For a non-prescription medicine that is registered goods, contains 6 active ingredients, and meets the conditions of subsection 8(2), what options are available for displaying the names and quantities\/proportions of the active ingredients on the label?\",    \n    \"Answer\": \"The medicine has no required location or text size for displaying the active ingredient names and quantities\/proportions, as it is exempt from complying with paragraphs 9(1)(b) and 9(1)(c).\",\n    \"Answer Explanation\": \"Based on 9(1)(c), a medicine with four or more active ingredients that meets subsection 8(2) conditions does not need to comply with 9(1)(b) and 9(1)(c) labeling requirements. Additionally, 9(1)(e)(ii) further specifies that registered goods meeting 8(2) conditions are exempt from 9(1)(b) and 9(1)(c). Since the medicine in question is registered goods with 6 active ingredients and meets 8(2), it has flexibility in how it displays that information on the label.\"\n  }\n]}",
    "misc_info":null
  },
  {
    "path":[
      1009010000,
      900000000
    ],
    "contexts":[
      "the strip, blister or dial dispenser pack is enclosed in a primary pack, the label of which complies with sections 8 and 9, then, in relation to compliance of the label on the strip, blister or dial dispenser pack with sections 8 and 9, it shall be sufficient if the following information is displayed: (iv) the name of the medicine; and (v) the name(s) of all active ingredients in the medicine; and (vi) the quantity or proportion of all active ingredients in the medicine; and (vii) the batch",
      "of the label on each individual wrapper or blister with sections 8 and 9, it shall be sufficient if the following information is displayed: (v) the name of the medicine; and (vi) the name(s) of all active ingredients in the medicine; and (vii) the quantity or proportion of all active ingredients in the medicine; and (viii) the batch number of the medicine preceded by the batch number prefix; and (ix) the expiry date of the medicine preceded by the expiry date prefix; and (x) the name of the"
    ],
    "result_dict":{
      "QuestionAnswers":[
        {
          "Question":"Assuming a non-prescription medicine is packaged in a strip, blister or dial dispenser pack that is enclosed in a primary pack with a label that complies with sections 8 and 9, what information must be displayed on the label of the strip, blister or dial dispenser pack itself to be compliant?",
          "Answer":"The name of the medicine, the name(s) of all active ingredients, the quantity or proportion of all active ingredients, and the batch number.",
          "Answer Explanation":"According to the first context provided, if a strip, blister or dial dispenser pack is enclosed in a primary pack with a compliant label, the label on the strip, blister or dial dispenser pack itself only needs to display the name of the medicine (iv), the name(s) of all active ingredients (v), the quantity or proportion of all active ingredients (vi), and the batch number (vii) to be considered compliant with sections 8 and 9."
        },
        {
          "Question":"Assuming a non-prescription medicine is packaged with individual wrappers or blisters, what information must be displayed on the label of each individual wrapper or blister to comply with sections 8 and 9?",
          "Answer":"The name of the medicine, the name(s) of all active ingredients, the quantity or proportion of all active ingredients, the batch number preceded by the batch number prefix, the expiry date preceded by the expiry date prefix, and the name of the sponsor.",
          "Answer Explanation":"Based on the second context provided, for a non-prescription medicine packaged with individual wrappers or blisters to have labels compliant with sections 8 and 9, each wrapper or blister must display the name of the medicine (v), the name(s) of all active ingredients (vi), the quantity or proportion of all active ingredients (vii), the batch number preceded by the batch number prefix (viii), the expiry date preceded by the expiry date prefix (ix), and the name of the sponsor (x)."
        },
        {
          "Question":"Comparing the labeling requirements for a strip, blister or dial dispenser pack enclosed in a primary pack versus individual wrappers or blisters, what additional information is required on the labels of individual wrappers or blisters?",
          "Answer":"In addition to the information required on the label of a strip, blister or dial dispenser pack enclosed in a primary pack, the labels on individual wrappers or blisters must also include the batch number prefix before the batch number, the expiry date prefix before the expiry date, and the name of the sponsor.",
          "Answer Explanation":"The first context specifies that a strip, blister or dial dispenser pack enclosed in a primary pack with a compliant label needs its own label to display the name of the medicine, active ingredients, quantities, and batch number. The second context adds that labels on individual wrappers or blisters must also have the batch number prefix before the batch number (viii), the expiry date prefix before the expiry date (ix), and the name of the sponsor (x)."
        },
        {
          "Question":"Assuming a non-prescription medicine is packaged in both a strip, blister or dial dispenser pack enclosed in a primary pack and individual wrappers or blisters, which packaging type requires more information to be displayed on its label for compliance with sections 8 and 9?",
          "Answer":"The individual wrappers or blisters require more information to be displayed on their labels compared to a strip, blister or dial dispenser pack enclosed in a primary pack. The individual wrappers or blisters must include the batch number prefix, expiry date prefix, and name of the sponsor in addition to the information required on the label of the enclosed pack.",
          "Answer Explanation":"Comparing the labeling requirements from the two provided contexts, a strip, blister or dial dispenser pack enclosed in a primary pack needs its label to display the name of the medicine (iv), active ingredients (v), quantities (vi), and batch number (vii). However, individual wrappers or blisters must also include the batch number prefix (viii), expiry date prefix (ix), and name of the sponsor (x) on their labels, in addition to the information required for the enclosed pack. Therefore, the individual wrappers or blisters require more information on their labels."
        }
      ]
    },
    "result_str":"{\"QuestionAnswers\": [{\"Question\": \"Assuming a non-prescription medicine is packaged in a strip, blister or dial dispenser pack that is enclosed in a primary pack with a label that complies with sections 8 and 9, what information must be displayed on the label of the strip, blister or dial dispenser pack itself to be compliant?\", \"Answer\": \"The name of the medicine, the name(s) of all active ingredients, the quantity or proportion of all active ingredients, and the batch number.\", \"Answer Explanation\": \"According to the first context provided, if a strip, blister or dial dispenser pack is enclosed in a primary pack with a compliant label, the label on the strip, blister or dial dispenser pack itself only needs to display the name of the medicine (iv), the name(s) of all active ingredients (v), the quantity or proportion of all active ingredients (vi), and the batch number (vii) to be considered compliant with sections 8 and 9.\"}, {\"Question\": \"Assuming a non-prescription medicine is packaged with individual wrappers or blisters, what information must be displayed on the label of each individual wrapper or blister to comply with sections 8 and 9?\", \"Answer\": \"The name of the medicine, the name(s) of all active ingredients, the quantity or proportion of all active ingredients, the batch number preceded by the batch number prefix, the expiry date preceded by the expiry date prefix, and the name of the sponsor.\", \"Answer Explanation\": \"Based on the second context provided, for a non-prescription medicine packaged with individual wrappers or blisters to have labels compliant with sections 8 and 9, each wrapper or blister must display the name of the medicine (v), the name(s) of all active ingredients (vi), the quantity or proportion of all active ingredients (vii), the batch number preceded by the batch number prefix (viii), the expiry date preceded by the expiry date prefix (ix), and the name of the sponsor (x).\"}, {\"Question\": \"Comparing the labeling requirements for a strip, blister or dial dispenser pack enclosed in a primary pack versus individual wrappers or blisters, what additional information is required on the labels of individual wrappers or blisters?\", \"Answer\": \"In addition to the information required on the label of a strip, blister or dial dispenser pack enclosed in a primary pack, the labels on individual wrappers or blisters must also include the batch number prefix before the batch number, the expiry date prefix before the expiry date, and the name of the sponsor.\", \"Answer Explanation\": \"The first context specifies that a strip, blister or dial dispenser pack enclosed in a primary pack with a compliant label needs its own label to display the name of the medicine, active ingredients, quantities, and batch number. The second context adds that labels on individual wrappers or blisters must also have the batch number prefix before the batch number (viii), the expiry date prefix before the expiry date (ix), and the name of the sponsor (x).\"}, {\"Question\": \"Assuming a non-prescription medicine is packaged in both a strip, blister or dial dispenser pack enclosed in a primary pack and individual wrappers or blisters, which packaging type requires more information to be displayed on its label for compliance with sections 8 and 9?\", \"Answer\": \"The individual wrappers or blisters require more information to be displayed on their labels compared to a strip, blister or dial dispenser pack enclosed in a primary pack. The individual wrappers or blisters must include the batch number prefix, expiry date prefix, and name of the sponsor in addition to the information required on the label of the enclosed pack.\", \"Answer Explanation\": \"Comparing the labeling requirements from the two provided contexts, a strip, blister or dial dispenser pack enclosed in a primary pack needs its label to display the name of the medicine (iv), active ingredients (v), quantities (vi), and batch number (vii). However, individual wrappers or blisters must also include the batch number prefix (viii), expiry date prefix (ix), and name of the sponsor (x) on their labels, in addition to the information required for the enclosed pack. Therefore, the individual wrappers or blisters require more information on their labels.\"}]}",
    "misc_info":null
  },
  {
    "path":[
      1001000000,
      1007000000
    ],
    "contexts":[
      "released for supply on or after 1 May 2028.  10 Qualifications and special requirements  (1) Preparations for ophthalmic use In addition to the requirements of sections 8 and 9 above, if a medicine is a preparation for ophthalmic use, the label on the container and on the primary pack or, where subsection 10(7) applies, the primary pack, must include:  (a) the name of any antimicrobial preservative in the medicine;  (b) if the medicine, other than an ophthalmic ointment, does not contain an",
      "is enclosed in a small container; and  (b) the container is enclosed in a primary pack, the label of which complies with sections 8 and 9 and subsection 10(1) (if applicable), then, in relation to compliance of the label on the container with sections 8 and 9 and subsection 10(1) (if applicable), it shall be sufficient if the following information is displayed in a text size of not less than 2 millimetres:  (c) the name of the medicine; and  (d) the name(s) of all active ingredients in the"
    ],
    "result_dict":{

    },
    "result_str":"Here is the output as a JSON object conforming to the specified schema:\n\n{\n  \"QuestionAnswers\": [\n    {\n      \"Question\": \"Assuming an ophthalmic ointment medicine is being supplied in a small container enclosed in a primary pack after May 1, 2028, what information must be included on the labels of the container and primary pack to comply with the regulations?\",\n      \"Answer\": \"The small container label must include, in text at least 2mm in size, the medicine name and active ingredient name(s). The primary pack label must fully comply with sections 8, 9, and 10(1) including the antimicrobial preservative name if applicable.\",\n      \"Answer Explanation\": \"Section 10(7) allows a small container label to just have medicine and active ingredient names in 2mm text if enclosed in a fully compliant primary pack. Sections 8-9 list general labelling requirements. Section 10(1) additionally requires ophthalmic preparations to list any antimicrobial preservatives on the primary pack label.\"\n    },\n    {\n      \"Question\": \"For an ophthalmic medicine supplied after May 1, 2028 that does not contain an antimicrobial preservative, what statement must be included on the container and primary pack labels, assuming all label space requirements can be met?\",\n      \"Answer\": \"If an ophthalmic medicine other than an ophthalmic ointment does not contain an antimicrobial preservative, the labels on the container and primary pack must state \"no antimicrobial preservative\", per section 10(1)(b).\",\n      \"Answer Explanation\": \"Section 1 states the regulations apply to medicines supplied on or after May 1, 2028. Section 10(1)(b) requires ophthalmic medicines other than ointments to state \"no antimicrobial preservative\" on container and primary pack labels if they do not contain one, in addition to the general label requirements in sections 8-9 that apply to all labels.\"\n    },\n    {\n      \"Question\": \"Assuming an ophthalmic ointment medicine containing the antimicrobial preservative benzalkonium chloride is supplied in a 5g tube after May 1, 2028, what information must be included on the tube label to comply with the regulations?\",\n      \"Answer\": \"The 5g ophthalmic ointment tube label must comply with the general label requirements in sections 8-9 and also state the name of the antimicrobial preservative benzalkonium chloride per section 10(1)(a). The \"no antimicrobial preservative\" statement in 10(1)(b) does not apply to ophthalmic ointments.\",\n      \"Answer Explanation\": \"Section 1 sets the May 1, 2028 applicability date. Sections 8-9 list general label requirements for all medicines. Section 10(1)(a) additionally requires ophthalmic preparations to name any antimicrobial preservatives on the container label. The 5g tube is large enough to fit this full labelling without needing the small container exemption in 10(7).\"\n    },\n    {\n      \"Question\": \"For an ophthalmic ointment medicine without an antimicrobial preservative supplied in a 2g tube enclosed in a primary pack after May 1, 2028, what information must be on the tube and primary pack labels to meet regulatory requirements, assuming label space is limited?\",\n      \"Answer\": \"The 2g tube label must state the medicine name and active ingredient name(s) in minimum 2mm text size per the small container exemption in section 10(7). The primary pack label must meet the general requirements in sections 8-9. Neither label has to state \"no antimicrobial preservative\" since section 10(1)(b) excludes ophthalmic ointments from this requirement.\",\n      \"Answer Explanation\": \"Section 1 sets the applicability date. The small 2g tube qualifies for the labelling exemption in 10(7) allowing just medicine and active ingredient names in 2mm text if in a fully labelled primary pack. Sections 8-9 define general primary pack labelling. The antimicrobial preservative statements in 10(1) are not required since 10(1)(a) only applies if a preservative is present and 10(1)(b) excludes ointments.\"\n    }\n  ]\n}",
    "misc_info":null
  },
  {
    "path":[
      905030000,
      802000000
    ],
    "contexts":[
      "and subsection 8(2) does not apply, then the names and the quantities or proportions of the active ingredients may be included on a side panel or side label or on a rear panel or rear label, when displayed in a text size of not less than 2.5 millimetres; or  (c) where the medicine contains four or more active ingredients and subsection 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) is not required; or  (d) if subsection 8(2) applies and the medicine: (i) includes one or more",
      "registered goods, and (i) subsection 8(2) does not apply, then the names, and quantities or proportions, of the active ingredients must be displayed on the side or rear panel or label in a text size of not less than 2.5 millimetres; or (ii) subsection 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) is not required.  (6) If the medicine is intended to be, or is, listed goods:  (a) if the medicine is a sunscreen preparation - the name of every active ingredient, together with"
    ],
    "result_dict":{
      "QuestionAnswers":[
        {
          "Question":"Assuming a non-prescription medicine contains 6 active ingredients and subsection 8(2) applies, are the names and quantities of the active ingredients required to be displayed on the side, rear panel or label in a minimum 2.5mm text size?",
          "Answer":"No",
          "Answer Explanation":"According to paragraph 9(1)(c), if the medicine contains four or more active ingredients and subsection 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) is not required. Paragraph 9(1)(b) requires displaying the names and quantities of active ingredients on the side or rear panel in minimum 2.5mm text when subsection 8(2) does not apply."
        },
        {
          "Question":"For a medicine that is registered goods containing 3 active ingredients, assuming subsection 8(2) does not apply, where must the names and quantities of the active ingredients be displayed and in what minimum text size?",
          "Answer":"The names and quantities or proportions of the active ingredients must be displayed on the side or rear panel or label in a text size of not less than 2.5 millimetres.",
          "Answer Explanation":"According to paragraph 9(5)(b)(i), for registered goods where the medicine contains less than four active ingredients and subsection 8(2) does not apply, the names and quantities or proportions of the active ingredients must be displayed on the side or rear panel or label in a text size of not less than 2.5 millimetres."
        },
        {
          "Question":"Assuming a medicine is listed goods and is a sunscreen preparation, what information about the active ingredients must be displayed?",
          "Answer":"The name of every active ingredient, together with its quantity or proportion, must be displayed for a medicine that is listed goods and is a sunscreen preparation.",
          "Answer Explanation":"Paragraph 9(6)(a) states that if the medicine is intended to be, or is, listed goods, and if the medicine is a sunscreen preparation, the name of every active ingredient, together with its quantity or proportion, must be displayed."
        },
        {
          "Question":"For a medicine that is registered goods containing 5 active ingredients, assuming subsection 8(2) applies, is it required to comply with paragraphs 9(1)(b) and 9(1)(c)?",
          "Answer":"No",
          "Answer Explanation":"According to paragraph 9(5)(b)(ii), for registered goods where the medicine contains four or more active ingredients and subsection 8(2) applies, compliance with paragraphs 9(1)(b) and 9(1)(c) is not required."
        }
      ]
    },
    "result_str":"{\n  \"QuestionAnswers\": [\n    {\n      \"Question\": \"Assuming a non-prescription medicine contains 6 active ingredients and subsection 8(2) applies, are the names and quantities of the active ingredients required to be displayed on the side, rear panel or label in a minimum 2.5mm text size?\",\n      \"Answer\": \"No\",\n      \"Answer Explanation\": \"According to paragraph 9(1)(c), if the medicine contains four or more active ingredients and subsection 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) is not required. Paragraph 9(1)(b) requires displaying the names and quantities of active ingredients on the side or rear panel in minimum 2.5mm text when subsection 8(2) does not apply.\"\n    },\n    {\n      \"Question\": \"For a medicine that is registered goods containing 3 active ingredients, assuming subsection 8(2) does not apply, where must the names and quantities of the active ingredients be displayed and in what minimum text size?\",\n      \"Answer\": \"The names and quantities or proportions of the active ingredients must be displayed on the side or rear panel or label in a text size of not less than 2.5 millimetres.\",\n      \"Answer Explanation\": \"According to paragraph 9(5)(b)(i), for registered goods where the medicine contains less than four active ingredients and subsection 8(2) does not apply, the names and quantities or proportions of the active ingredients must be displayed on the side or rear panel or label in a text size of not less than 2.5 millimetres.\"\n    },\n    {\n      \"Question\": \"Assuming a medicine is listed goods and is a sunscreen preparation, what information about the active ingredients must be displayed?\",\n      \"Answer\": \"The name of every active ingredient, together with its quantity or proportion, must be displayed for a medicine that is listed goods and is a sunscreen preparation.\",\n      \"Answer Explanation\": \"Paragraph 9(6)(a) states that if the medicine is intended to be, or is, listed goods, and if the medicine is a sunscreen preparation, the name of every active ingredient, together with its quantity or proportion, must be displayed.\"\n    },\n    {\n      \"Question\": \"For a medicine that is registered goods containing 5 active ingredients, assuming subsection 8(2) applies, is it required to comply with paragraphs 9(1)(b) and 9(1)(c)?\",\n      \"Answer\": \"No\",\n      \"Answer Explanation\": \"According to paragraph 9(5)(b)(ii), for registered goods where the medicine contains four or more active ingredients and subsection 8(2) applies, compliance with paragraphs 9(1)(b) and 9(1)(c) is not required.\"\n    }\n  ]\n}",
    "misc_info":null
  },
  {
    "path":[
      907030000,
      901020000
    ],
    "contexts":[
      "and subsection 8(2) does not apply, then the names and the quantities or proportions of the active ingredients may be included on a side panel or side label or on a rear panel or rear label, when displayed in a text size of not less than 2.5 millimetres; or  (c) where the medicine contains four or more active ingredients and subsection 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) is not required; or  (d) if subsection 8(2) applies and the medicine: (i) includes one or more",
      "(d) the name(s) of all active ingredients in the medicine, unless there are four or more active ingredients; and the following information is displayed in a text size of not less than 1.5 millimetres:  (e) where there are four or more active ingredients, the names of the active ingredients; and  (f) the quantity or proportion of all active ingredients in the medicine; and  (g) the name of the dosage form; and  (h) the quantity of the medicine in the container; and  (i) the batch number of the"
    ],
    "result_dict":{
      "QuestionAnswers":[
        {
          "Question":"Assuming a medicine contains 5 active ingredients and subsection 8(2) does not apply, what is the minimum text size required to include the names and quantities of the active ingredients on a side panel or rear label?",
          "Answer":"2.5 millimetres",
          "Answer Explanation":"According to section 9(1)(b), if a medicine contains four or more active ingredients and subsection 8(2) does not apply, the names and quantities or proportions of the active ingredients may be included on a side panel, side label, rear panel or rear label, when displayed in a text size of not less than 2.5 millimetres."
        },
        {
          "Question":"Assuming subsection 8(2) applies to a medicine with 4 or more active ingredients, is compliance with paragraphs 9(1)(b) and 9(1)(c) required?",
          "Answer":"No",
          "Answer Explanation":"Section 9(1)(c) states that if a medicine contains four or more active ingredients and subsection 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) is not required."
        },
        {
          "Question":"What is the minimum text size required to display the batch number of a medicine on the label, assuming there are less than 4 active ingredients?",
          "Answer":"1.5 millimetres",
          "Answer Explanation":"Section 9(1)(i) specifies that the batch number of the medicine must be displayed in a text size of not less than 1.5 millimetres, in conjunction with sections 9(1)(d) through 9(1)(h) which apply when there are less than four active ingredients."
        },
        {
          "Question":"If a medicine has 4 or more active ingredients, and subsection 8(2) does not apply, can the names and quantities of the ingredients be omitted from the main label if they are included on a side or rear label in text at least 2.5mm in size?",
          "Answer":"Yes",
          "Answer Explanation":"Paragraph 9(1)(b) allows the names and quantities\/proportions of active ingredients to be on a side or rear label in at least 2.5mm text if there are 4+ ingredients and subsection 8(2) doesn't apply. Paragraph 9(1)(e) only requires ingredient names on the main label when there are 4+ ingredients, so quantities can be omitted from the main label in this case."
        }
      ]
    },
    "result_str":"{\"QuestionAnswers\": [\n  {\n    \"Question\": \"Assuming a medicine contains 5 active ingredients and subsection 8(2) does not apply, what is the minimum text size required to include the names and quantities of the active ingredients on a side panel or rear label?\",\n    \"Answer\": \"2.5 millimetres\",\n    \"Answer Explanation\": \"According to section 9(1)(b), if a medicine contains four or more active ingredients and subsection 8(2) does not apply, the names and quantities or proportions of the active ingredients may be included on a side panel, side label, rear panel or rear label, when displayed in a text size of not less than 2.5 millimetres.\"\n  },\n  {\n    \"Question\": \"Assuming subsection 8(2) applies to a medicine with 4 or more active ingredients, is compliance with paragraphs 9(1)(b) and 9(1)(c) required?\",\n    \"Answer\": \"No\",\n    \"Answer Explanation\": \"Section 9(1)(c) states that if a medicine contains four or more active ingredients and subsection 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) is not required.\"\n  },\n  {\n    \"Question\": \"What is the minimum text size required to display the batch number of a medicine on the label, assuming there are less than 4 active ingredients?\",\n    \"Answer\": \"1.5 millimetres\",\n    \"Answer Explanation\": \"Section 9(1)(i) specifies that the batch number of the medicine must be displayed in a text size of not less than 1.5 millimetres, in conjunction with sections 9(1)(d) through 9(1)(h) which apply when there are less than four active ingredients.\"\n  },\n  {\n    \"Question\": \"If a medicine has 4 or more active ingredients, and subsection 8(2) does not apply, can the names and quantities of the ingredients be omitted from the main label if they are included on a side or rear label in text at least 2.5mm in size?\",\n    \"Answer\": \"Yes\",\n    \"Answer Explanation\": \"Paragraph 9(1)(b) allows the names and quantities\/proportions of active ingredients to be on a side or rear label in at least 2.5mm text if there are 4+ ingredients and subsection 8(2) doesn't apply. Paragraph 9(1)(e) only requires ingredient names on the main label when there are 4+ ingredients, so quantities can be omitted from the main label in this case.\"\n  }\n]}",
    "misc_info":null
  },
  {
    "path":[
      1007000000,
      1001000000
    ],
    "contexts":[
      "released for supply on or after 1 May 2028.  10 Qualifications and special requirements  (1) Preparations for ophthalmic use In addition to the requirements of sections 8 and 9 above, if a medicine is a preparation for ophthalmic use, the label on the container and on the primary pack or, where subsection 10(7) applies, the primary pack, must include:  (a) the name of any antimicrobial preservative in the medicine;  (b) if the medicine, other than an ophthalmic ointment, does not contain an",
      "is enclosed in a small container; and  (b) the container is enclosed in a primary pack, the label of which complies with sections 8 and 9 and subsection 10(1) (if applicable), then, in relation to compliance of the label on the container with sections 8 and 9 and subsection 10(1) (if applicable), it shall be sufficient if the following information is displayed in a text size of not less than 2 millimetres:  (c) the name of the medicine; and  (d) the name(s) of all active ingredients in the"
    ],
    "result_dict":{
      "QuestionAnswers":[
        {
          "Question":"Assuming a medicine is a preparation for ophthalmic use and is enclosed in a small container within a primary pack, what information must be displayed on the label of the small container in a text size of at least 2 millimetres?",
          "Answer":"The name of the medicine and the name(s) of all active ingredients in the medicine.",
          "Answer Explanation":"Section 10(7) states that if a medicine is enclosed in a small container and that container is enclosed in a primary pack with a label complying with sections 8, 9 and 10(1) if applicable, then the label on the small container only needs to display the name of the medicine and the name(s) of all active ingredients in a text size of at least 2 millimetres to be considered compliant."
        },
        {
          "Question":"For preparations for ophthalmic use released for supply on or after 1 May 2028, what additional information must be included on the label of the container and primary pack compared to the general labelling requirements in sections 8 and 9?",
          "Answer":"The label must include the name of any antimicrobial preservative in the medicine. If the medicine, other than an ophthalmic ointment, does not contain an antimicrobial preservative, the label must state that there is no antimicrobial preservative.",
          "Answer Explanation":"Section 10(1) specifies that in addition to the general labelling requirements in sections 8 and 9, preparations for ophthalmic use must have labels that include the name of any antimicrobial preservative. If there is no antimicrobial preservative and it is not an ointment, the label must state this fact."
        },
        {
          "Question":"Assuming an ophthalmic medicine is released for supply after the 1 May 2028 date mentioned in the regulation and it is enclosed in a small container within a primary pack, what information must the primary pack label contain?",
          "Answer":"The primary pack label must comply with the general labelling requirements in sections 8 and 9. It must also state the name of any antimicrobial preservative in the medicine, or state that there is no antimicrobial preservative if none is present and it is not an ophthalmic ointment, as per section 10(1).",
          "Answer Explanation":"Section 10(7) allows the small container label to only state medicine and active ingredient names in 2mm text if enclosed in a primary pack. However, section 10(1) still requires the primary pack label to meet sections 8 and 9 as well as stating antimicrobial preservative information for ophthalmic preparations supplied after 1 May 2028."
        },
        {
          "Question":"Assuming an ophthalmic ointment is released for supply after 1 May 2028 and does not contain an antimicrobial preservative, what statement regarding the lack of preservative must be included on the label of the container and primary pack?",
          "Answer":"No statement about the lack of an antimicrobial preservative is required on the label for an ophthalmic ointment.",
          "Answer Explanation":"Section 10(1)(b) only requires a statement that there is no antimicrobial preservative for ophthalmic medicines other than ointments. Since this medicine is specified to be an ophthalmic ointment, this requirement does not apply, even though it is supplied after 1 May 2028 and lacks a preservative."
        }
      ]
    },
    "result_str":"{\"QuestionAnswers\": [{\"Question\": \"Assuming a medicine is a preparation for ophthalmic use and is enclosed in a small container within a primary pack, what information must be displayed on the label of the small container in a text size of at least 2 millimetres?\", \"Answer\": \"The name of the medicine and the name(s) of all active ingredients in the medicine.\", \"Answer Explanation\": \"Section 10(7) states that if a medicine is enclosed in a small container and that container is enclosed in a primary pack with a label complying with sections 8, 9 and 10(1) if applicable, then the label on the small container only needs to display the name of the medicine and the name(s) of all active ingredients in a text size of at least 2 millimetres to be considered compliant.\"}, {\"Question\": \"For preparations for ophthalmic use released for supply on or after 1 May 2028, what additional information must be included on the label of the container and primary pack compared to the general labelling requirements in sections 8 and 9?\", \"Answer\": \"The label must include the name of any antimicrobial preservative in the medicine. If the medicine, other than an ophthalmic ointment, does not contain an antimicrobial preservative, the label must state that there is no antimicrobial preservative.\", \"Answer Explanation\": \"Section 10(1) specifies that in addition to the general labelling requirements in sections 8 and 9, preparations for ophthalmic use must have labels that include the name of any antimicrobial preservative. If there is no antimicrobial preservative and it is not an ointment, the label must state this fact.\"}, {\"Question\": \"Assuming an ophthalmic medicine is released for supply after the 1 May 2028 date mentioned in the regulation and it is enclosed in a small container within a primary pack, what information must the primary pack label contain?\", \"Answer\": \"The primary pack label must comply with the general labelling requirements in sections 8 and 9. It must also state the name of any antimicrobial preservative in the medicine, or state that there is no antimicrobial preservative if none is present and it is not an ophthalmic ointment, as per section 10(1).\", \"Answer Explanation\": \"Section 10(7) allows the small container label to only state medicine and active ingredient names in 2mm text if enclosed in a primary pack. However, section 10(1) still requires the primary pack label to meet sections 8 and 9 as well as stating antimicrobial preservative information for ophthalmic preparations supplied after 1 May 2028.\"}, {\"Question\": \"Assuming an ophthalmic ointment is released for supply after 1 May 2028 and does not contain an antimicrobial preservative, what statement regarding the lack of preservative must be included on the label of the container and primary pack?\", \"Answer\": \"No statement about the lack of an antimicrobial preservative is required on the label for an ophthalmic ointment.\", \"Answer Explanation\": \"Section 10(1)(b) only requires a statement that there is no antimicrobial preservative for ophthalmic medicines other than ointments. Since this medicine is specified to be an ophthalmic ointment, this requirement does not apply, even though it is supplied after 1 May 2028 and lacks a preservative.\"}]}",
    "misc_info":null
  },
  {
    "path":[
      1009010000,
      800000000
    ],
    "contexts":[
      "the strip, blister or dial dispenser pack is enclosed in a primary pack, the label of which complies with sections 8 and 9, then, in relation to compliance of the label on the strip, blister or dial dispenser pack with sections 8 and 9, it shall be sufficient if the following information is displayed: (iv) the name of the medicine; and (v) the name(s) of all active ingredients in the medicine; and (vi) the quantity or proportion of all active ingredients in the medicine; and (vii) the batch",
      "and the medicine is intended to be, or is, registered goods; or (ii) two or more active ingredients in the medicine and the medicine is intended to be, or is, listed goods, then, in relation to compliance of the label on the strip, blister or dial dispenser pack with sections 8 and 9, it shall be sufficient if the following information is displayed: (iii) the name of the medicine; and (iv) the batch number of the medicine preceded by the batch number prefix; and (v) the expiry date of the"
    ],
    "result_dict":{
      "QuestionAnswers":[
        {
          "Question":"Assuming a non-prescription medicine is a registered good containing a single active ingredient and is packaged in a blister pack enclosed in a primary pack, what information must be displayed on the label of the blister pack to comply with the relevant regulations?",
          "Answer":"The name of the medicine, the name of the active ingredient, the quantity or proportion of the active ingredient, and the batch number.",
          "Answer Explanation":"For a registered non-prescription medicine with a single active ingredient in a blister pack enclosed in a primary pack, the blister pack label must display the name of the medicine (section iv), the name of the active ingredient (section v), the quantity or proportion of the active ingredient (section vi), and the batch number (section vii) to comply with sections 8 and 9 of the regulations, provided the primary pack label fully complies with those sections."
        },
        {
          "Question":"Consider a listed non-prescription medicine with multiple active ingredients that is packaged in a strip pack enclosed in a primary pack. Assuming the primary pack label is fully compliant, what are the minimum labeling requirements for the strip pack to meet the relevant regulations?",
          "Answer":"The minimum labeling requirements for the strip pack are the name of the medicine, the batch number of the medicine preceded by the batch number prefix, and the expiry date of the medicine.",
          "Answer Explanation":"For a listed non-prescription medicine with multiple active ingredients in a strip pack enclosed in a compliant primary pack, section (ii) states that the strip pack label must display, at minimum, the name of the medicine (section iii), the batch number preceded by the batch number prefix (section iv), and the expiry date of the medicine (section v) to comply with sections 8 and 9 of the regulations."
        },
        {
          "Question":"Suppose a registered non-prescription medicine with two active ingredients is packaged in a dial dispenser pack that is not enclosed in a primary pack. What information must be on the label of the dial dispenser pack to fully comply with the relevant regulations?",
          "Answer":"The dial dispenser pack label must include all information required by sections 8 and 9 of the regulations, as it is not enclosed in a primary pack with a compliant label.",
          "Answer Explanation":"The provided context only specifies reduced labeling requirements for strip, blister or dial dispenser packs of non-prescription medicines when they are enclosed in a primary pack with a fully compliant label. Since the dial dispenser pack in this scenario is not enclosed in a primary pack, its label must fully comply with all requirements of sections 8 and 9 of the regulations."
        },
        {
          "Question":"For a listed non-prescription medicine with one active ingredient in a blister pack that is enclosed in a primary pack, is it necessary for the blister pack label to include the name and proportion of the active ingredient if the primary pack label is fully compliant with the relevant regulations?",
          "Answer":"No, it is not necessary for the blister pack label to include the name and proportion of the active ingredient in this scenario.",
          "Answer Explanation":"Section (i) states that for a listed non-prescription medicine with a single active ingredient in a blister pack enclosed in a primary pack with a fully compliant label, the blister pack label need only display the name of the medicine (section iv), the name of the active ingredient (section v), the quantity or proportion of the active ingredient (section vi), and the batch number (section vii) to comply with sections 8 and 9. The name and proportion of the active ingredient are not required on the blister pack label in this case."
        }
      ]
    },
    "result_str":"{\"QuestionAnswers\": [{\"Question\": \"Assuming a non-prescription medicine is a registered good containing a single active ingredient and is packaged in a blister pack enclosed in a primary pack, what information must be displayed on the label of the blister pack to comply with the relevant regulations?\", \"Answer\": \"The name of the medicine, the name of the active ingredient, the quantity or proportion of the active ingredient, and the batch number.\", \"Answer Explanation\": \"For a registered non-prescription medicine with a single active ingredient in a blister pack enclosed in a primary pack, the blister pack label must display the name of the medicine (section iv), the name of the active ingredient (section v), the quantity or proportion of the active ingredient (section vi), and the batch number (section vii) to comply with sections 8 and 9 of the regulations, provided the primary pack label fully complies with those sections.\"}, {\"Question\": \"Consider a listed non-prescription medicine with multiple active ingredients that is packaged in a strip pack enclosed in a primary pack. Assuming the primary pack label is fully compliant, what are the minimum labeling requirements for the strip pack to meet the relevant regulations?\", \"Answer\": \"The minimum labeling requirements for the strip pack are the name of the medicine, the batch number of the medicine preceded by the batch number prefix, and the expiry date of the medicine.\", \"Answer Explanation\": \"For a listed non-prescription medicine with multiple active ingredients in a strip pack enclosed in a compliant primary pack, section (ii) states that the strip pack label must display, at minimum, the name of the medicine (section iii), the batch number preceded by the batch number prefix (section iv), and the expiry date of the medicine (section v) to comply with sections 8 and 9 of the regulations.\"}, {\"Question\": \"Suppose a registered non-prescription medicine with two active ingredients is packaged in a dial dispenser pack that is not enclosed in a primary pack. What information must be on the label of the dial dispenser pack to fully comply with the relevant regulations?\", \"Answer\": \"The dial dispenser pack label must include all information required by sections 8 and 9 of the regulations, as it is not enclosed in a primary pack with a compliant label.\", \"Answer Explanation\": \"The provided context only specifies reduced labeling requirements for strip, blister or dial dispenser packs of non-prescription medicines when they are enclosed in a primary pack with a fully compliant label. Since the dial dispenser pack in this scenario is not enclosed in a primary pack, its label must fully comply with all requirements of sections 8 and 9 of the regulations.\"}, {\"Question\": \"For a listed non-prescription medicine with one active ingredient in a blister pack that is enclosed in a primary pack, is it necessary for the blister pack label to include the name and proportion of the active ingredient if the primary pack label is fully compliant with the relevant regulations?\", \"Answer\": \"No, it is not necessary for the blister pack label to include the name and proportion of the active ingredient in this scenario.\", \"Answer Explanation\": \"Section (i) states that for a listed non-prescription medicine with a single active ingredient in a blister pack enclosed in a primary pack with a fully compliant label, the blister pack label need only display the name of the medicine (section iv), the name of the active ingredient (section v), the quantity or proportion of the active ingredient (section vi), and the batch number (section vii) to comply with sections 8 and 9. The name and proportion of the active ingredient are not required on the blister pack label in this case.\"}]}",
    "misc_info":null
  },
  {
    "path":[
      910020000,
      911000000
    ],
    "contexts":[
      "2026; or  (c) where the medicine is not supplied in a small container and is labelled in accordance with subsection 9(13) and Part 2 of Schedule 2\u2014after 30 April 2028. Note: The minimum text size for active ingredients on labels of small containers is less than 2.5 millimetres and specified elsewhere in this Order.  (11) An active ingredient specified in Part 1 of Schedule 2, either alone or in combination with any other descriptors, may be included on the main label of a medicine containing",
      "on the main label of a medicine containing that ingredient as specified in that Part for medicine released for supply before 1 May 2026.  (12) To avoid doubt, an active ingredient specified in Part 1 of Schedule 2 must be included on the main label of a medicine containing that ingredient in accordance with the Australian Approved Names List for medicine released for supply on or after 1 May 2026.  (13) An active ingredient specified in Part 2 of Schedule 2, either alone or in combination with"
    ],
    "result_dict":{
      "QuestionAnswers":[
        {
          "Question":"Assuming a medicine is not supplied in a small container and is labelled in accordance with subsection 9(13) and Part 2 of Schedule 2, what is the latest date the minimum text size requirements for active ingredients on the label must be met?",
          "Answer":"30 April 2028",
          "Answer Explanation":"According to subsection 9(10)(c), for a medicine not supplied in a small container and labelled in accordance with subsection 9(13) and Part 2 of Schedule 2, the minimum text size requirements for active ingredients on the label must be met after 30 April 2028."
        },
        {
          "Question":"Assuming a medicine containing an active ingredient specified in Part 1 of Schedule 2 is released for supply before 1 May 2026, what naming conventions may be used for that active ingredient on the main label?",
          "Answer":"The active ingredient may be included on the main label either alone or in combination with any other descriptors, as specified in Part 1 of Schedule 2.",
          "Answer Explanation":"Subsection 9(11) states that for medicine released for supply before 1 May 2026, an active ingredient specified in Part 1 of Schedule 2 may be included on the main label either alone or in combination with any other descriptors, as specified in that Part."
        },
        {
          "Question":"Assuming a medicine containing an active ingredient specified in Part 1 of Schedule 2 is released for supply on or after 1 May 2026, how must that active ingredient be included on the main label?",
          "Answer":"The active ingredient must be included on the main label in accordance with the Australian Approved Names List.",
          "Answer Explanation":"Subsection 9(12) clarifies that for medicine released for supply on or after 1 May 2026, an active ingredient specified in Part 1 of Schedule 2 must be included on the main label in accordance with the Australian Approved Names List, to avoid doubt."
        },
        {
          "Question":"Assuming a medicine contains an active ingredient specified in Part 2 of Schedule 2, what naming conventions may be used for that active ingredient on the main label?",
          "Answer":"The active ingredient may be included on the main label either alone or in combination with any other descriptors.",
          "Answer Explanation":"According to subsection 9(13), an active ingredient specified in Part 2 of Schedule 2 may be included on the main label either alone or in combination with any other descriptors. The provided context does not specify any restrictions based on the medicine's release date for Part 2 ingredients."
        }
      ]
    },
    "result_str":"{\"QuestionAnswers\": [{\"Question\": \"Assuming a medicine is not supplied in a small container and is labelled in accordance with subsection 9(13) and Part 2 of Schedule 2, what is the latest date the minimum text size requirements for active ingredients on the label must be met?\", \"Answer\": \"30 April 2028\", \"Answer Explanation\": \"According to subsection 9(10)(c), for a medicine not supplied in a small container and labelled in accordance with subsection 9(13) and Part 2 of Schedule 2, the minimum text size requirements for active ingredients on the label must be met after 30 April 2028.\"}, {\"Question\": \"Assuming a medicine containing an active ingredient specified in Part 1 of Schedule 2 is released for supply before 1 May 2026, what naming conventions may be used for that active ingredient on the main label?\", \"Answer\": \"The active ingredient may be included on the main label either alone or in combination with any other descriptors, as specified in Part 1 of Schedule 2.\", \"Answer Explanation\": \"Subsection 9(11) states that for medicine released for supply before 1 May 2026, an active ingredient specified in Part 1 of Schedule 2 may be included on the main label either alone or in combination with any other descriptors, as specified in that Part.\"}, {\"Question\": \"Assuming a medicine containing an active ingredient specified in Part 1 of Schedule 2 is released for supply on or after 1 May 2026, how must that active ingredient be included on the main label?\", \"Answer\": \"The active ingredient must be included on the main label in accordance with the Australian Approved Names List.\", \"Answer Explanation\": \"Subsection 9(12) clarifies that for medicine released for supply on or after 1 May 2026, an active ingredient specified in Part 1 of Schedule 2 must be included on the main label in accordance with the Australian Approved Names List, to avoid doubt.\"}, {\"Question\": \"Assuming a medicine contains an active ingredient specified in Part 2 of Schedule 2, what naming conventions may be used for that active ingredient on the main label?\", \"Answer\": \"The active ingredient may be included on the main label either alone or in combination with any other descriptors.\", \"Answer Explanation\": \"According to subsection 9(13), an active ingredient specified in Part 2 of Schedule 2 may be included on the main label either alone or in combination with any other descriptors. The provided context does not specify any restrictions based on the medicine's release date for Part 2 ingredients.\"}]}",
    "misc_info":null
  },
  {
    "path":[
      907030000,
      802000000
    ],
    "contexts":[
      "and subsection 8(2) does not apply, then the names and the quantities or proportions of the active ingredients may be included on a side panel or side label or on a rear panel or rear label, when displayed in a text size of not less than 2.5 millimetres; or  (c) where the medicine contains four or more active ingredients and subsection 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) is not required; or  (d) if subsection 8(2) applies and the medicine: (i) includes one or more",
      "of the medicine; and  (b) not be separated by any text or graphics, except where additional information is: (i) required or permitted by: (A) paragraph 11(2)(h); or (B) subparagraphs 11(2)(i)(i) or 11(2)(i)(ii)(A); or (C) subsection 11(5); or (ii) in relation to identifying the different formulations of the medicines contained in a composite pack or a medicine kit;  (c) if the medicine is: (i) supplied in either a small or a medium container; and (ii) contains multiple active ingredients then,"
    ],
    "result_dict":{
      "QuestionAnswers":[
        {
          "Question":"Assuming a non-prescription medicine is supplied in a medium container and contains 5 active ingredients, what are the requirements for the placement and text size of the names and quantities or proportions of the active ingredients according to the given regulation sections?",
          "Answer":"The names and quantities or proportions of the active ingredients may be included on a side panel, side label, rear panel, or rear label, with a text size of at least 2.5 millimetres.",
          "Answer Explanation":"According to section 9(1)(b), if the medicine contains four or more active ingredients and subsection 8(2) applies, compliance with paragraphs 9(1)(b) and 9(1)(c) is not required. Since the medicine contains 5 active ingredients, subsection 8(2) does not apply. Therefore, as per section 9(1)(a), the names and quantities or proportions of the active ingredients may be included on a side panel, side label, rear panel, or rear label, with a text size of at least 2.5 millimetres."
        },
        {
          "Question":"Assuming a non-prescription medicine is supplied in a small container and contains multiple active ingredients, what are the requirements for the placement of the names and quantities or proportions of the active ingredients according to the given regulation sections?",
          "Answer":"The requirements for the placement of the names and quantities or proportions of the active ingredients are not specified in the given regulation sections for a medicine supplied in a small container with multiple active ingredients.",
          "Answer Explanation":"Section 9(1)(c) states that if the medicine is supplied in either a small or a medium container and contains multiple active ingredients, then the regulation does not provide any further information. The given regulation sections do not specify the requirements for the placement of the names and quantities or proportions of the active ingredients in this case."
        },
        {
          "Question":"According to the given regulation sections, what are the two exceptions that allow the names and quantities or proportions of the active ingredients to be separated by text or graphics?",
          "Answer":"The two exceptions that allow the names and quantities or proportions of the active ingredients to be separated by text or graphics are: 1) when additional information is required or permitted by paragraph 11(2)(h), subparagraphs 11(2)(i)(i) or 11(2)(i)(ii)(A), or subsection 11(5); and 2) when the additional information is related to identifying the different formulations of the medicines contained in a composite pack or a medicine kit.",
          "Answer Explanation":"Section 9(1)(b) states that the names and quantities or proportions of the active ingredients must not be separated by any text or graphics, except in two cases. The first case is when additional information is required or permitted by paragraph 11(2)(h), subparagraphs 11(2)(i)(i) or 11(2)(i)(ii)(A), or subsection 11(5). The second case is when the additional information is related to identifying the different formulations of the medicines contained in a composite pack or a medicine kit."
        },
        {
          "Question":"Assuming a non-prescription medicine contains one or more unspecified attributes and subsection 8(2) applies, what does the given regulation section state about the requirements for this medicine?",
          "Answer":"The given regulation sections do not provide complete information about the requirements for a non-prescription medicine that contains one or more unspecified attributes and where subsection 8(2) applies.",
          "Answer Explanation":"Section 9(1)(d) mentions a scenario where a medicine includes one or more unspecified attributes and subsection 8(2) applies. However, the provided regulation text is incomplete and does not specify the requirements for this case. More information is needed to determine the requirements for such a medicine."
        }
      ]
    },
    "result_str":"{\n  \"QuestionAnswers\": [\n    {\n      \"Question\": \"Assuming a non-prescription medicine is supplied in a medium container and contains 5 active ingredients, what are the requirements for the placement and text size of the names and quantities or proportions of the active ingredients according to the given regulation sections?\",\n      \"Answer\": \"The names and quantities or proportions of the active ingredients may be included on a side panel, side label, rear panel, or rear label, with a text size of at least 2.5 millimetres.\",\n      \"Answer Explanation\": \"According to section 9(1)(b), if the medicine contains four or more active ingredients and subsection 8(2) applies, compliance with paragraphs 9(1)(b) and 9(1)(c) is not required. Since the medicine contains 5 active ingredients, subsection 8(2) does not apply. Therefore, as per section 9(1)(a), the names and quantities or proportions of the active ingredients may be included on a side panel, side label, rear panel, or rear label, with a text size of at least 2.5 millimetres.\"\n    },\n    {\n      \"Question\": \"Assuming a non-prescription medicine is supplied in a small container and contains multiple active ingredients, what are the requirements for the placement of the names and quantities or proportions of the active ingredients according to the given regulation sections?\",\n      \"Answer\": \"The requirements for the placement of the names and quantities or proportions of the active ingredients are not specified in the given regulation sections for a medicine supplied in a small container with multiple active ingredients.\",\n      \"Answer Explanation\": \"Section 9(1)(c) states that if the medicine is supplied in either a small or a medium container and contains multiple active ingredients, then the regulation does not provide any further information. The given regulation sections do not specify the requirements for the placement of the names and quantities or proportions of the active ingredients in this case.\"\n    },\n    {\n      \"Question\": \"According to the given regulation sections, what are the two exceptions that allow the names and quantities or proportions of the active ingredients to be separated by text or graphics?\",\n      \"Answer\": \"The two exceptions that allow the names and quantities or proportions of the active ingredients to be separated by text or graphics are: 1) when additional information is required or permitted by paragraph 11(2)(h), subparagraphs 11(2)(i)(i) or 11(2)(i)(ii)(A), or subsection 11(5); and 2) when the additional information is related to identifying the different formulations of the medicines contained in a composite pack or a medicine kit.\",\n      \"Answer Explanation\": \"Section 9(1)(b) states that the names and quantities or proportions of the active ingredients must not be separated by any text or graphics, except in two cases. The first case is when additional information is required or permitted by paragraph 11(2)(h), subparagraphs 11(2)(i)(i) or 11(2)(i)(ii)(A), or subsection 11(5). The second case is when the additional information is related to identifying the different formulations of the medicines contained in a composite pack or a medicine kit.\"\n    },\n    {\n      \"Question\": \"Assuming a non-prescription medicine contains one or more unspecified attributes and subsection 8(2) applies, what does the given regulation section state about the requirements for this medicine?\",\n      \"Answer\": \"The given regulation sections do not provide complete information about the requirements for a non-prescription medicine that contains one or more unspecified attributes and where subsection 8(2) applies.\",\n      \"Answer Explanation\": \"Section 9(1)(d) mentions a scenario where a medicine includes one or more unspecified attributes and subsection 8(2) applies. However, the provided regulation text is incomplete and does not specify the requirements for this case. More information is needed to determine the requirements for such a medicine.\"\n    }\n  ]\n}",
    "misc_info":null
  },
  {
    "path":[
      903020000,
      1102090000
    ],
    "contexts":[
      "of the active ingredient; and (ii) the name and quantity of the element intended for mineral supplementation.  (i) In addition to the requirements of paragraphs 11(2)(a) \u201311(2)(g), the following requirements apply in the circumstances specified in the following subparagraphs: (i) where the active ingredient is a herbal material, such as a dry, fresh, milled or powdered herb, as the weight of the herbal material; except where standardisation is claimed on the label, then the minimum dry or fresh",
      "of the medicine; and  (b) not be separated by any text or graphics, except where additional information is: (i) required or permitted by: (A) paragraph 11(2)(h); or (B) subparagraphs 11(2)(i)(i) or 11(2)(i)(ii)(A); or (C) subsection 11(5); or (ii) in relation to identifying the different formulations of the medicines contained in a composite pack or a medicine kit;  (c) if the medicine is: (i) supplied in either a small or a medium container; and (ii) contains multiple active ingredients then,"
    ],
    "result_dict":{
      "QuestionAnswers":[
        {
          "Question":"Assuming a non-prescription medicine contains a herbal material as the active ingredient and is in a small container with multiple active ingredients, what naming and quantity requirements apply on the label if no standardization is claimed?",
          "Answer":"The active ingredient must be named as the herbal material with the weight of the material listed. The names and quantities of all active ingredients must be listed together without any intervening text or graphics.",
          "Answer Explanation":"Paragraph 11(2)(i)(i) states that if the active ingredient is a herbal material and no standardization is claimed, it must be named as the weight of the herbal material. Paragraph 11(2)(c) requires that for a medicine in a small container with multiple active ingredients, the names and quantities of the active ingredients must be grouped together without any intervening text or graphics, except for specific permitted additional information."
        },
        {
          "Question":"For a non-prescription medicine in a small container with multiple active ingredients where one is a mineral supplement, what information must be grouped together on the label without intervening text or graphics?",
          "Answer":"The names and quantities of all active ingredients, including for the mineral supplement the name and quantity of the element intended for supplementation, must be grouped together on the label without any intervening text or graphics, except for specific permitted additional information.",
          "Answer Explanation":"Paragraph 11(2)(c) requires that for a medicine in a small container with multiple active ingredients, the names and quantities of the active ingredients must be grouped together without any intervening text or graphics, except for specific permitted additional information. Subparagraph 11(2)(i)(ii) further specifies that for a mineral supplement, the name and quantity of the element intended for supplementation must be listed."
        },
        {
          "Question":"Assuming a non-prescription medicine contains a standardized herbal material as the active ingredient, what is required to be listed for the quantity of this ingredient?",
          "Answer":"If the herbal active ingredient is standardized, the minimum quantity of the herbal material must be listed, either as a dry or fresh weight.",
          "Answer Explanation":"Paragraph 11(2)(i)(i) states that where the active ingredient is a herbal material and standardization is claimed on the label, the minimum dry or fresh weight of the herbal material must be listed as the quantity."
        },
        {
          "Question":"For a non-prescription medicine in a medium container with multiple active ingredients including a mineral supplement and standardized herbal material, what naming and quantity information must be grouped together on the label?",
          "Answer":"The names and quantities of all active ingredients must be grouped together on the label without intervening text or graphics, listing: the element name and quantity for the mineral supplement; the standardized herbal material name with its minimum dry or fresh weight quantity; and the names and quantities of any other active ingredients.",
          "Answer Explanation":"Paragraph 11(2)(c) requires that for a medicine in a medium container with multiple active ingredients, the names and quantities must be grouped together without intervening text or graphics, except for permitted information. Subparagraph 11(2)(i)(i) specifies that for a standardized herbal material, the minimum dry or fresh weight quantity must be listed. Subparagraph 11(2)(i)(ii) requires the element name and quantity to be listed for a mineral supplement."
        }
      ]
    },
    "result_str":"{\"QuestionAnswers\": [{\"Question\": \"Assuming a non-prescription medicine contains a herbal material as the active ingredient and is in a small container with multiple active ingredients, what naming and quantity requirements apply on the label if no standardization is claimed?\", \"Answer\": \"The active ingredient must be named as the herbal material with the weight of the material listed. The names and quantities of all active ingredients must be listed together without any intervening text or graphics.\", \"Answer Explanation\": \"Paragraph 11(2)(i)(i) states that if the active ingredient is a herbal material and no standardization is claimed, it must be named as the weight of the herbal material. Paragraph 11(2)(c) requires that for a medicine in a small container with multiple active ingredients, the names and quantities of the active ingredients must be grouped together without any intervening text or graphics, except for specific permitted additional information.\"}, {\"Question\": \"For a non-prescription medicine in a small container with multiple active ingredients where one is a mineral supplement, what information must be grouped together on the label without intervening text or graphics?\", \"Answer\": \"The names and quantities of all active ingredients, including for the mineral supplement the name and quantity of the element intended for supplementation, must be grouped together on the label without any intervening text or graphics, except for specific permitted additional information.\", \"Answer Explanation\": \"Paragraph 11(2)(c) requires that for a medicine in a small container with multiple active ingredients, the names and quantities of the active ingredients must be grouped together without any intervening text or graphics, except for specific permitted additional information. Subparagraph 11(2)(i)(ii) further specifies that for a mineral supplement, the name and quantity of the element intended for supplementation must be listed.\"}, {\"Question\": \"Assuming a non-prescription medicine contains a standardized herbal material as the active ingredient, what is required to be listed for the quantity of this ingredient?\", \"Answer\": \"If the herbal active ingredient is standardized, the minimum quantity of the herbal material must be listed, either as a dry or fresh weight.\", \"Answer Explanation\": \"Paragraph 11(2)(i)(i) states that where the active ingredient is a herbal material and standardization is claimed on the label, the minimum dry or fresh weight of the herbal material must be listed as the quantity.\"}, {\"Question\": \"For a non-prescription medicine in a medium container with multiple active ingredients including a mineral supplement and standardized herbal material, what naming and quantity information must be grouped together on the label?\", \"Answer\": \"The names and quantities of all active ingredients must be grouped together on the label without intervening text or graphics, listing: the element name and quantity for the mineral supplement; the standardized herbal material name with its minimum dry or fresh weight quantity; and the names and quantities of any other active ingredients.\", \"Answer Explanation\": \"Paragraph 11(2)(c) requires that for a medicine in a medium container with multiple active ingredients, the names and quantities must be grouped together without intervening text or graphics, except for permitted information. Subparagraph 11(2)(i)(i) specifies that for a standardized herbal material, the minimum dry or fresh weight quantity must be listed. Subparagraph 11(2)(i)(ii) requires the element name and quantity to be listed for a mineral supplement.\"}]}",
    "misc_info":null
  },
  {
    "path":[
      1102080000,
      1102040000
    ],
    "contexts":[
      "the quantity of the active ingredient contained in the stated volume of a suitable dose of the liquid with the quantity or proportion of active ingredient expressed consistently across the series in terms of the same stated dose volume. Example: Where the dose volume is 5 mL, and there are strengths of 1 mg\/mL and 5 mg\/mL, these must be labelled as 5 mg in 5 mL and 25 mg in 5 mL, respectively.  (d) for a medicine required to be prepared before use, and: (i) where the process results in a",
      "in the stated volume of a suitable dose of the liquid after preparation in accordance with the instructions set out on the label of the medicine with the quantity or proportion of active ingredient expressed consistently across the series in terms of the same stated dose volume; and Example: Where the dose volume is 5 mL after preparation, and there are strengths of 1 mg\/mL and 5 mg\/mL, these must be labelled as 5 mg in 5 mL and 25 mg in 5 mL, respectively. (ii) for any other medicines - as the"
    ],
    "result_dict":{

    },
    "result_str":"{\"QuestionAnswers\": [\n  {\n    \"Question\": \"Assuming a liquid medicine has strengths of 2 mg\/mL and 10 mg\/mL and the suitable dose volume is 5 mL, how should the quantity of active ingredient be expressed on the label?\",\n    \"Answer\": \"The medicine with 2 mg\/mL strength should be labelled as '10 mg in 5 mL' and the medicine with 10 mg\/mL strength should be labelled as '50 mg in 5 mL'.\",\n    \"Answer Explanation\": \"The regulation states that the quantity of active ingredient must be expressed consistently across a series in terms of the same stated dose volume. The example provided shows that for a dose volume of 5 mL, strengths of 1 mg\/mL and 5 mg\/mL should be labelled as 5 mg in 5 mL and 25 mg in 5 mL respectively. Applying this to the given strengths of 2 mg\/mL and 10 mg\/mL with the same 5 mL dose volume, they should be labelled as 10 mg in 5 mL and 50 mg in 5 mL.\"\n  },\n  {\n    \"Question\": \"For a medicine that needs to be prepared before use, resulting in a change in active ingredient concentration, and the dose volume after preparation is 10 mL, how should the quantity of active ingredient be expressed on the label assuming strengths of 0.5 mg\/mL and 2 mg\/mL after preparation?\",\n    \"Answer\": \"The medicine with 0.5 mg\/mL strength after preparation should be labelled as '5 mg in 10 mL' and the medicine with 2 mg\/mL strength after preparation should be labelled as '20 mg in 10 mL'.\",\n    \"Answer Explanation\": \"The regulation states that for a medicine required to be prepared before use, if the preparation process results in a change in active ingredient concentration, the quantity should be expressed in terms of the stated dose volume after preparation. The example shows that for a dose volume of 5 mL after preparation, strengths of 1 mg\/mL and 5 mg\/mL should be labelled as 5 mg in 5 mL and 25 mg in 5 mL respectively. Applying this to the given scenario with a dose volume of 10 mL after preparation and strengths of 0.5 mg\/mL and 2 mg\/mL, they should be labelled as 5 mg in 10 mL and 20 mg in 10 mL.\"\n  },\n  {\n    \"Question\": \"Assuming a liquid medicine has strengths of 20 mg\/mL and 100 mg\/mL and the suitable dose volume is 2.5 mL, how should the quantity of active ingredient be expressed on the label?\", \n    \"Answer\": \"The medicine with 20 mg\/mL strength should be labelled as '50 mg in 2.5 mL' and the medicine with 100 mg\/mL strength should be labelled as '250 mg in 2.5 mL'.\",\n    \"Answer Explanation\": \"The first excerpt of the regulation states that the quantity of active ingredient should be expressed consistently across a series in terms of the same stated dose volume, which is a suitable dose of the liquid. The provided example demonstrates that for a dose volume of 5 mL, strengths of 1 mg\/mL and 5 mg\/mL should be labelled as 5 mg in 5 mL and 25 mg in 5 mL respectively. Applying this rule to the given scenario with a dose volume of 2.5 mL and strengths of 20 mg\/mL and 100 mg\/mL, the correct labelling would be 50 mg in 2.5 mL and 250 mg in 2.5 mL respectively.\"\n  },\n  {\n    \"Question\": \"For medicines that do not require preparation before use and are not liquids administered as a suitable dose volume, how should the quantity of active ingredient be expressed on the label?\",\n    \"Answer\": \"For medicines that do not require preparation before use and are not liquids administered as a suitable dose volume, the quantity of active ingredient should be expressed as the quantity contained in each dosage unit.\",\n    ",
    "misc_info":null
  },
  {
    "path":[
      1008030000,
      800000000
    ],
    "contexts":[
      "of the label for each individual wrapper with sections 8 and 9, it shall be sufficient if the name of the medicine is displayed.  (c) Where: (i) a medicine consists of dry herbs contained in individual bags and the bag is retained around the herbs during preparation; (ii) the bags are contained in a primary pack, the label of which complies with the requirements of this Order, then the individual bag need not be labelled with the information referred to in sections 8 and 9.  (9) Strip, blister",
      "is enclosed in a small container; and  (b) the container is enclosed in a primary pack, the label of which complies with sections 8 and 9 and subsection 10(1) (if applicable), then, in relation to compliance of the label on the container with sections 8 and 9 and subsection 10(1) (if applicable), it shall be sufficient if the following information is displayed in a text size of not less than 2 millimetres:  (c) the name of the medicine; and  (d) the name(s) of all active ingredients in the"
    ],
    "result_dict":{
      "QuestionAnswers":[
        {
          "Question":"Assuming a non-prescription medicine consists of dry herbs in individual bags that are kept around the herbs during preparation, and these bags are inside a properly labeled primary pack, what labeling is required on the individual herb bags?",
          "Answer":"The individual herb bags do not require the information from sections 8 and 9 on their labels.",
          "Answer Explanation":"According to the regulation, if a medicine consists of dry herbs in individual bags retained around the herbs during preparation, and these bags are in a primary pack with a label that complies with sections 8 and 9, then the individual herb bags do not need to be labeled with the information from sections 8 and 9 (10(8)(c)(i)-(ii))."
        },
        {
          "Question":"For a medicine in a small container inside a primary pack that has a fully compliant label, what is the minimum information and text size required on the small container label to comply with sections 8, 9 and 10(1)?",
          "Answer":"The small container label must display the name of the medicine and the name(s) of all active ingredients in a minimum 2mm text size.",
          "Answer Explanation":"Subsection 10(8)(a)-(b) states that if a medicine is in a small container inside a primary pack with a label complying with sections 8, 9 and 10(1), then for the small container label to comply with those same sections, it only needs to display the medicine name and active ingredient name(s) in a text size of at least 2 millimetres (10(8)(c)-(d))."
        },
        {
          "Question":"Assuming a medicine is packaged in individual wrappers inside a primary pack, what information must be on each wrapper label for it to comply with sections 8 and 9?",
          "Answer":"It is sufficient for each individual wrapper label to display just the name of the medicine to comply with sections 8 and 9.",
          "Answer Explanation":"Subsection 10(8)(b) specifies that if a medicine has individual wrappers inside a primary pack with a label that complies with sections 8 and 9, then for the label of each individual wrapper to also comply with sections 8 and 9, it only needs to display the name of the medicine."
        },
        {
          "Question":"If a non-prescription medicine is packaged in a strip or blister pack enclosed in a small container, which is then enclosed in a primary pack with a fully compliant label, what labeling is required on the small container to satisfy sections 8, 9 and 10(1)?",
          "Answer":"The small container label must display the medicine name and active ingredient name(s) in at least 2mm text size to satisfy sections 8, 9 and 10(1).",
          "Answer Explanation":"Based on subsections 10(8)(a)-(d) and 10(9), if a medicine is in a strip\/blister pack inside a small container that is inside a primary pack with a label fully complying with sections 8, 9 and 10(1), then for the small container label to also comply, it is sufficient for it to display the medicine name and names of all active ingredients in a minimum 2 millimetre text size."
        }
      ]
    },
    "result_str":"{\"QuestionAnswers\": [\n  {\n    \"Question\": \"Assuming a non-prescription medicine consists of dry herbs in individual bags that are kept around the herbs during preparation, and these bags are inside a properly labeled primary pack, what labeling is required on the individual herb bags?\",\n    \"Answer\": \"The individual herb bags do not require the information from sections 8 and 9 on their labels.\",\n    \"Answer Explanation\": \"According to the regulation, if a medicine consists of dry herbs in individual bags retained around the herbs during preparation, and these bags are in a primary pack with a label that complies with sections 8 and 9, then the individual herb bags do not need to be labeled with the information from sections 8 and 9 (10(8)(c)(i)-(ii)).\"\n  },\n  {\n    \"Question\": \"For a medicine in a small container inside a primary pack that has a fully compliant label, what is the minimum information and text size required on the small container label to comply with sections 8, 9 and 10(1)?\",\n    \"Answer\": \"The small container label must display the name of the medicine and the name(s) of all active ingredients in a minimum 2mm text size.\",\n    \"Answer Explanation\": \"Subsection 10(8)(a)-(b) states that if a medicine is in a small container inside a primary pack with a label complying with sections 8, 9 and 10(1), then for the small container label to comply with those same sections, it only needs to display the medicine name and active ingredient name(s) in a text size of at least 2 millimetres (10(8)(c)-(d)).\"\n  },\n  {\n    \"Question\": \"Assuming a medicine is packaged in individual wrappers inside a primary pack, what information must be on each wrapper label for it to comply with sections 8 and 9?\",\n    \"Answer\": \"It is sufficient for each individual wrapper label to display just the name of the medicine to comply with sections 8 and 9.\",\n    \"Answer Explanation\": \"Subsection 10(8)(b) specifies that if a medicine has individual wrappers inside a primary pack with a label that complies with sections 8 and 9, then for the label of each individual wrapper to also comply with sections 8 and 9, it only needs to display the name of the medicine.\"\n  },\n  {\n    \"Question\": \"If a non-prescription medicine is packaged in a strip or blister pack enclosed in a small container, which is then enclosed in a primary pack with a fully compliant label, what labeling is required on the small container to satisfy sections 8, 9 and 10(1)?\",\n    \"Answer\": \"The small container label must display the medicine name and active ingredient name(s) in at least 2mm text size to satisfy sections 8, 9 and 10(1).\",\n    \"Answer Explanation\": \"Based on subsections 10(8)(a)-(d) and 10(9), if a medicine is in a strip\/blister pack inside a small container that is inside a primary pack with a label fully complying with sections 8, 9 and 10(1), then for the small container label to also comply, it is sufficient for it to display the medicine name and names of all active ingredients in a minimum 2 millimetre text size.\"\n  }\n]}",
    "misc_info":null
  },
  {
    "path":[
      1102080000,
      1102020000
    ],
    "contexts":[
      "(f) - as a percentage expressed in terms of w\/w, w\/v, v\/v or v\/w, as appropriate, or as the weight or volume in a stated weight or volume of the medicine, as appropriate;  (h) for the purposes of paragraphs 11(2)(a) \u2013 11(2)(d), for oral preparations that contain active ingredients intended for mineral supplementation, it is sufficient that the quantity or proportion of that active ingredient to be included on a label be expressed as: (i) the name of the active ingredient; and (ii) the name and",
      "is no discrete dosage unit - as the quantity of the active ingredient contained in the stated weight of a suitable dose of the solid;  (c) subject to paragraph (d) below, if the medicine is a liquid for ingestion: (i) as the quantity of the active ingredient contained in the stated volume of a suitable dose of the liquid; or (ii) in the case where the liquid for ingestion is one of a series of strengths containing the same active ingredient \u2013 as the quantity of the active ingredient contained"
    ],
    "result_dict":{
      "QuestionAnswers":[
        {
          "Question":"Assuming a liquid medicine for ingestion contains the same active ingredient across a series of strengths, what two ways can the quantity of the active ingredient be expressed on the label as per the given regulation sections?",
          "Answer":"The quantity of the active ingredient can be expressed as either: (1) the quantity contained in the stated volume of a suitable dose of the liquid, or (2) the quantity contained in a stated volume of the liquid.",
          "Answer Explanation":"As per section (c), for a liquid medicine for ingestion that is one of a series of strengths containing the same active ingredient, the quantity of the active ingredient can be expressed on the label in two ways: (i) as the quantity of the active ingredient contained in the stated volume of a suitable dose of the liquid; or (ii) as the quantity of the active ingredient contained in a stated volume of the liquid."
        },
        {
          "Question":"Based on the given regulation sections, if an oral preparation contains active ingredients intended for mineral supplementation, what is considered sufficient information to include on the label regarding the quantity or proportion of that active ingredient?",
          "Answer":"For oral preparations containing active ingredients intended for mineral supplementation, it is considered sufficient to include the name of the active ingredient and the name and quantity of the active ingredient per dosage unit on the label.",
          "Answer Explanation":"Paragraph (h) states that for the purposes of paragraphs 11(2)(a) \u2013 11(2)(d), for oral preparations that contain active ingredients intended for mineral supplementation, it is sufficient that the quantity or proportion of that active ingredient to be included on a label be expressed as: (i) the name of the active ingredient; and (ii) the name and quantity of the active ingredient per dosage unit."
        },
        {
          "Question":"According to the provided regulation sections, in what ways can the quantity or proportion of an active ingredient in a medicine be expressed on the label?",
          "Answer":"The quantity or proportion of an active ingredient in a medicine can be expressed on the label as a percentage in terms of w\/w, w\/v, v\/v or v\/w, as appropriate, or as the weight or volume in a stated weight or volume of the medicine, as appropriate.",
          "Answer Explanation":"Section (f) directly states that the quantity or proportion of an active ingredient can be expressed as a percentage in terms of w\/w, w\/v, v\/v or v\/w, as appropriate, or as the weight or volume in a stated weight or volume of the medicine, as appropriate."
        },
        {
          "Question":"Assuming a medicine is a solid with no discrete dosage unit, how should the quantity of the active ingredient be expressed on the label based on the given regulation sections?",
          "Answer":"If a medicine is a solid with no discrete dosage unit, the quantity of the active ingredient should be expressed on the label as the quantity contained in the stated weight of a suitable dose of the solid.",
          "Answer Explanation":"According to the regulation section starting with 'is no discrete dosage unit', if the medicine is a solid with no discrete dosage unit, the quantity of the active ingredient should be expressed on the label as the quantity of the active ingredient contained in the stated weight of a suitable dose of the solid."
        }
      ]
    },
    "result_str":"{\"QuestionAnswers\": [{\"Question\": \"Assuming a liquid medicine for ingestion contains the same active ingredient across a series of strengths, what two ways can the quantity of the active ingredient be expressed on the label as per the given regulation sections?\", \"Answer\": \"The quantity of the active ingredient can be expressed as either: (1) the quantity contained in the stated volume of a suitable dose of the liquid, or (2) the quantity contained in a stated volume of the liquid.\", \"Answer Explanation\": \"As per section (c), for a liquid medicine for ingestion that is one of a series of strengths containing the same active ingredient, the quantity of the active ingredient can be expressed on the label in two ways: (i) as the quantity of the active ingredient contained in the stated volume of a suitable dose of the liquid; or (ii) as the quantity of the active ingredient contained in a stated volume of the liquid.\"}, {\"Question\": \"Based on the given regulation sections, if an oral preparation contains active ingredients intended for mineral supplementation, what is considered sufficient information to include on the label regarding the quantity or proportion of that active ingredient?\", \"Answer\": \"For oral preparations containing active ingredients intended for mineral supplementation, it is considered sufficient to include the name of the active ingredient and the name and quantity of the active ingredient per dosage unit on the label.\", \"Answer Explanation\": \"Paragraph (h) states that for the purposes of paragraphs 11(2)(a) \u2013 11(2)(d), for oral preparations that contain active ingredients intended for mineral supplementation, it is sufficient that the quantity or proportion of that active ingredient to be included on a label be expressed as: (i) the name of the active ingredient; and (ii) the name and quantity of the active ingredient per dosage unit.\"}, {\"Question\": \"According to the provided regulation sections, in what ways can the quantity or proportion of an active ingredient in a medicine be expressed on the label?\", \"Answer\": \"The quantity or proportion of an active ingredient in a medicine can be expressed on the label as a percentage in terms of w\/w, w\/v, v\/v or v\/w, as appropriate, or as the weight or volume in a stated weight or volume of the medicine, as appropriate.\", \"Answer Explanation\": \"Section (f) directly states that the quantity or proportion of an active ingredient can be expressed as a percentage in terms of w\/w, w\/v, v\/v or v\/w, as appropriate, or as the weight or volume in a stated weight or volume of the medicine, as appropriate.\"}, {\"Question\": \"Assuming a medicine is a solid with no discrete dosage unit, how should the quantity of the active ingredient be expressed on the label based on the given regulation sections?\", \"Answer\": \"If a medicine is a solid with no discrete dosage unit, the quantity of the active ingredient should be expressed on the label as the quantity contained in the stated weight of a suitable dose of the solid.\", \"Answer Explanation\": \"According to the regulation section starting with 'is no discrete dosage unit', if the medicine is a solid with no discrete dosage unit, the quantity of the active ingredient should be expressed on the label as the quantity of the active ingredient contained in the stated weight of a suitable dose of the solid.\"}]}",
    "misc_info":null
  },
  {
    "path":[
      802050000,
      802030000
    ],
    "contexts":[
      "ingredients (ii) Indications (iii) Warnings (iv) Directions for use (v) Other information.  (c) The information provided under paragraph 8(2)(b)(i) may include words describing the purpose of the active ingredient(s) by indicating the pharmacological category or the principal intended actions that are not required by this Order.  (d) The information provided under paragraph 8(2)(b)(iii) may include safety related information not required by this Order (such as allergen advice, caution,",
      "by this Order (such as allergen advice, caution, additional warning or advisory statements).  (e) If information other than the critical health information or information of a kind mentioned in subsections 8(2)(c) or 8(2)(d) is to be included, it must be placed under the \u2018Other information\u2019 heading or under another separate appropriate heading(s) that follow immediately below the headings mentioned in 8(2)(b) and must not contain any additional information other than: A. requirements relating"
    ],
    "result_dict":{
      "QuestionAnswers":[
        {
          "Question":"Assuming a non-prescription medicine label includes the words 'Antihistamine - for relief of allergy symptoms' under the 'Active ingredients' heading, does this comply with the regulations?",
          "Answer":"Yes",
          "Answer Explanation":"Paragraph 8(2)(c) allows including words describing the purpose of the active ingredients by indicating the pharmacological category or principal intended actions that are not required by the Order. 'Antihistamine' indicates the pharmacological category and 'for relief of allergy symptoms' indicates the principal intended actions, so this additional information is permitted under the 'Active ingredients' heading according to 8(2)(c)."
        },
        {
          "Question":"Assuming a non-prescription medicine label includes a 'Caution' section with additional safety information not required by the Order, and this section is placed after the 'Directions for use' section but before the 'Other information' section, does this comply with the regulations?",
          "Answer":"No",
          "Answer Explanation":"Paragraph 8(2)(d) allows including additional safety information like cautions that are not required by the Order. However, paragraph 8(2)(e) requires that if any information other than the critical health information listed in 8(2)(b)(i)-(v) or the permitted additional information under 8(2)(c) and 8(2)(d) is included, it must be placed under the 'Other information' heading or another separate appropriate heading that follows immediately below the 8(2)(b) headings. Putting the 'Caution' section before 'Other information' violates 8(2)(e)."
        },
        {
          "Question":"Assuming a non-prescription medicine label includes all the critical health information headings listed in 8(2)(b), as well as an additional 'Interactions' section containing information about drug interactions placed after the 'Other information' section, does this comply with the regulations?",
          "Answer":"Yes",
          "Answer Explanation":"Paragraph 8(2)(b) requires the critical health information to be listed under the headings (i) Ingredients (ii) Indications (iii) Warnings (iv) Directions for use (v) Other information. Paragraph 8(2)(e) allows additional information to be included under the 'Other information' heading or under another separate appropriate heading that follows immediately below the 8(2)(b) headings. Since the 'Interactions' section is placed after the required 'Other information' section, this additional information is permitted by 8(2)(e)."
        },
        {
          "Question":"Assuming a non-prescription medicine label includes the critical health information headings required by 8(2)(b), with the pharmacological category of the active ingredients listed under 'Ingredients' as permitted by 8(2)(c), allergen advice included under 'Warnings' as permitted by 8(2)(d), and an additional 'Interactions' section after 'Other information' containing only information relating to medication interactions as required by 8(2)(e), does the label comply with all the regulations?",
          "Answer":"Yes",
          "Answer Explanation":"The label satisfies all the requirements: \n- It has the required critical health information headings under 8(2)(b)\n- The pharmacological category under 'Ingredients' is permitted additional information according to 8(2)(c)\n- The allergen advice under 'Warnings' is permitted additional information according to 8(2)(d) \n- The 'Interactions' section after 'Other information' is permitted by 8(2)(e) since it follows the required headings and contains only information relating to interactions as required. \nTherefore, the label is fully compliant with paragraphs 8(2)(b) through 8(2)(e) of the regulations."
        }
      ]
    },
    "result_str":"{\"QuestionAnswers\": [{\"Question\": \"Assuming a non-prescription medicine label includes the words 'Antihistamine - for relief of allergy symptoms' under the 'Active ingredients' heading, does this comply with the regulations?\", \"Answer\": \"Yes\", \"Answer Explanation\": \"Paragraph 8(2)(c) allows including words describing the purpose of the active ingredients by indicating the pharmacological category or principal intended actions that are not required by the Order. 'Antihistamine' indicates the pharmacological category and 'for relief of allergy symptoms' indicates the principal intended actions, so this additional information is permitted under the 'Active ingredients' heading according to 8(2)(c).\"}, {\"Question\": \"Assuming a non-prescription medicine label includes a 'Caution' section with additional safety information not required by the Order, and this section is placed after the 'Directions for use' section but before the 'Other information' section, does this comply with the regulations?\", \"Answer\": \"No\", \"Answer Explanation\": \"Paragraph 8(2)(d) allows including additional safety information like cautions that are not required by the Order. However, paragraph 8(2)(e) requires that if any information other than the critical health information listed in 8(2)(b)(i)-(v) or the permitted additional information under 8(2)(c) and 8(2)(d) is included, it must be placed under the 'Other information' heading or another separate appropriate heading that follows immediately below the 8(2)(b) headings. Putting the 'Caution' section before 'Other information' violates 8(2)(e).\"}, {\"Question\": \"Assuming a non-prescription medicine label includes all the critical health information headings listed in 8(2)(b), as well as an additional 'Interactions' section containing information about drug interactions placed after the 'Other information' section, does this comply with the regulations?\", \"Answer\": \"Yes\", \"Answer Explanation\": \"Paragraph 8(2)(b) requires the critical health information to be listed under the headings (i) Ingredients (ii) Indications (iii) Warnings (iv) Directions for use (v) Other information. Paragraph 8(2)(e) allows additional information to be included under the 'Other information' heading or under another separate appropriate heading that follows immediately below the 8(2)(b) headings. Since the 'Interactions' section is placed after the required 'Other information' section, this additional information is permitted by 8(2)(e).\"}, {\"Question\": \"Assuming a non-prescription medicine label includes the critical health information headings required by 8(2)(b), with the pharmacological category of the active ingredients listed under 'Ingredients' as permitted by 8(2)(c), allergen advice included under 'Warnings' as permitted by 8(2)(d), and an additional 'Interactions' section after 'Other information' containing only information relating to medication interactions as required by 8(2)(e), does the label comply with all the regulations?\", \"Answer\": \"Yes\", \"Answer Explanation\": \"The label satisfies all the requirements: \\n- It has the required critical health information headings under 8(2)(b)\\n- The pharmacological category under 'Ingredients' is permitted additional information according to 8(2)(c)\\n- The allergen advice under 'Warnings' is permitted additional information according to 8(2)(d) \\n- The 'Interactions' section after 'Other information' is permitted by 8(2)(e) since it follows the required headings and contains only information relating to interactions as required. \\nTherefore, the label is fully compliant with paragraphs 8(2)(b) through 8(2)(e) of the regulations.\"}]}",
    "misc_info":null
  },
  {
    "path":[
      910030000,
      913000000
    ],
    "contexts":[
      "2026; or  (c) where the medicine is not supplied in a small container and is labelled in accordance with subsection 9(13) and Part 2 of Schedule 2\u2014after 30 April 2028. Note: The minimum text size for active ingredients on labels of small containers is less than 2.5 millimetres and specified elsewhere in this Order.  (11) An active ingredient specified in Part 1 of Schedule 2, either alone or in combination with any other descriptors, may be included on the main label of a medicine containing",
      "with any other descriptors, then the names of all active ingredients in the medicine, together with their quantity or proportion, must be displayed in a text size of not less than 2.5 millimetres.  (10) Subsection 9(9) does not apply:  (a) where the medicine is supplied in a small container; or  (b) where the medicine is not supplied in a small container and is labelled in accordance with subsection 9(11) and Part 1 of Schedule 2\u2014after 30 April 2026; or  (c) where the medicine is not supplied"
    ],
    "result_dict":{
      "QuestionAnswers":[
        {
          "Question":"Assuming a medicine is supplied in a small container and the active ingredients are specified in Part 1 of Schedule 2, what is the minimum text size required for the active ingredients on the main label after April 30, 2026?",
          "Answer":"Less than 2.5 millimetres",
          "Answer Explanation":"According to subsection 9(10)(a), subsection 9(9) does not apply where the medicine is supplied in a small container. The note under 9(10) states that the minimum text size for active ingredients on labels of small containers is less than 2.5 millimetres and specified elsewhere in the Order."
        },
        {
          "Question":"Assuming a medicine is not supplied in a small container and is labelled in accordance with subsection 9(13) and Part 2 of Schedule 2, until what date does subsection 9(9) not apply?",
          "Answer":"April 30, 2028",
          "Answer Explanation":"According to subsection 9(10)(c), subsection 9(9) does not apply where the medicine is not supplied in a small container and is labelled in accordance with subsection 9(13) and Part 2 of Schedule 2, after April 30, 2028."
        },
        {
          "Question":"Assuming a medicine is not supplied in a small container and contains active ingredients specified in Part 1 of Schedule 2, what is the minimum text size required for displaying the names and quantities of all active ingredients if it is labelled in accordance with subsection 9(11)?",
          "Answer":"Not less than 2.5 millimetres",
          "Answer Explanation":"According to the second context, if an active ingredient specified in Part 1 of Schedule 2 is included on the main label, either alone or with other descriptors, then the names and quantities of all active ingredients must be displayed in a text size of not less than 2.5 millimetres. Subsection 9(10)(b) states that 9(9) does not apply in this case until after April 30, 2026 if labelled per 9(11)."
        },
        {
          "Question":"Assuming a medicine is not supplied in a small container, contains active ingredients from Part 1 of Schedule 2, and is not labelled according to subsections 9(11) or 9(13), what minimum text size applies for the active ingredients?",
          "Answer":"Not less than 2.5 millimetres",
          "Answer Explanation":"The contexts imply that subsection 9(9) applies in this case, since none of the exceptions in 9(10) are met. The second context states that when 9(9) applies and Part 1 Schedule 2 ingredients are present, the names and quantities of all active ingredients must be displayed in a text size not less than 2.5 millimetres."
        }
      ]
    },
    "result_str":"{\"QuestionAnswers\": [\n  {\n    \"Question\": \"Assuming a medicine is supplied in a small container and the active ingredients are specified in Part 1 of Schedule 2, what is the minimum text size required for the active ingredients on the main label after April 30, 2026?\",\n    \"Answer\": \"Less than 2.5 millimetres\",\n    \"Answer Explanation\": \"According to subsection 9(10)(a), subsection 9(9) does not apply where the medicine is supplied in a small container. The note under 9(10) states that the minimum text size for active ingredients on labels of small containers is less than 2.5 millimetres and specified elsewhere in the Order.\"\n  },\n  {\n    \"Question\": \"Assuming a medicine is not supplied in a small container and is labelled in accordance with subsection 9(13) and Part 2 of Schedule 2, until what date does subsection 9(9) not apply?\",\n    \"Answer\": \"April 30, 2028\",\n    \"Answer Explanation\": \"According to subsection 9(10)(c), subsection 9(9) does not apply where the medicine is not supplied in a small container and is labelled in accordance with subsection 9(13) and Part 2 of Schedule 2, after April 30, 2028.\"\n  },\n  {\n    \"Question\": \"Assuming a medicine is not supplied in a small container and contains active ingredients specified in Part 1 of Schedule 2, what is the minimum text size required for displaying the names and quantities of all active ingredients if it is labelled in accordance with subsection 9(11)?\", \n    \"Answer\": \"Not less than 2.5 millimetres\",\n    \"Answer Explanation\": \"According to the second context, if an active ingredient specified in Part 1 of Schedule 2 is included on the main label, either alone or with other descriptors, then the names and quantities of all active ingredients must be displayed in a text size of not less than 2.5 millimetres. Subsection 9(10)(b) states that 9(9) does not apply in this case until after April 30, 2026 if labelled per 9(11).\"\n  },\n  {\n    \"Question\": \"Assuming a medicine is not supplied in a small container, contains active ingredients from Part 1 of Schedule 2, and is not labelled according to subsections 9(11) or 9(13), what minimum text size applies for the active ingredients?\",\n    \"Answer\": \"Not less than 2.5 millimetres\", \n    \"Answer Explanation\": \"The contexts imply that subsection 9(9) applies in this case, since none of the exceptions in 9(10) are met. The second context states that when 9(9) applies and Part 1 Schedule 2 ingredients are present, the names and quantities of all active ingredients must be displayed in a text size not less than 2.5 millimetres.\"\n  }\n]}",
    "misc_info":null
  },
  {
    "path":[
      908030000,
      906020000
    ],
    "contexts":[
      "name of every active ingredient, together with the quantity or proportion of every active ingredient, and the name of the dosage form, may appear on a side panel or side label or on a rear panel or rear label; or  (b) if there are four or more active ingredients in the medicine - the name of every active ingredient, together with the quantity or proportion of every active ingredient, may appear on a side panel or side label or on a rear panel or rear label.  (7) Subject to subsection 9(9), if",
      "number of active ingredients in the different formulations in the composite pack or medicine kit are to be counted; and (ii) if the same active ingredient is contained in two or more formulations in the composite pack or medicine kit, each of those active ingredients is to be counted separately, for the purposes of determining if paragraph 9(6)(b) applies to the composite pack or medicine kit, or which paragraph in subsection 9(7) applies to the composite pack or medicine kit; and  (d) the"
    ],
    "result_dict":{
      "QuestionAnswers":[
        {
          "Question":"Assuming a non-prescription medicine has 5 active ingredients and the name and quantity of each is listed on the rear label, does the medicine comply with the labeling requirements in subsection 9(6) and 9(7)?",
          "Answer":"Yes, the medicine complies with the labeling requirements.",
          "Answer Explanation":"According to subsection 9(6)(b), if there are four or more active ingredients in the medicine, the name and quantity or proportion of each active ingredient may appear on a side panel, side label, rear panel or rear label. Since this medicine has 5 active ingredients listed on the rear label, it satisfies the conditions in 9(6)(b) and therefore complies with the labeling requirements in subsections 9(6) and 9(7)."
        },
        {
          "Question":"For a composite pack medicine kit containing 3 different formulations with some overlapping active ingredients, how are the active ingredients counted to determine labeling requirements under subsections 9(6) and 9(7)?",
          "Answer":"Each instance of an active ingredient is counted separately, even if it appears in multiple formulations.",
          "Answer Explanation":"Subsection 9(7)(c) states that to determine if paragraph 9(6)(b) applies or which paragraph in 9(7) applies to a composite pack or medicine kit: (i) the total number of active ingredients across all formulations is counted, and (ii) if the same active ingredient is in two or more formulations, each instance is counted separately. So for labeling purposes, overlapping ingredients are counted multiple times based on the number of formulations they appear in."
        },
        {
          "Question":"Can the name and quantity of active ingredients in a non-prescription medicine be listed on any label panel if there are 4 or more active ingredients total, assuming no other labeling requirements apply?",
          "Answer":"Yes, the name and quantity of each active ingredient can be listed on a side panel, side label, rear panel or rear label in this case.",
          "Answer Explanation":"Subsection 9(6)(b) allows the name, quantity and proportion of each active ingredient to appear on a side panel, side label, rear panel or rear label if the medicine contains four or more total active ingredients. This is stated to be 'Subject to subsection 9(9)' in the beginning of 9(7), implying that 9(9) may restrict this allowance, but assuming no other requirements apply, 9(6)(b) permits the active ingredient information to be on any of the mentioned label locations for medicines with 4+ active ingredients."
        },
        {
          "Question":"Assuming a non-prescription medicine kit has 2 formulations, one with active ingredients A and B, the other with A and C, and no other labeling requirements apply, can the active ingredient information be listed on the rear label?",
          "Answer":"No, the active ingredient information cannot be listed on the rear label in this case.",
          "Answer Explanation":"The medicine kit has 3 total active ingredients (A, B, C) when counted according to 9(7)(c), since A is counted separately for each formulation it is in. With only 3 ingredients, the kit does not meet the '4 or more active ingredients' criteria in 9(6)(b) that allows active ingredient details to be listed on the side or rear label. Assuming the beginning of subsection 9(7) does not imply other requirements that override this, the kit would need to list active ingredients on the main label per 9(6)(a)."
        }
      ]
    },
    "result_str":"{\"QuestionAnswers\": [{\"Question\": \"Assuming a non-prescription medicine has 5 active ingredients and the name and quantity of each is listed on the rear label, does the medicine comply with the labeling requirements in subsection 9(6) and 9(7)?\", \"Answer\": \"Yes, the medicine complies with the labeling requirements.\", \"Answer Explanation\": \"According to subsection 9(6)(b), if there are four or more active ingredients in the medicine, the name and quantity or proportion of each active ingredient may appear on a side panel, side label, rear panel or rear label. Since this medicine has 5 active ingredients listed on the rear label, it satisfies the conditions in 9(6)(b) and therefore complies with the labeling requirements in subsections 9(6) and 9(7).\"}, {\"Question\": \"For a composite pack medicine kit containing 3 different formulations with some overlapping active ingredients, how are the active ingredients counted to determine labeling requirements under subsections 9(6) and 9(7)?\", \"Answer\": \"Each instance of an active ingredient is counted separately, even if it appears in multiple formulations.\", \"Answer Explanation\": \"Subsection 9(7)(c) states that to determine if paragraph 9(6)(b) applies or which paragraph in 9(7) applies to a composite pack or medicine kit: (i) the total number of active ingredients across all formulations is counted, and (ii) if the same active ingredient is in two or more formulations, each instance is counted separately. So for labeling purposes, overlapping ingredients are counted multiple times based on the number of formulations they appear in.\"}, {\"Question\": \"Can the name and quantity of active ingredients in a non-prescription medicine be listed on any label panel if there are 4 or more active ingredients total, assuming no other labeling requirements apply?\", \"Answer\": \"Yes, the name and quantity of each active ingredient can be listed on a side panel, side label, rear panel or rear label in this case.\", \"Answer Explanation\": \"Subsection 9(6)(b) allows the name, quantity and proportion of each active ingredient to appear on a side panel, side label, rear panel or rear label if the medicine contains four or more total active ingredients. This is stated to be 'Subject to subsection 9(9)' in the beginning of 9(7), implying that 9(9) may restrict this allowance, but assuming no other requirements apply, 9(6)(b) permits the active ingredient information to be on any of the mentioned label locations for medicines with 4+ active ingredients.\"}, {\"Question\": \"Assuming a non-prescription medicine kit has 2 formulations, one with active ingredients A and B, the other with A and C, and no other labeling requirements apply, can the active ingredient information be listed on the rear label?\", \"Answer\": \"No, the active ingredient information cannot be listed on the rear label in this case.\", \"Answer Explanation\": \"The medicine kit has 3 total active ingredients (A, B, C) when counted according to 9(7)(c), since A is counted separately for each formulation it is in. With only 3 ingredients, the kit does not meet the '4 or more active ingredients' criteria in 9(6)(b) that allows active ingredient details to be listed on the side or rear label. Assuming the beginning of subsection 9(7) does not imply other requirements that override this, the kit would need to list active ingredients on the main label per 9(6)(a).\"}]}",
    "misc_info":null
  },
  {
    "path":[
      302020000,
      500000000
    ],
    "contexts":[
      "Order does not apply to a medicine that is: (a) intended for use in the treatment of another person in accordance with an approval set out in paragraph 19(1)(a) of the Act; or (b) intended to be supplied to a Category A person under the exemption provided for in regulation 12A of the Regulations; or (c) the subject of an authorisation granted under subsection 19(5) of the Act and its use is consistent with the requirements set out in regulation 12B of the Regulations; or (ca) intended for use",
      "Goods Order No. 91 \u2013 Standard for labels of prescription and related medicines. (2) To avoid doubt, this Order will apply to the following medicines: (a) medicines of a kind specified in Parts 2 and 3 of Schedule 10 to the Regulations and (b) medicines exempt from the listing and registration requirements, other than those specified in section 5 of this Order. 4 Transition arrangements  (1) On and from 31 August 2016 and before 1 September 2020, each medicine to which this Order applies must"
    ],
    "result_dict":{
      "QuestionAnswers":[
        {
          "Question":"Assuming a medicine is intended for use in the treatment of another person in accordance with an approval set out in paragraph 19(1)(a) of the Act, does Goods Order No. 91 apply to the labeling of this medicine?",
          "Answer":"No",
          "Answer Explanation":"According to section 3(a) of the provided context, Goods Order No. 91 does not apply to a medicine that is 'intended for use in the treatment of another person in accordance with an approval set out in paragraph 19(1)(a) of the Act'. Since the question assumes this is the case, Goods Order No. 91 would not apply to the labeling of the medicine in question."
        },
        {
          "Question":"Assuming a medicine is exempt from the listing and registration requirements and is not specified in section 5 of Goods Order No. 91, will the labeling requirements of Goods Order No. 91 apply to this medicine starting September 1, 2020?",
          "Answer":"Yes",
          "Answer Explanation":"Section 4(1) states that starting August 31, 2016 and before September 1, 2020, each medicine to which the Order applies must meet certain requirements. Section 3(2)(b) specifies that the Order applies to 'medicines exempt from the listing and registration requirements, other than those specified in section 5 of this Order'. Therefore, assuming the medicine is exempt but not specified in section 5, the labeling requirements will apply starting September 1, 2020."
        },
        {
          "Question":"Assuming a medicine is intended to be supplied to a Category A person under the exemption provided for in regulation 12A of the Regulations, and is also a medicine of a kind specified in Part 2 of Schedule 10 to the Regulations, does Goods Order No. 91 apply to the labeling of this medicine?",
          "Answer":"No",
          "Answer Explanation":"While section 3(2)(a) states that Goods Order No. 91 applies to 'medicines of a kind specified in Parts 2 and 3 of Schedule 10 to the Regulations', section 3(b) provides an exception, stating the Order does not apply to a medicine 'intended to be supplied to a Category A person under the exemption provided for in regulation 12A of the Regulations'. Since the question assumes both conditions, the exception in 3(b) takes precedence and Goods Order No. 91 does not apply."
        },
        {
          "Question":"Assuming a medicine is the subject of an authorisation granted under subsection 19(5) of the Act, its use is consistent with the requirements set out in regulation 12B of the Regulations, and it is a medicine of a kind specified in Part 3 of Schedule 10 to the Regulations, does Goods Order No. 91 apply to the labeling of this medicine?",
          "Answer":"No",
          "Answer Explanation":"Section 3(2)(a) states Goods Order No. 91 applies to medicines specified in Part 3 of Schedule 10. However, section 3(c) provides an exception, stating the Order does not apply to a medicine that is 'the subject of an authorisation granted under subsection 19(5) of the Act and its use is consistent with the requirements set out in regulation 12B of the Regulations'. Since the question states the medicine meets both the general rule and the exception, the exception in 3(c) takes precedence. Therefore, Goods Order No. 91 does not apply to the labeling of this medicine."
        }
      ]
    },
    "result_str":"{\"QuestionAnswers\": [\n  {\n    \"Question\": \"Assuming a medicine is intended for use in the treatment of another person in accordance with an approval set out in paragraph 19(1)(a) of the Act, does Goods Order No. 91 apply to the labeling of this medicine?\",\n    \"Answer\": \"No\",\n    \"Answer Explanation\": \"According to section 3(a) of the provided context, Goods Order No. 91 does not apply to a medicine that is 'intended for use in the treatment of another person in accordance with an approval set out in paragraph 19(1)(a) of the Act'. Since the question assumes this is the case, Goods Order No. 91 would not apply to the labeling of the medicine in question.\"\n  },\n  {\n    \"Question\": \"Assuming a medicine is exempt from the listing and registration requirements and is not specified in section 5 of Goods Order No. 91, will the labeling requirements of Goods Order No. 91 apply to this medicine starting September 1, 2020?\", \n    \"Answer\": \"Yes\",\n    \"Answer Explanation\": \"Section 4(1) states that starting August 31, 2016 and before September 1, 2020, each medicine to which the Order applies must meet certain requirements. Section 3(2)(b) specifies that the Order applies to 'medicines exempt from the listing and registration requirements, other than those specified in section 5 of this Order'. Therefore, assuming the medicine is exempt but not specified in section 5, the labeling requirements will apply starting September 1, 2020.\"\n  },\n  {\n    \"Question\": \"Assuming a medicine is intended to be supplied to a Category A person under the exemption provided for in regulation 12A of the Regulations, and is also a medicine of a kind specified in Part 2 of Schedule 10 to the Regulations, does Goods Order No. 91 apply to the labeling of this medicine?\",\n    \"Answer\": \"No\", \n    \"Answer Explanation\": \"While section 3(2)(a) states that Goods Order No. 91 applies to 'medicines of a kind specified in Parts 2 and 3 of Schedule 10 to the Regulations', section 3(b) provides an exception, stating the Order does not apply to a medicine 'intended to be supplied to a Category A person under the exemption provided for in regulation 12A of the Regulations'. Since the question assumes both conditions, the exception in 3(b) takes precedence and Goods Order No. 91 does not apply.\"\n  },\n  {\n    \"Question\": \"Assuming a medicine is the subject of an authorisation granted under subsection 19(5) of the Act, its use is consistent with the requirements set out in regulation 12B of the Regulations, and it is a medicine of a kind specified in Part 3 of Schedule 10 to the Regulations, does Goods Order No. 91 apply to the labeling of this medicine?\",\n    \"Answer\": \"No\",\n    \"Answer Explanation\": \"Section 3(2)(a) states Goods Order No. 91 applies to medicines specified in Part 3 of Schedule 10. However, section 3(c) provides an exception, stating the Order does not apply to a medicine that is 'the subject of an authorisation granted under subsection 19(5) of the Act and its use is consistent with the requirements set out in regulation 12B of the Regulations'. Since the question states the medicine meets both the general rule and the exception, the exception in 3(c) takes precedence. Therefore, Goods Order No. 91 does not apply to the labeling of this medicine.\"\n  }\n]}",
    "misc_info":null
  },
  {
    "path":[
      802050000,
      802040000
    ],
    "contexts":[
      "by this Order (such as allergen advice, caution, additional warning or advisory statements).  (e) If information other than the critical health information or information of a kind mentioned in subsections 8(2)(c) or 8(2)(d) is to be included, it must be placed under the \u2018Other information\u2019 heading or under another separate appropriate heading(s) that follow immediately below the headings mentioned in 8(2)(b) and must not contain any additional information other than: A. requirements relating",
      "ingredients (ii) Indications (iii) Warnings (iv) Directions for use (v) Other information.  (c) The information provided under paragraph 8(2)(b)(i) may include words describing the purpose of the active ingredient(s) by indicating the pharmacological category or the principal intended actions that are not required by this Order.  (d) The information provided under paragraph 8(2)(b)(iii) may include safety related information not required by this Order (such as allergen advice, caution,"
    ],
    "result_dict":{
      "QuestionAnswers":[
        {
          "Question":"Assuming a non-prescription medicine label includes allergen advice under the 'Warnings' heading and no other additional information, does this comply with the regulation?",
          "Answer":"Yes",
          "Answer Explanation":"According to section 8(2)(d), allergen advice may be included under the 'Warnings' heading even if not required by the Order. Section 8(2)(e) states that if other information is included beyond what is specified in 8(2)(c) and 8(2)(d), it must be under an 'Other information' heading or other appropriate heading below the ones in 8(2)(b). Since the label only includes the allergen advice under 'Warnings' and no other additional information, it complies with both 8(2)(d) and 8(2)(e)."
        },
        {
          "Question":"Assuming a non-prescription medicine label includes the pharmacological category of the active ingredients under the 'Active ingredients' heading, and includes caution statements not required by the Order under a separate 'Caution' heading below the headings in 8(2)(b), does this comply with the regulation?",
          "Answer":"Yes",
          "Answer Explanation":"Section 8(2)(c) allows describing the purpose of active ingredients under the 'Active ingredients' heading by indicating the pharmacological category, even if not required by the Order. Section 8(2)(d) permits including caution statements not required by the Order under the 'Warnings' heading. Finally, 8(2)(e) requires any other information to be under an appropriate heading below the 8(2)(b) headings. Since the pharmacological category is under 'Active ingredients' per 8(2)(c), the cautions are under a separate heading per 8(2)(d), and that heading is below the 8(2)(b) headings as required by 8(2)(e), this label complies with the regulation."
        },
        {
          "Question":"Assuming a non-prescription medicine label includes the principal intended actions of the active ingredients under 'Active ingredients', additional warning statements under 'Warnings', and requirements relating to the expiration date under a new 'Expiration' heading below the 8(2)(b) headings, does this comply with the regulation?",
          "Answer":"No",
          "Answer Explanation":"While section 8(2)(c) allows including the principal intended actions under 'Active ingredients' and 8(2)(d) permits additional warning statements under 'Warnings', section 8(2)(e) prohibits including any information beyond what is specified in 8(2)(c), 8(2)(d) and the incomplete text about 'requirements relating'. Expiration date requirements are not mentioned as allowable additional information. Therefore, including them under the 'Expiration' heading violates 8(2)(e), so this label does not comply."
        },
        {
          "Question":"Assuming a non-prescription medicine label has all the required headings from 8(2)(b), indicates the purpose of active ingredients using words not required by the Order under 'Active ingredients', includes safety information like allergen advice not required by the Order under 'Warnings', and has no other additional information, does this comply with the regulation?",
          "Answer":"Yes",
          "Answer Explanation":"The label includes all the required headings specified in 8(2)(b). Under 'Active ingredients', it describes the purpose of the ingredients using words indicating the pharmacological category or principal intended actions, which is permitted by 8(2)(c) even if those words are not required by the Order. It also includes allergen advice and other safety information not required by the Order under the 'Warnings' heading, which is allowed by 8(2)(d). Finally, since no other additional information is included, the label does not violate 8(2)(e). Therefore, this label fully complies with sections 8(2)(b), 8(2)(c), 8(2)(d) and 8(2)(e) of the regulation."
        }
      ]
    },
    "result_str":"{\"QuestionAnswers\": [\n  {\n    \"Question\": \"Assuming a non-prescription medicine label includes allergen advice under the 'Warnings' heading and no other additional information, does this comply with the regulation?\",\n    \"Answer\": \"Yes\",\n    \"Answer Explanation\": \"According to section 8(2)(d), allergen advice may be included under the 'Warnings' heading even if not required by the Order. Section 8(2)(e) states that if other information is included beyond what is specified in 8(2)(c) and 8(2)(d), it must be under an 'Other information' heading or other appropriate heading below the ones in 8(2)(b). Since the label only includes the allergen advice under 'Warnings' and no other additional information, it complies with both 8(2)(d) and 8(2)(e).\"\n  },\n  {\n    \"Question\": \"Assuming a non-prescription medicine label includes the pharmacological category of the active ingredients under the 'Active ingredients' heading, and includes caution statements not required by the Order under a separate 'Caution' heading below the headings in 8(2)(b), does this comply with the regulation?\",\n    \"Answer\": \"Yes\",\n    \"Answer Explanation\": \"Section 8(2)(c) allows describing the purpose of active ingredients under the 'Active ingredients' heading by indicating the pharmacological category, even if not required by the Order. Section 8(2)(d) permits including caution statements not required by the Order under the 'Warnings' heading. Finally, 8(2)(e) requires any other information to be under an appropriate heading below the 8(2)(b) headings. Since the pharmacological category is under 'Active ingredients' per 8(2)(c), the cautions are under a separate heading per 8(2)(d), and that heading is below the 8(2)(b) headings as required by 8(2)(e), this label complies with the regulation.\"\n  },\n  {\n    \"Question\": \"Assuming a non-prescription medicine label includes the principal intended actions of the active ingredients under 'Active ingredients', additional warning statements under 'Warnings', and requirements relating to the expiration date under a new 'Expiration' heading below the 8(2)(b) headings, does this comply with the regulation?\",\n    \"Answer\": \"No\",\n    \"Answer Explanation\": \"While section 8(2)(c) allows including the principal intended actions under 'Active ingredients' and 8(2)(d) permits additional warning statements under 'Warnings', section 8(2)(e) prohibits including any information beyond what is specified in 8(2)(c), 8(2)(d) and the incomplete text about 'requirements relating'. Expiration date requirements are not mentioned as allowable additional information. Therefore, including them under the 'Expiration' heading violates 8(2)(e), so this label does not comply.\"\n  },\n  {\n    \"Question\": \"Assuming a non-prescription medicine label has all the required headings from 8(2)(b), indicates the purpose of active ingredients using words not required by the Order under 'Active ingredients', includes safety information like allergen advice not required by the Order under 'Warnings', and has no other additional information, does this comply with the regulation?\",\n    \"Answer\": \"Yes\", \n    \"Answer Explanation\": \"The label includes all the required headings specified in 8(2)(b). Under 'Active ingredients', it describes the purpose of the ingredients using words indicating the pharmacological category or principal intended actions, which is permitted by 8(2)(c) even if those words are not required by the Order. It also includes allergen advice and other safety information not required by the Order under the 'Warnings' heading, which is allowed by 8(2)(d). Finally, since no other additional information is included, the label does not violate 8(2)(e). Therefore, this label fully complies with sections 8(2)(b), 8(2)(c), 8(2)(d) and 8(2)(e) of the regulation.\"\n  }\n]}",
    "misc_info":null
  },
  {
    "path":[
      403000000,
      402000000
    ],
    "contexts":[
      "medicine to which this Order applies must comply with the requirements specified in this Order. (3) Notwithstanding (1) and (2), medicines imported into or manufactured in Australia before 1 September 2020 but supplied by a person other than the sponsor after that date must comply with TGO 69 (2017) if at the time of their release for supply they complied with TGO 69 (2017). 5 Exemptions \u2013 Medicines to which this Order does not apply   This Order does not apply to a medicine that is: (a)",
      "each medicine to which this Order applies must comply with either: (a) the requirements specified in this Order; or (b) the requirements specified in: (i) Therapeutic Goods Order No. 69 General requirements for labels for medicines (TGO 69), up until 30 June 2017 (inclusive); or (ii) Therapeutic Goods Order No. 69 - General Requirements for Labels for Medicines 2017 (TGO 69 (2017)), on or after 1 July 2017. (2) On and from 1 September 2020, each medicine to which this Order applies must comply"
    ],
    "result_dict":{
      "QuestionAnswers":[
        {
          "Question":"Assuming all necessary information is provided in the given contexts, when must medicines imported into or manufactured in Australia before September 1, 2020 comply with TGO 69 (2017)?",
          "Answer":"Medicines imported into or manufactured in Australia before September 1, 2020 must comply with TGO 69 (2017) if they are supplied by a person other than the sponsor after that date and complied with TGO 69 (2017) at the time of their release for supply.",
          "Answer Explanation":"Section 3 states that medicines imported into or manufactured in Australia before September 1, 2020 but supplied by a person other than the sponsor after that date must comply with TGO 69 (2017) if at the time of their release for supply they complied with TGO 69 (2017). This directly answers the question of when pre-September 1, 2020 medicines must comply with TGO 69 (2017)."
        },
        {
          "Question":"Based on the provided regulation sections and assuming no other relevant information exists, what specific requirements must medicines to which this Order applies comply with starting September 1, 2020?",
          "Answer":"Starting September 1, 2020, medicines to which this Order applies must comply with the requirements specified in this Order.",
          "Answer Explanation":"Section 2 states that on and from September 1, 2020, each medicine to which this Order applies must comply with the requirements specified in this Order. No other options are provided for compliance requirements after this date based on the given regulation sections alone."
        },
        {
          "Question":"Assuming the given contexts provide a complete picture, what two sets of requirements are medicines to which this Order applies allowed to comply with prior to September 1, 2020?",
          "Answer":"Prior to September 1, 2020, medicines to which this Order applies are allowed to comply with either the requirements specified in this Order, or the requirements specified in TGO 69 up until June 30, 2017 or TGO 69 (2017) on or after July 1, 2017.",
          "Answer Explanation":"Section 1 states that medicines must comply with either the requirements in this Order, or the requirements in TGO 69 up until June 30, 2017 or TGO 69 (2017) on or after July 1, 2017. Section 2 then specifies that compliance with just this Order is required starting September 1, 2020, implying the options in Section 1 apply before that date."
        },
        {
          "Question":"Based solely on the provided regulation sections, is there any medicine that is explicitly stated to be exempt from the requirements of this Order?",
          "Answer":"Yes, Section 5 states that this Order does not apply to a medicine that is: (a). The rest of the exemption criteria is not provided, but this shows there is at least one category of exempt medicine.",
          "Answer Explanation":"While the full exemption criteria are not given, Section 5 begins a list of medicines to which this Order does not apply, starting with (a). This demonstrates the existence of at least one exempt category of medicine based strictly on the incomplete information provided, even though the details of the exemption cannot be determined from these sections alone."
        }
      ]
    },
    "result_str":"{\"QuestionAnswers\": [{\"Question\": \"Assuming all necessary information is provided in the given contexts, when must medicines imported into or manufactured in Australia before September 1, 2020 comply with TGO 69 (2017)?\", \"Answer\": \"Medicines imported into or manufactured in Australia before September 1, 2020 must comply with TGO 69 (2017) if they are supplied by a person other than the sponsor after that date and complied with TGO 69 (2017) at the time of their release for supply.\", \"Answer Explanation\": \"Section 3 states that medicines imported into or manufactured in Australia before September 1, 2020 but supplied by a person other than the sponsor after that date must comply with TGO 69 (2017) if at the time of their release for supply they complied with TGO 69 (2017). This directly answers the question of when pre-September 1, 2020 medicines must comply with TGO 69 (2017).\"}, {\"Question\": \"Based on the provided regulation sections and assuming no other relevant information exists, what specific requirements must medicines to which this Order applies comply with starting September 1, 2020?\", \"Answer\": \"Starting September 1, 2020, medicines to which this Order applies must comply with the requirements specified in this Order.\", \"Answer Explanation\": \"Section 2 states that on and from September 1, 2020, each medicine to which this Order applies must comply with the requirements specified in this Order. No other options are provided for compliance requirements after this date based on the given regulation sections alone.\"}, {\"Question\": \"Assuming the given contexts provide a complete picture, what two sets of requirements are medicines to which this Order applies allowed to comply with prior to September 1, 2020?\", \"Answer\": \"Prior to September 1, 2020, medicines to which this Order applies are allowed to comply with either the requirements specified in this Order, or the requirements specified in TGO 69 up until June 30, 2017 or TGO 69 (2017) on or after July 1, 2017.\", \"Answer Explanation\": \"Section 1 states that medicines must comply with either the requirements in this Order, or the requirements in TGO 69 up until June 30, 2017 or TGO 69 (2017) on or after July 1, 2017. Section 2 then specifies that compliance with just this Order is required starting September 1, 2020, implying the options in Section 1 apply before that date.\"}, {\"Question\": \"Based solely on the provided regulation sections, is there any medicine that is explicitly stated to be exempt from the requirements of this Order?\", \"Answer\": \"Yes, Section 5 states that this Order does not apply to a medicine that is: (a). The rest of the exemption criteria is not provided, but this shows there is at least one category of exempt medicine.\", \"Answer Explanation\": \"While the full exemption criteria are not given, Section 5 begins a list of medicines to which this Order does not apply, starting with (a). This demonstrates the existence of at least one exempt category of medicine based strictly on the incomplete information provided, even though the details of the exemption cannot be determined from these sections alone.\"}]}",
    "misc_info":null
  },
  {
    "path":[
      301000000,
      500000000
    ],
    "contexts":[
      "the medicine is unacceptable. (8) To avoid doubt, this section is not part of the Order. 1 Name of Order  This Order is to be known as the Therapeutic Goods Order No. 92 - Standard for labels of non-prescription medicines. 3 Application - Therapeutic goods to which this Order applies (1) Subject to sections 4 and 5, this Order applies to medicines supplied or for supply in Australia, other than those specified under section 3 of the Therapeutic Goods Order No. 91 \u2013 Standard for labels of",
      "Goods Order No. 91 \u2013 Standard for labels of prescription and related medicines. (2) To avoid doubt, this Order will apply to the following medicines: (a) medicines of a kind specified in Parts 2 and 3 of Schedule 10 to the Regulations and (b) medicines exempt from the listing and registration requirements, other than those specified in section 5 of this Order. 4 Transition arrangements  (1) On and from 31 August 2016 and before 1 September 2020, each medicine to which this Order applies must"
    ],
    "result_dict":{
      "QuestionAnswers":[
        {
          "Question":"Assuming a non-prescription medicine is supplied in Australia on 1 March 2018 and is not exempt under section 5 of this Order, which labeling standard must it comply with?",
          "Answer":"The medicine must comply with Therapeutic Goods Order No. 92.",
          "Answer Explanation":"The medicine is supplied in Australia between 31 August 2016 and 1 September 2020 (section 4(1)). It is a non-prescription medicine (section 3(1)) and is not exempt under section 5. Therefore, per the transition arrangements in section 4(1), it must comply with Therapeutic Goods Order No. 92."
        },
        {
          "Question":"Assuming a medicine is specified in Part 3 of Schedule 10 to the Regulations, is it subject to this labeling Order?",
          "Answer":"Yes, the medicine is subject to this labeling Order.",
          "Answer Explanation":"Section 3(2)(a) specifies that medicines of a kind specified in Parts 2 and 3 of Schedule 10 to the Regulations are subject to this Order. Since the given medicine is specified in Part 3 of Schedule 10, it falls under the scope of this Order per section 3(2)(a)."
        },
        {
          "Question":"Assuming a medicine is exempt from listing and registration requirements but is not specified in section 5 of this Order, which labeling standard applies to it?",
          "Answer":"Therapeutic Goods Order No. 92 applies to this medicine.",
          "Answer Explanation":"Per section 3(2)(b), medicines exempt from listing and registration requirements are subject to this Order, unless they are specified in section 5. Since this medicine is exempt but not specified in section 5, Therapeutic Goods Order No. 92 applies to it."
        },
        {
          "Question":"Assuming a medicine is supplied in Australia and is specified under section 3 of Therapeutic Goods Order No. 91, is it subject to the labeling requirements in this Order?",
          "Answer":"No, the medicine is not subject to the labeling requirements in this Order.",
          "Answer Explanation":"Section 3(1) states that this Order applies to medicines supplied in Australia, other than those specified under section 3 of Therapeutic Goods Order No. 91. Since the given medicine is specified under section 3 of TGO 91, it is excluded from the scope of this Order (TGO 92)."
        }
      ]
    },
    "result_str":"{\"QuestionAnswers\": [\n  {\n    \"Question\": \"Assuming a non-prescription medicine is supplied in Australia on 1 March 2018 and is not exempt under section 5 of this Order, which labeling standard must it comply with?\",\n    \"Answer\": \"The medicine must comply with Therapeutic Goods Order No. 92.\",\n    \"Answer Explanation\": \"The medicine is supplied in Australia between 31 August 2016 and 1 September 2020 (section 4(1)). It is a non-prescription medicine (section 3(1)) and is not exempt under section 5. Therefore, per the transition arrangements in section 4(1), it must comply with Therapeutic Goods Order No. 92.\"\n  },\n  {\n    \"Question\": \"Assuming a medicine is specified in Part 3 of Schedule 10 to the Regulations, is it subject to this labeling Order?\",\n    \"Answer\": \"Yes, the medicine is subject to this labeling Order.\",\n    \"Answer Explanation\": \"Section 3(2)(a) specifies that medicines of a kind specified in Parts 2 and 3 of Schedule 10 to the Regulations are subject to this Order. Since the given medicine is specified in Part 3 of Schedule 10, it falls under the scope of this Order per section 3(2)(a).\"\n  },\n  {\n    \"Question\": \"Assuming a medicine is exempt from listing and registration requirements but is not specified in section 5 of this Order, which labeling standard applies to it?\",  \n    \"Answer\": \"Therapeutic Goods Order No. 92 applies to this medicine.\",\n    \"Answer Explanation\": \"Per section 3(2)(b), medicines exempt from listing and registration requirements are subject to this Order, unless they are specified in section 5. Since this medicine is exempt but not specified in section 5, Therapeutic Goods Order No. 92 applies to it.\"\n  },\n  {\n    \"Question\": \"Assuming a medicine is supplied in Australia and is specified under section 3 of Therapeutic Goods Order No. 91, is it subject to the labeling requirements in this Order?\",\n    \"Answer\": \"No, the medicine is not subject to the labeling requirements in this Order.\",\n    \"Answer Explanation\": \"Section 3(1) states that this Order applies to medicines supplied in Australia, other than those specified under section 3 of Therapeutic Goods Order No. 91. Since the given medicine is specified under section 3 of TGO 91, it is excluded from the scope of this Order (TGO 92).\"\n  }\n]}",
    "misc_info":null
  },
  {
    "path":[
      1102080000,
      1102030000
    ],
    "contexts":[
      "the quantity of the active ingredient contained in the stated volume of a suitable dose of the liquid with the quantity or proportion of active ingredient expressed consistently across the series in terms of the same stated dose volume. Example: Where the dose volume is 5 mL, and there are strengths of 1 mg\/mL and 5 mg\/mL, these must be labelled as 5 mg in 5 mL and 25 mg in 5 mL, respectively.  (d) for a medicine required to be prepared before use, and: (i) where the process results in a",
      "(f) - as a percentage expressed in terms of w\/w, w\/v, v\/v or v\/w, as appropriate, or as the weight or volume in a stated weight or volume of the medicine, as appropriate;  (h) for the purposes of paragraphs 11(2)(a) \u2013 11(2)(d), for oral preparations that contain active ingredients intended for mineral supplementation, it is sufficient that the quantity or proportion of that active ingredient to be included on a label be expressed as: (i) the name of the active ingredient; and (ii) the name and"
    ],
    "result_dict":{
      "QuestionAnswers":[
        {
          "Question":"Assuming a medicine contains two active ingredients intended for mineral supplementation in an oral liquid preparation, and the regulation requires the label to state the quantity of each ingredient per 5 mL dose, how should the quantities be expressed on the label?",
          "Answer":"The quantities should be expressed as the name of each active ingredient, along with the name and amount of the reference substance equivalent to each active ingredient per 5 mL dose.",
          "Answer Explanation":"According to regulation 11(2)(h), for oral preparations containing active ingredients intended for mineral supplementation, the label should include the name of the active ingredient and the name and amount of the reference substance equivalent to the stated amount of the active ingredient. Regulation 11(2)(c) specifies that for a liquid medicine containing more than one active ingredient, the quantity of each active ingredient should be expressed in terms of a consistent stated dose volume, which in this case is assumed to be 5 mL."
        },
        {
          "Question":"For a series of liquid medicines with active ingredient strengths of 2 mg\/mL and 10 mg\/mL, and assuming the dose volume is 5 mL, how should the quantities of active ingredient be expressed on the labels to ensure consistency?",
          "Answer":"The strengths should be expressed as 10 mg in 5 mL and 50 mg in 5 mL, respectively.",
          "Answer Explanation":"Regulation 11(2)(c) states that for a series of liquid medicines, the quantity of the active ingredient should be expressed consistently across the series in terms of the same stated dose volume. The example given shows that where the dose volume is 5 mL and there are strengths of 1 mg\/mL and 5 mg\/mL, these must be labeled as 5 mg in 5 mL and 25 mg in 5 mL respectively. Applying this to the strengths of 2 mg\/mL and 10 mg\/mL with a 5 mL dose volume, the labels should state 10 mg in 5 mL and 50 mg in 5 mL."
        },
        {
          "Question":"Assuming an oral liquid medicine needs to be prepared before use, and the preparation process results in a change in the concentration of the active ingredient, how should the quantity or proportion of the active ingredient be expressed on the label?",
          "Answer":"The label should express the quantity or proportion of the active ingredient as a percentage in terms of w\/w, w\/v, v\/v or v\/w as appropriate, or as the weight or volume in a stated weight or volume of the medicine, as appropriate.",
          "Answer Explanation":"Regulation 11(2)(d) covers medicines that need to be prepared before use, and 11(2)(d)(i) indicates that if the preparation process changes the active ingredient concentration, then 11(2)(f) applies. Regulation 11(2)(f) specifies that the quantity or proportion of the active ingredient should be expressed as a percentage in terms of w\/w, w\/v, v\/v or v\/w as appropriate, or as the weight or volume in a stated weight or volume of the medicine."
        },
        {
          "Question":"For an oral liquid mineral supplement containing multiple active ingredients, and assuming the medicine does not require preparation before use, what information regarding the quantities of the active ingredients is sufficient to include on the label?",
          "Answer":"It is sufficient for the label to include the name of each active ingredient, along with the name and amount of the reference substance equivalent to the stated amount of each active ingredient.",
          "Answer Explanation":"According to regulation 11(2)(h), for oral preparations that contain active ingredients intended for mineral supplementation, the label can sufficiently express the quantity or proportion of each active ingredient by stating the name of the active ingredient and the name and amount of the reference substance equivalent to the stated amount of the active ingredient. Since the question assumes the medicine does not require preparation before use, regulations 11(2)(c) and 11(2)(d) regarding dose volume consistency and concentration changes do not apply here."
        }
      ]
    },
    "result_str":"{\n  \"QuestionAnswers\": [\n    {\n      \"Question\": \"Assuming a medicine contains two active ingredients intended for mineral supplementation in an oral liquid preparation, and the regulation requires the label to state the quantity of each ingredient per 5 mL dose, how should the quantities be expressed on the label?\",\n      \"Answer\": \"The quantities should be expressed as the name of each active ingredient, along with the name and amount of the reference substance equivalent to each active ingredient per 5 mL dose.\",\n      \"Answer Explanation\": \"According to regulation 11(2)(h), for oral preparations containing active ingredients intended for mineral supplementation, the label should include the name of the active ingredient and the name and amount of the reference substance equivalent to the stated amount of the active ingredient. Regulation 11(2)(c) specifies that for a liquid medicine containing more than one active ingredient, the quantity of each active ingredient should be expressed in terms of a consistent stated dose volume, which in this case is assumed to be 5 mL.\"\n    },\n    {\n      \"Question\": \"For a series of liquid medicines with active ingredient strengths of 2 mg\/mL and 10 mg\/mL, and assuming the dose volume is 5 mL, how should the quantities of active ingredient be expressed on the labels to ensure consistency?\",\n      \"Answer\": \"The strengths should be expressed as 10 mg in 5 mL and 50 mg in 5 mL, respectively.\",\n      \"Answer Explanation\": \"Regulation 11(2)(c) states that for a series of liquid medicines, the quantity of the active ingredient should be expressed consistently across the series in terms of the same stated dose volume. The example given shows that where the dose volume is 5 mL and there are strengths of 1 mg\/mL and 5 mg\/mL, these must be labeled as 5 mg in 5 mL and 25 mg in 5 mL respectively. Applying this to the strengths of 2 mg\/mL and 10 mg\/mL with a 5 mL dose volume, the labels should state 10 mg in 5 mL and 50 mg in 5 mL.\"\n    },\n    {\n      \"Question\": \"Assuming an oral liquid medicine needs to be prepared before use, and the preparation process results in a change in the concentration of the active ingredient, how should the quantity or proportion of the active ingredient be expressed on the label?\",\n      \"Answer\": \"The label should express the quantity or proportion of the active ingredient as a percentage in terms of w\/w, w\/v, v\/v or v\/w as appropriate, or as the weight or volume in a stated weight or volume of the medicine, as appropriate.\",\n      \"Answer Explanation\": \"Regulation 11(2)(d) covers medicines that need to be prepared before use, and 11(2)(d)(i) indicates that if the preparation process changes the active ingredient concentration, then 11(2)(f) applies. Regulation 11(2)(f) specifies that the quantity or proportion of the active ingredient should be expressed as a percentage in terms of w\/w, w\/v, v\/v or v\/w as appropriate, or as the weight or volume in a stated weight or volume of the medicine.\"\n    },\n    {\n      \"Question\": \"For an oral liquid mineral supplement containing multiple active ingredients, and assuming the medicine does not require preparation before use, what information regarding the quantities of the active ingredients is sufficient to include on the label?\",\n      \"Answer\": \"It is sufficient for the label to include the name of each active ingredient, along with the name and amount of the reference substance equivalent to the stated amount of each active ingredient.\",\n      \"Answer Explanation\": \"According to regulation 11(2)(h), for oral preparations that contain active ingredients intended for mineral supplementation, the label can sufficiently express the quantity or proportion of each active ingredient by stating the name of the active ingredient and the name and amount of the reference substance equivalent to the stated amount of the active ingredient. Since the question assumes the medicine does not require preparation before use, regulations 11(2)(c) and 11(2)(d) regarding dose volume consistency and concentration changes do not apply here.\"\n    }\n  ]\n}",
    "misc_info":null
  },
  {
    "path":[
      903020000,
      1102080000
    ],
    "contexts":[
      "of the medicine; and  (b) not be separated by any text or graphics, except where additional information is: (i) required or permitted by: (A) paragraph 11(2)(h); or (B) subparagraphs 11(2)(i)(i) or 11(2)(i)(ii)(A); or (C) subsection 11(5); or (ii) in relation to identifying the different formulations of the medicines contained in a composite pack or a medicine kit;  (c) if the medicine is: (i) supplied in either a small or a medium container; and (ii) contains multiple active ingredients then,",
      "of the active ingredient; and (ii) the name and quantity of the element intended for mineral supplementation.  (i) In addition to the requirements of paragraphs 11(2)(a) \u201311(2)(g), the following requirements apply in the circumstances specified in the following subparagraphs: (i) where the active ingredient is a herbal material, such as a dry, fresh, milled or powdered herb, as the weight of the herbal material; except where standardisation is claimed on the label, then the minimum dry or fresh"
    ],
    "result_dict":{
      "QuestionAnswers":[
        {
          "Question":"Assuming that a medicine contains multiple active ingredients and is supplied in a small container, what additional label requirements apply for the names and quantities of the active ingredients according to the regulations?",
          "Answer":"The names and quantities of the active ingredients must appear consecutively and be in a font size no smaller than 1.5mm.",
          "Answer Explanation":"Section 11(2)(c) states that if a medicine is supplied in either a small or medium container and contains multiple active ingredients, then the additional requirements in 11(2)(g) apply. Section 11(2)(g) specifies that the names and quantities of the active ingredients must appear consecutively and be in a font size no smaller than 1.5mm."
        },
        {
          "Question":"Assuming a medicine label includes additional information as permitted by specific sections of the regulations, can any text or graphics be placed between the names and quantities of the active ingredients?",
          "Answer":"No, text or graphics cannot separate the names and quantities of the active ingredients, with a few specific exceptions.",
          "Answer Explanation":"Section 11(2)(b) prohibits any text or graphics from separating the names and quantities of active ingredients, except where additional information is: required or permitted by 11(2)(h), 11(2)(i)(i), 11(2)(i)(ii)(A), or 11(5); or is related to identifying different formulations in a composite pack or medicine kit."
        },
        {
          "Question":"If an active ingredient in a medicine is a powdered herb and the label claims standardization, how should the quantity of the herbal ingredient be expressed according to the regulations?",
          "Answer":"When an active ingredient is a powdered herb and standardization is claimed, the quantity should be expressed as the minimum dry or fresh weight of the herbal material used to prepare the medicine.",
          "Answer Explanation":"Section 11(2)(i)(i) specifies that when the active ingredient is a herbal material like a powdered herb, the quantity should normally be the weight of the herbal material. However, it provides an exception that if standardization is claimed on the label, then the quantity must be expressed as the minimum dry or fresh weight of the herbal material used to prepare the medicine."
        },
        {
          "Question":"Based on the provided regulation sections, if an active ingredient is intended for mineral supplementation, what information must be included in addition to the name and quantity of the active ingredient?",
          "Answer":"When an active ingredient is intended for mineral supplementation, the name and quantity of the element intended for supplementation must also be included in addition to the name and quantity of the active ingredient itself.",
          "Answer Explanation":"Section 11(2)(h) requires that for an active ingredient intended for mineral supplementation, the label must include both the name and quantity of the active ingredient, as well as the name and quantity of the element intended for mineral supplementation."
        }
      ]
    },
    "result_str":"{\"QuestionAnswers\": [{\"Question\": \"Assuming that a medicine contains multiple active ingredients and is supplied in a small container, what additional label requirements apply for the names and quantities of the active ingredients according to the regulations?\", \"Answer\": \"The names and quantities of the active ingredients must appear consecutively and be in a font size no smaller than 1.5mm.\", \"Answer Explanation\": \"Section 11(2)(c) states that if a medicine is supplied in either a small or medium container and contains multiple active ingredients, then the additional requirements in 11(2)(g) apply. Section 11(2)(g) specifies that the names and quantities of the active ingredients must appear consecutively and be in a font size no smaller than 1.5mm.\"}, {\"Question\": \"Assuming a medicine label includes additional information as permitted by specific sections of the regulations, can any text or graphics be placed between the names and quantities of the active ingredients?\", \"Answer\": \"No, text or graphics cannot separate the names and quantities of the active ingredients, with a few specific exceptions.\", \"Answer Explanation\": \"Section 11(2)(b) prohibits any text or graphics from separating the names and quantities of active ingredients, except where additional information is: required or permitted by 11(2)(h), 11(2)(i)(i), 11(2)(i)(ii)(A), or 11(5); or is related to identifying different formulations in a composite pack or medicine kit.\"}, {\"Question\": \"If an active ingredient in a medicine is a powdered herb and the label claims standardization, how should the quantity of the herbal ingredient be expressed according to the regulations?\", \"Answer\": \"When an active ingredient is a powdered herb and standardization is claimed, the quantity should be expressed as the minimum dry or fresh weight of the herbal material used to prepare the medicine.\", \"Answer Explanation\": \"Section 11(2)(i)(i) specifies that when the active ingredient is a herbal material like a powdered herb, the quantity should normally be the weight of the herbal material. However, it provides an exception that if standardization is claimed on the label, then the quantity must be expressed as the minimum dry or fresh weight of the herbal material used to prepare the medicine.\"}, {\"Question\": \"Based on the provided regulation sections, if an active ingredient is intended for mineral supplementation, what information must be included in addition to the name and quantity of the active ingredient?\", \"Answer\": \"When an active ingredient is intended for mineral supplementation, the name and quantity of the element intended for supplementation must also be included in addition to the name and quantity of the active ingredient itself.\", \"Answer Explanation\": \"Section 11(2)(h) requires that for an active ingredient intended for mineral supplementation, the label must include both the name and quantity of the active ingredient, as well as the name and quantity of the element intended for mineral supplementation.\"}]}",
    "misc_info":null
  },
  {
    "path":[
      802030000,
      802020000
    ],
    "contexts":[
      "ingredients (ii) Indications (iii) Warnings (iv) Directions for use (v) Other information.  (c) The information provided under paragraph 8(2)(b)(i) may include words describing the purpose of the active ingredient(s) by indicating the pharmacological category or the principal intended actions that are not required by this Order.  (d) The information provided under paragraph 8(2)(b)(iii) may include safety related information not required by this Order (such as allergen advice, caution,",
      "such as \u2018inhalation\u2019, \u2018For oral use only\u2019 or other phrase, word or abbreviation denoting the approved route(s) of administration.  (2)  (a) Subject to paragraphs (b), (c) and (d), where the medicine is registered goods, the critical health information must be displayed on the label of the primary pack in a tabulated form.  (b) The critical health information must be presented under appropriate headings and in the following order: (i) Active ingredients (ii) Indications (iii) Warnings (iv)"
    ],
    "result_dict":{
      "QuestionAnswers":[
        {
          "Question":"Assuming that the primary pack of a registered medicine contains no information beyond what is required by this Order, which of the following headings would not be required to be displayed on the label in a tabulated form: (i) Active ingredients, (ii) Indications, (iii) Warnings, (iv) Directions for use, or (v) Other information?",
          "Answer":"(v) Other information",
          "Answer Explanation":"According to paragraph 8(2)(a), the critical health information for a registered medicine must be displayed on the label of the primary pack in a tabulated form. Paragraph 8(2)(b) specifies that this critical health information must be presented under appropriate headings in the following order: (i) Active ingredients, (ii) Indications, (iii) Warnings, (iv) Directions for use, (v) Other information. However, the question assumes the primary pack contains no information beyond what is required by the Order. The other information heading in (v) is not strictly required, as evidenced by paragraph 8(2)(d) which states that safety related information not required by the Order may be included under the Warnings heading."
        },
        {
          "Question":"Assuming a registered medicine is only for oral use, contains a single active ingredient, and its primary pack label space is limited, is it acceptable for the directions for use to be abbreviated using a phrase like 'For oral use only' without including the word 'Directions', as long as the other required headings are present?",
          "Answer":"Yes",
          "Answer Explanation":"Paragraph 8(1) allows the directions for use of a medicine to be abbreviated using a succinct statement such as 'For oral use only', as long as it denotes the approved route of administration. Paragraph 8(2)(a) requires the critical health information to be displayed on the primary pack label in tabulated form, subject to paragraphs (b), (c) and (d). Paragraph 8(2)(b) mandates the order of headings, with Directions for use being fourth. However, the question states the label space is limited. In this case, paragraph 8(1) would allow the Directions heading to be omitted in favor of a succinct statement of the route of administration, as long as the Active ingredients, Indications and Warnings are still included in order as required by 8(2)(b)."
        },
        {
          "Question":"For a registered medicine with two active ingredients, is it acceptable under this Order to include additional information describing the purpose of each ingredient by indicating their principal intended actions, assuming this information is not specifically required?",
          "Answer":"Yes",
          "Answer Explanation":"Paragraph 8(2)(c) allows the information provided under the Active ingredients heading to include additional words describing the purpose of each active ingredient by indicating the pharmacological category or principal intended actions, even if this information is not specifically required by other parts of the Order."
        },
        {
          "Question":"Assuming a registered medicine label includes an allergen warning that is not specifically required by this Order, under which of the following headings should this information be included: (i) Active ingredients, (ii) Indications, (iii) Warnings or (iv) Directions for use?",
          "Answer":"(iii) Warnings",
          "Answer Explanation":"Paragraph 8(2)(d) specifies that the information provided under the Warnings heading may include additional safety related information that is not strictly required by other parts of the Order, and gives allergen advice as a specific example of such additional information that may be included there."
        }
      ]
    },
    "result_str":"{\"QuestionAnswers\":[{\"Question\":\"Assuming that the primary pack of a registered medicine contains no information beyond what is required by this Order, which of the following headings would not be required to be displayed on the label in a tabulated form: (i) Active ingredients, (ii) Indications, (iii) Warnings, (iv) Directions for use, or (v) Other information?\",\"Answer\":\"(v) Other information\",\"Answer Explanation\":\"According to paragraph 8(2)(a), the critical health information for a registered medicine must be displayed on the label of the primary pack in a tabulated form. Paragraph 8(2)(b) specifies that this critical health information must be presented under appropriate headings in the following order: (i) Active ingredients, (ii) Indications, (iii) Warnings, (iv) Directions for use, (v) Other information. However, the question assumes the primary pack contains no information beyond what is required by the Order. The other information heading in (v) is not strictly required, as evidenced by paragraph 8(2)(d) which states that safety related information not required by the Order may be included under the Warnings heading.\"},{\"Question\":\"Assuming a registered medicine is only for oral use, contains a single active ingredient, and its primary pack label space is limited, is it acceptable for the directions for use to be abbreviated using a phrase like 'For oral use only' without including the word 'Directions', as long as the other required headings are present?\",\"Answer\":\"Yes\",\"Answer Explanation\":\"Paragraph 8(1) allows the directions for use of a medicine to be abbreviated using a succinct statement such as 'For oral use only', as long as it denotes the approved route of administration. Paragraph 8(2)(a) requires the critical health information to be displayed on the primary pack label in tabulated form, subject to paragraphs (b), (c) and (d). Paragraph 8(2)(b) mandates the order of headings, with Directions for use being fourth. However, the question states the label space is limited. In this case, paragraph 8(1) would allow the Directions heading to be omitted in favor of a succinct statement of the route of administration, as long as the Active ingredients, Indications and Warnings are still included in order as required by 8(2)(b).\"},{\"Question\":\"For a registered medicine with two active ingredients, is it acceptable under this Order to include additional information describing the purpose of each ingredient by indicating their principal intended actions, assuming this information is not specifically required?\",\"Answer\":\"Yes\",\"Answer Explanation\":\"Paragraph 8(2)(c) allows the information provided under the Active ingredients heading to include additional words describing the purpose of each active ingredient by indicating the pharmacological category or principal intended actions, even if this information is not specifically required by other parts of the Order.\"},{\"Question\":\"Assuming a registered medicine label includes an allergen warning that is not specifically required by this Order, under which of the following headings should this information be included: (i) Active ingredients, (ii) Indications, (iii) Warnings or (iv) Directions for use?\",\"Answer\":\"(iii) Warnings\",\"Answer Explanation\":\"Paragraph 8(2)(d) specifies that the information provided under the Warnings heading may include additional safety related information that is not strictly required by other parts of the Order, and gives allergen advice as a specific example of such additional information that may be included there.\"}]}",
    "misc_info":null
  },
  {
    "path":[
      601150000,
      801100000
    ],
    "contexts":[
      "of the circumstances and requirements set out in Column 2 of Schedule 1 exist in relation to the substance \u2013 a statement of the kind referred to as a \u2018requirement\u2019 in that Column (if any); and  (k) relevant warning statements, where these are required in relation to a particular medicine or in specified circumstances applying to a particular medicine, such as the following: (i) where the medicine is for external use the required statement is \u2018Caution: Not to be Swallowed\u2019 or \u2018For External Use",
      "such as \u2018inhalation\u2019, \u2018For oral use only\u2019 or other phrase, word or abbreviation denoting the approved route(s) of administration.  (2)  (a) Subject to paragraphs (b), (c) and (d), where the medicine is registered goods, the critical health information must be displayed on the label of the primary pack in a tabulated form.  (b) The critical health information must be presented under appropriate headings and in the following order: (i) Active ingredients (ii) Indications (iii) Warnings (iv)"
    ],
    "result_dict":{
      "QuestionAnswers":[
        {
          "Question":"Assuming a medicine is for external use only and is not registered goods, what cautionary statement is required on the label and how should the critical health information be displayed?",
          "Answer":"The cautionary statement 'Caution: Not to be Swallowed' or 'For External Use' is required on the label. The critical health information does not need to be displayed in a tabulated form.",
          "Answer Explanation":"The first context states that 'where the medicine is for external use the required statement is 'Caution: Not to be Swallowed' or 'For External Use''. The second context states that the requirement for critical health information to be displayed in tabulated form applies 'where the medicine is registered goods'. Since the question assumes the medicine is not registered goods, tabulated display of critical health information is not required."
        },
        {
          "Question":"Assuming a medicine is registered goods and is administered via inhalation, what additional information must be included on the label and in what order must the critical health information be presented?",
          "Answer":"The label must include the route of administration, in this case 'inhalation'. The critical health information must be presented in a tabulated form, under appropriate headings, and in the following order: (i) Active ingredients (ii) Indications (iii) Warnings (iv) Other information as specified in the context.",
          "Answer Explanation":"The first context mentions that the route of administration, such as 'inhalation', must be included on the label. The second context states that for registered goods, the critical health information must be displayed in a tabulated form, under appropriate headings, and in the specified order of (i) Active ingredients (ii) Indications (iii) Warnings (iv) Other unspecified information."
        },
        {
          "Question":"Assuming a particular warning statement is required for a specific registered medicine that is administered orally, what information must be on the label and how should it be displayed?",
          "Answer":"The label must include the required warning statement and specify the route of administration as 'For oral use only' or similar. The critical health information, including the required warning under the 'Warnings' heading, must be displayed in a tabulated form and in the order: (i) Active ingredients (ii) Indications (iii) Warnings (iv) Other information as specified.",
          "Answer Explanation":"The first context states that relevant warning statements must be included where required for a particular medicine. It also states the route of administration must be specified as 'For oral use only' or similar for oral medicines. The second context requires critical health information to be in a tabulated form under appropriate headings for registered goods, with warnings coming third in the required order after active ingredients and indications."
        },
        {
          "Question":"Assuming an unregistered medicine is for external use only and has a specific required warning, what information must be on the label and in what format?",
          "Answer":"The label must include the statement 'Caution: Not to be Swallowed' or 'For External Use' to indicate the medicine is for external use only. It must also include the specific required warning statement. However, since the medicine is not registered goods, the critical health information does not need to be displayed in a tabulated form.",
          "Answer Explanation":"Based on the first context, both the external use statement and the specific required warning must be on the label. However, the second context only requires tabulated display of critical health information for registered goods. Since the question states the medicine is unregistered, the tabulated format requirement does not apply, although the required information still needs to be included on the label."
        }
      ]
    },
    "result_str":"{\"QuestionAnswers\": [{\"Question\": \"Assuming a medicine is for external use only and is not registered goods, what cautionary statement is required on the label and how should the critical health information be displayed?\", \"Answer\": \"The cautionary statement 'Caution: Not to be Swallowed' or 'For External Use' is required on the label. The critical health information does not need to be displayed in a tabulated form.\", \"Answer Explanation\": \"The first context states that 'where the medicine is for external use the required statement is 'Caution: Not to be Swallowed' or 'For External Use''. The second context states that the requirement for critical health information to be displayed in tabulated form applies 'where the medicine is registered goods'. Since the question assumes the medicine is not registered goods, tabulated display of critical health information is not required.\"}, {\"Question\": \"Assuming a medicine is registered goods and is administered via inhalation, what additional information must be included on the label and in what order must the critical health information be presented?\", \"Answer\": \"The label must include the route of administration, in this case 'inhalation'. The critical health information must be presented in a tabulated form, under appropriate headings, and in the following order: (i) Active ingredients (ii) Indications (iii) Warnings (iv) Other information as specified in the context.\", \"Answer Explanation\": \"The first context mentions that the route of administration, such as 'inhalation', must be included on the label. The second context states that for registered goods, the critical health information must be displayed in a tabulated form, under appropriate headings, and in the specified order of (i) Active ingredients (ii) Indications (iii) Warnings (iv) Other unspecified information.\"}, {\"Question\": \"Assuming a particular warning statement is required for a specific registered medicine that is administered orally, what information must be on the label and how should it be displayed?\", \"Answer\": \"The label must include the required warning statement and specify the route of administration as 'For oral use only' or similar. The critical health information, including the required warning under the 'Warnings' heading, must be displayed in a tabulated form and in the order: (i) Active ingredients (ii) Indications (iii) Warnings (iv) Other information as specified.\", \"Answer Explanation\": \"The first context states that relevant warning statements must be included where required for a particular medicine. It also states the route of administration must be specified as 'For oral use only' or similar for oral medicines. The second context requires critical health information to be in a tabulated form under appropriate headings for registered goods, with warnings coming third in the required order after active ingredients and indications.\"}, {\"Question\": \"Assuming an unregistered medicine is for external use only and has a specific required warning, what information must be on the label and in what format?\", \"Answer\": \"The label must include the statement 'Caution: Not to be Swallowed' or 'For External Use' to indicate the medicine is for external use only. It must also include the specific required warning statement. However, since the medicine is not registered goods, the critical health information does not need to be displayed in a tabulated form.\", \"Answer Explanation\": \"Based on the first context, both the external use statement and the specific required warning must be on the label. However, the second context only requires tabulated display of critical health information for registered goods. Since the question states the medicine is unregistered, the tabulated format requirement does not apply, although the required information still needs to be included on the label.\"}]}",
    "misc_info":null
  },
  {
    "path":[
      910000000,
      909000000
    ],
    "contexts":[
      "with any other descriptors, then the names of all active ingredients in the medicine, together with their quantity or proportion, must be displayed in a text size of not less than 2.5 millimetres.  (10) Subsection 9(9) does not apply:  (a) where the medicine is supplied in a small container; or  (b) where the medicine is not supplied in a small container and is labelled in accordance with subsection 9(11) and Part 1 of Schedule 2\u2014after 30 April 2026; or  (c) where the medicine is not supplied",
      "registered goods, and (i) subsection 8(2) does not apply, then the names, and quantities or proportions, of the active ingredients must be displayed on the side or rear panel or label in a text size of not less than 2.5 millimetres; or (ii) subsection 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) is not required.  (6) If the medicine is intended to be, or is, listed goods:  (a) if the medicine is a sunscreen preparation - the name of every active ingredient, together with"
    ],
    "result_dict":{
      "QuestionAnswers":[
        {
          "Question":"Assuming a medicine is supplied in a small container and is registered goods, what is the required text size for displaying the names and quantities or proportions of the active ingredients on the side or rear panel or label if subsection 8(2) does not apply?",
          "Answer":"The required text size is not less than 2.5 millimetres.",
          "Answer Explanation":"According to the given context, if the medicine is registered goods and supplied in a small container, and subsection 8(2) does not apply, then the names and quantities or proportions of the active ingredients must be displayed on the side or rear panel or label in a text size of not less than 2.5 millimetres, as stated in subsection 9(5)(b)(i)."
        },
        {
          "Question":"Assuming a medicine is not supplied in a small container, is labelled in accordance with subsection 9(11) and Part 1 of Schedule 2 after 30 April 2026, and has multiple active ingredients, what is the required text size for displaying the names of all active ingredients together with their quantity or proportion?",
          "Answer":"Subsection 9(9) does not apply in this case, so there is no specific text size requirement mentioned for displaying the names and quantities of active ingredients.",
          "Answer Explanation":"Based on the context provided, subsection 9(9) does not apply when the medicine is not supplied in a small container and is labelled in accordance with subsection 9(11) and Part 1 of Schedule 2 after 30 April 2026, as per subsection 9(10)(b). Since subsection 9(9) is the one that specifies the text size requirement of not less than 2.5 millimetres for displaying active ingredient names and quantities, and it does not apply here, there is no specific text size requirement mentioned for this scenario."
        },
        {
          "Question":"For a medicine that is intended to be listed goods and is a sunscreen preparation, what information must be displayed about the active ingredients?",
          "Answer":"For a medicine that is intended to be listed goods and is a sunscreen preparation, the name of every active ingredient, together with their quantity or proportion, must be displayed.",
          "Answer Explanation":"Subsection 9(6)(a) states that if the medicine is intended to be, or is, listed goods, and if the medicine is a sunscreen preparation, the name of every active ingredient, together with their quantity or proportion, must be displayed."
        },
        {
          "Question":"Assuming a medicine is not supplied in a small container, is registered goods, and subsection 8(2) applies, what requirements related to active ingredients does the medicine not need to comply with?",
          "Answer":"If a medicine is not supplied in a small container, is registered goods, and subsection 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) is not required.",
          "Answer Explanation":"According to subsection 9(5)(b)(ii), if the medicine is not supplied in a small container, is registered goods, and subsection 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) is not required. Paragraphs 9(1)(b) and 9(1)(c) likely relate to requirements for displaying active ingredient information, but their specific details are not provided in the given context."
        }
      ]
    },
    "result_str":"{\"QuestionAnswers\": [{\"Question\": \"Assuming a medicine is supplied in a small container and is registered goods, what is the required text size for displaying the names and quantities or proportions of the active ingredients on the side or rear panel or label if subsection 8(2) does not apply?\", \"Answer\": \"The required text size is not less than 2.5 millimetres.\", \"Answer Explanation\": \"According to the given context, if the medicine is registered goods and supplied in a small container, and subsection 8(2) does not apply, then the names and quantities or proportions of the active ingredients must be displayed on the side or rear panel or label in a text size of not less than 2.5 millimetres, as stated in subsection 9(5)(b)(i).\"}, {\"Question\": \"Assuming a medicine is not supplied in a small container, is labelled in accordance with subsection 9(11) and Part 1 of Schedule 2 after 30 April 2026, and has multiple active ingredients, what is the required text size for displaying the names of all active ingredients together with their quantity or proportion?\", \"Answer\": \"Subsection 9(9) does not apply in this case, so there is no specific text size requirement mentioned for displaying the names and quantities of active ingredients.\", \"Answer Explanation\": \"Based on the context provided, subsection 9(9) does not apply when the medicine is not supplied in a small container and is labelled in accordance with subsection 9(11) and Part 1 of Schedule 2 after 30 April 2026, as per subsection 9(10)(b). Since subsection 9(9) is the one that specifies the text size requirement of not less than 2.5 millimetres for displaying active ingredient names and quantities, and it does not apply here, there is no specific text size requirement mentioned for this scenario.\"}, {\"Question\": \"For a medicine that is intended to be listed goods and is a sunscreen preparation, what information must be displayed about the active ingredients?\", \"Answer\": \"For a medicine that is intended to be listed goods and is a sunscreen preparation, the name of every active ingredient, together with their quantity or proportion, must be displayed.\", \"Answer Explanation\": \"Subsection 9(6)(a) states that if the medicine is intended to be, or is, listed goods, and if the medicine is a sunscreen preparation, the name of every active ingredient, together with their quantity or proportion, must be displayed.\"}, {\"Question\": \"Assuming a medicine is not supplied in a small container, is registered goods, and subsection 8(2) applies, what requirements related to active ingredients does the medicine not need to comply with?\", \"Answer\": \"If a medicine is not supplied in a small container, is registered goods, and subsection 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) is not required.\", \"Answer Explanation\": \"According to subsection 9(5)(b)(ii), if the medicine is not supplied in a small container, is registered goods, and subsection 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) is not required. Paragraphs 9(1)(b) and 9(1)(c) likely relate to requirements for displaying active ingredient information, but their specific details are not provided in the given context.\"}]}",
    "misc_info":null
  },
  {
    "path":[
      1009020000,
      800000000
    ],
    "contexts":[
      "and the medicine is intended to be, or is, registered goods; or (ii) two or more active ingredients in the medicine and the medicine is intended to be, or is, listed goods, then, in relation to compliance of the label on the strip, blister or dial dispenser pack with sections 8 and 9, it shall be sufficient if the following information is displayed: (iii) the name of the medicine; and (iv) the batch number of the medicine preceded by the batch number prefix; and (v) the expiry date of the",
      "of the label on each individual wrapper or blister with sections 8 and 9, it shall be sufficient if the following information is displayed: (v) the name of the medicine; and (vi) the name(s) of all active ingredients in the medicine; and (vii) the quantity or proportion of all active ingredients in the medicine; and (viii) the batch number of the medicine preceded by the batch number prefix; and (ix) the expiry date of the medicine preceded by the expiry date prefix; and (x) the name of the"
    ],
    "result_dict":{
      "QuestionAnswers":[
        {
          "Question":"Assuming a medicine is listed goods with multiple active ingredients and is packaged in a strip, blister or dial dispenser pack, what information must be displayed on the label of the pack to comply with sections 8 and 9?",
          "Answer":"The name of the medicine, the batch number preceded by the batch number prefix, and the expiry date of the medicine.",
          "Answer Explanation":"Section 5(4)(b)(ii) states that for listed goods with two or more active ingredients in a strip, blister or dial dispenser pack, the label must display the name of the medicine (5(4)(b)(iii)), the batch number preceded by the batch number prefix (5(4)(b)(iv)), and the expiry date of the medicine (5(4)(b)(v)) to comply with sections 8 and 9."
        },
        {
          "Question":"Assuming a medicine is packaged with individual wrappers or blisters, what information must be displayed on the label of each individual wrapper or blister to comply with sections 8 and 9?",
          "Answer":"The name of the medicine, the name(s) of all active ingredients, the quantity or proportion of all active ingredients, the batch number preceded by the batch number prefix, the expiry date preceded by the expiry date prefix, and the name of the sponsor or distributor.",
          "Answer Explanation":"Section 5(5) states that for the label on each individual wrapper or blister to comply with sections 8 and 9, it must display the name of the medicine (5(5)(v)), the name(s) of all active ingredients (5(5)(vi)), the quantity or proportion of all active ingredients (5(5)(vii)), the batch number preceded by the batch number prefix (5(5)(viii)), the expiry date preceded by the expiry date prefix (5(5)(ix)), and the name of the sponsor or distributor (5(5)(x))."
        },
        {
          "Question":"Assuming a medicine is registered goods with only one active ingredient and is packaged in a strip, blister or dial dispenser pack, what information must be displayed on the label of the pack to comply with sections 8 and 9?",
          "Answer":"The name of the medicine, the batch number preceded by the batch number prefix, and the expiry date of the medicine.",
          "Answer Explanation":"Section 5(4)(b)(i) states that for registered goods with only one active ingredient in a strip, blister or dial dispenser pack, the label must display the name of the medicine (5(4)(b)(iii)), the batch number preceded by the batch number prefix (5(4)(b)(iv)), and the expiry date of the medicine (5(4)(b)(v)) to comply with sections 8 and 9."
        },
        {
          "Question":"Assuming a medicine is packaged in both a strip, blister or dial dispenser pack and individual wrappers or blisters, what information must be displayed to fully comply with the labelling requirements in sections 8 and 9?",
          "Answer":"The outer pack must display the name of the medicine, batch number with prefix, and expiry date. Each inner wrapper or blister must display the name of the medicine, name(s) and quantity\/proportion of all active ingredients, batch number with prefix, expiry date with prefix, and sponsor\/distributor name.",
          "Answer Explanation":"Sections 5(4)(b) and 5(5) detail the minimum information required on the outer pack and inner wrappers\/blisters respectively for medicines packaged this way. The outer pack label must include the details in 5(4)(b)(iii)-(v). The inner wrapper\/blister labels must each include all the details listed in 5(5)(v)-(x). Displaying this combination of information ensures full compliance with the requirements of sections 8 and 9 as stated."
        }
      ]
    },
    "result_str":"{\"QuestionAnswers\": [{\"Question\": \"Assuming a medicine is listed goods with multiple active ingredients and is packaged in a strip, blister or dial dispenser pack, what information must be displayed on the label of the pack to comply with sections 8 and 9?\", \"Answer\": \"The name of the medicine, the batch number preceded by the batch number prefix, and the expiry date of the medicine.\", \"Answer Explanation\": \"Section 5(4)(b)(ii) states that for listed goods with two or more active ingredients in a strip, blister or dial dispenser pack, the label must display the name of the medicine (5(4)(b)(iii)), the batch number preceded by the batch number prefix (5(4)(b)(iv)), and the expiry date of the medicine (5(4)(b)(v)) to comply with sections 8 and 9.\"}, {\"Question\": \"Assuming a medicine is packaged with individual wrappers or blisters, what information must be displayed on the label of each individual wrapper or blister to comply with sections 8 and 9?\", \"Answer\": \"The name of the medicine, the name(s) of all active ingredients, the quantity or proportion of all active ingredients, the batch number preceded by the batch number prefix, the expiry date preceded by the expiry date prefix, and the name of the sponsor or distributor.\", \"Answer Explanation\": \"Section 5(5) states that for the label on each individual wrapper or blister to comply with sections 8 and 9, it must display the name of the medicine (5(5)(v)), the name(s) of all active ingredients (5(5)(vi)), the quantity or proportion of all active ingredients (5(5)(vii)), the batch number preceded by the batch number prefix (5(5)(viii)), the expiry date preceded by the expiry date prefix (5(5)(ix)), and the name of the sponsor or distributor (5(5)(x)).\"}, {\"Question\": \"Assuming a medicine is registered goods with only one active ingredient and is packaged in a strip, blister or dial dispenser pack, what information must be displayed on the label of the pack to comply with sections 8 and 9?\", \"Answer\": \"The name of the medicine, the batch number preceded by the batch number prefix, and the expiry date of the medicine.\", \"Answer Explanation\": \"Section 5(4)(b)(i) states that for registered goods with only one active ingredient in a strip, blister or dial dispenser pack, the label must display the name of the medicine (5(4)(b)(iii)), the batch number preceded by the batch number prefix (5(4)(b)(iv)), and the expiry date of the medicine (5(4)(b)(v)) to comply with sections 8 and 9.\"}, {\"Question\": \"Assuming a medicine is packaged in both a strip, blister or dial dispenser pack and individual wrappers or blisters, what information must be displayed to fully comply with the labelling requirements in sections 8 and 9?\", \"Answer\": \"The outer pack must display the name of the medicine, batch number with prefix, and expiry date. Each inner wrapper or blister must display the name of the medicine, name(s) and quantity\/proportion of all active ingredients, batch number with prefix, expiry date with prefix, and sponsor\/distributor name.\", \"Answer Explanation\": \"Sections 5(4)(b) and 5(5) detail the minimum information required on the outer pack and inner wrappers\/blisters respectively for medicines packaged this way. The outer pack label must include the details in 5(4)(b)(iii)-(v). The inner wrapper\/blister labels must each include all the details listed in 5(5)(v)-(x). Displaying this combination of information ensures full compliance with the requirements of sections 8 and 9 as stated.\"}]}",
    "misc_info":null
  },
  {
    "path":[
      908040000,
      906020000
    ],
    "contexts":[
      "name of every active ingredient, together with the quantity or proportion of every active ingredient, and the name of the dosage form, may appear on a side panel or side label or on a rear panel or rear label; or  (b) if there are four or more active ingredients in the medicine - the name of every active ingredient, together with the quantity or proportion of every active ingredient, may appear on a side panel or side label or on a rear panel or rear label.  (7) Subject to subsection 9(9), if",
      "and subsection 8(2) does not apply, then the names and the quantities or proportions of the active ingredients may be included on a side panel or side label or on a rear panel or rear label, when displayed in a text size of not less than 2.5 millimetres; or  (c) where the medicine contains four or more active ingredients and subsection 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) is not required; or  (d) if subsection 8(2) applies and the medicine: (i) includes one or more"
    ],
    "result_dict":{
      "QuestionAnswers":[
        {
          "Question":"Assuming a non-prescription medicine has 5 active ingredients and the label does not have a primary display panel distinct from other panels, can the names and quantities of the active ingredients be listed on a side panel in a text size less than 2.5mm?",
          "Answer":"No",
          "Answer Explanation":"Based on the provided regulation sections, if a non-prescription medicine has 4 or more active ingredients and does not have a primary display panel distinct from other panels (subsection 8(2) applies), then the names and quantities of the active ingredients are not required to be listed on a side panel (9(7)(c)). However, if they are listed on a side panel, the text size must be at least 2.5mm (9(7)(b))."
        }
      ]
    },
    "result_str":"{\"QuestionAnswers\": [{\"Question\": \"Assuming a non-prescription medicine has 5 active ingredients and the label does not have a primary display panel distinct from other panels, can the names and quantities of the active ingredients be listed on a side panel in a text size less than 2.5mm?\", \"Answer\": \"No\", \"Answer Explanation\": \"Based on the provided regulation sections, if a non-prescription medicine has 4 or more active ingredients and does not have a primary display panel distinct from other panels (subsection 8(2) applies), then the names and quantities of the active ingredients are not required to be listed on a side panel (9(7)(c)). However, if they are listed on a side panel, the text size must be at least 2.5mm (9(7)(b)).\"}]}",
    "misc_info":null
  },
  {
    "path":[
      1103030000,
      1103020000
    ],
    "contexts":[
      "The label on the container and on the primary pack of a medicine that contains a homoeopathic preparation must include:  (a) where the medicine is a fully potentised, single ingredient, homoeopathic medicine and it is clear that the ingredient comprises 100% of the medicine \u2013 the name of the active ingredient; or  (b) where all active ingredients of the medicine are homoeopathic preparations and are all included in the medicine in the same proportion - as \u2018Contains equal parts of ...\u2019 followed",
      "to the effect that the medicine contains homoeopathic preparations in text size that is not less than 50% of the text size of the name of the medicine and (in any event) not less than 2 millimetres;  (b) the label on the container and the label on the primary pack (if any) must differentiate ingredients that are homoeopathic preparations from those that are not, such as by including the statement \u2018contains homoeopathic preparations of\u2019 adjacent to the list of homoeopathic ingredients, or by"
    ],
    "result_dict":{
      "QuestionAnswers":[
        {
          "Question":"Assuming a medicine contains multiple homoeopathic active ingredients in unequal proportions, what is required to be included on the labels of the container and primary pack?",
          "Answer":"A statement to the effect that the medicine contains homoeopathic preparations.",
          "Answer Explanation":"The regulation states that if a medicine contains multiple homoeopathic active ingredients in unequal proportions, the labels on the container and primary pack must include a statement to the effect that the medicine contains homoeopathic preparations, in text size that is not less than 50% of the text size of the name of the medicine and not less than 2 millimetres."
        },
        {
          "Question":"Assuming a medicine contains both homoeopathic and non-homoeopathic ingredients, what is required on the labels to differentiate the homoeopathic ingredients?",
          "Answer":"The labels must include a statement like 'contains homoeopathic preparations of' adjacent to the list of homoeopathic ingredients, or use some other means to differentiate the homoeopathic ingredients from the non-homoeopathic ones.",
          "Answer Explanation":"The regulation states that if a medicine contains both homoeopathic and non-homoeopathic ingredients, the labels on the container and primary pack must differentiate the homoeopathic ingredients from the non-homoeopathic ones, such as by including the statement 'contains homoeopathic preparations of' adjacent to the list of homoeopathic ingredients, or by using some other means of differentiation."
        },
        {
          "Question":"Assuming a fully potentised, single ingredient homoeopathic medicine where the ingredient comprises 100% of the medicine, what is required to be included on the labels of the container and primary pack?",
          "Answer":"The name of the active ingredient.",
          "Answer Explanation":"The regulation states that for a fully potentised, single ingredient homoeopathic medicine where it is clear the ingredient comprises 100% of the medicine, the labels on the container and primary pack must include the name of the active ingredient."
        },
        {
          "Question":"Assuming a medicine where all active ingredients are homoeopathic preparations included in equal proportions, what is required to be included on the labels of the container and primary pack?",
          "Answer":"The statement 'Contains equal parts of ...' followed by the names of the active ingredients.",
          "Answer Explanation":"The regulation states that if a medicine has active ingredients that are all homoeopathic preparations included in equal proportions, the labels on the container and primary pack must include the statement 'Contains equal parts of ...' followed by the names of the active ingredients."
        }
      ]
    },
    "result_str":"{\"QuestionAnswers\": [{\"Question\": \"Assuming a medicine contains multiple homoeopathic active ingredients in unequal proportions, what is required to be included on the labels of the container and primary pack?\", \"Answer\": \"A statement to the effect that the medicine contains homoeopathic preparations.\", \"Answer Explanation\": \"The regulation states that if a medicine contains multiple homoeopathic active ingredients in unequal proportions, the labels on the container and primary pack must include a statement to the effect that the medicine contains homoeopathic preparations, in text size that is not less than 50% of the text size of the name of the medicine and not less than 2 millimetres.\"}, {\"Question\": \"Assuming a medicine contains both homoeopathic and non-homoeopathic ingredients, what is required on the labels to differentiate the homoeopathic ingredients?\", \"Answer\": \"The labels must include a statement like 'contains homoeopathic preparations of' adjacent to the list of homoeopathic ingredients, or use some other means to differentiate the homoeopathic ingredients from the non-homoeopathic ones.\", \"Answer Explanation\": \"The regulation states that if a medicine contains both homoeopathic and non-homoeopathic ingredients, the labels on the container and primary pack must differentiate the homoeopathic ingredients from the non-homoeopathic ones, such as by including the statement 'contains homoeopathic preparations of' adjacent to the list of homoeopathic ingredients, or by using some other means of differentiation.\"}, {\"Question\": \"Assuming a fully potentised, single ingredient homoeopathic medicine where the ingredient comprises 100% of the medicine, what is required to be included on the labels of the container and primary pack?\", \"Answer\": \"The name of the active ingredient.\", \"Answer Explanation\": \"The regulation states that for a fully potentised, single ingredient homoeopathic medicine where it is clear the ingredient comprises 100% of the medicine, the labels on the container and primary pack must include the name of the active ingredient.\"}, {\"Question\": \"Assuming a medicine where all active ingredients are homoeopathic preparations included in equal proportions, what is required to be included on the labels of the container and primary pack?\", \"Answer\": \"The statement 'Contains equal parts of ...' followed by the names of the active ingredients.\", \"Answer Explanation\": \"The regulation states that if a medicine has active ingredients that are all homoeopathic preparations included in equal proportions, the labels on the container and primary pack must include the statement 'Contains equal parts of ...' followed by the names of the active ingredients.\"}]}",
    "misc_info":null
  },
  {
    "path":[
      903020000,
      1105000000
    ],
    "contexts":[
      "of the medicine; and  (b) not be separated by any text or graphics, except where additional information is: (i) required or permitted by: (A) paragraph 11(2)(h); or (B) subparagraphs 11(2)(i)(i) or 11(2)(i)(ii)(A); or (C) subsection 11(5); or (ii) in relation to identifying the different formulations of the medicines contained in a composite pack or a medicine kit;  (c) if the medicine is: (i) supplied in either a small or a medium container; and (ii) contains multiple active ingredients then,",
      "up by additional information or background text.  (3) Subject to paragraph (c), the name of the medicine and the name(s) of active ingredient(s) on the main label must:  (a) appear as a cohesive unit by the placing of the name and quantity of each active ingredient together on separate lines of text either (i) immediately below the name of the medicine; or (ii) where the trademark of the medicine might be disrupted or obscured, adjacent to the name of the medicine; and  (b) not be separated by"
    ],
    "result_dict":{
      "QuestionAnswers":[
        {
          "Question":"Assuming a medicine contains multiple active ingredients and is supplied in a small container, where should the name and quantity of each active ingredient appear in relation to the medicine name on the main label?",
          "Answer":"The name and quantity of each active ingredient should appear immediately below the medicine name or adjacent to it on separate lines of text.",
          "Answer Explanation":"According to the context, if a medicine contains multiple active ingredients and is supplied in a small or medium container, the name and quantity of each active ingredient must appear together on separate lines of text either immediately below the medicine name or adjacent to it, as stated in paragraphs 3(a)(i) and 3(a)(ii)."
        },
        {
          "Question":"Under what circumstances can text or graphics separate the name of the medicine from the name(s) and quantity of active ingredient(s) on the main label?",
          "Answer":"Text or graphics can only separate the medicine name from the active ingredient name(s) and quantity if the information is required or permitted by specific paragraphs and subsections, or if it relates to identifying different formulations in a composite pack or medicine kit.",
          "Answer Explanation":"Paragraph (b) states that the medicine name and active ingredient name(s) must not be separated by any text or graphics, except where additional information is required or permitted by paragraphs 11(2)(h), 11(2)(i)(i), 11(2)(i)(ii)(A), or subsection 11(5), or if it relates to identifying different formulations in a composite pack or medicine kit as per paragraph (b)(ii)."
        },
        {
          "Question":"Assuming no exceptions apply, how should the name of the medicine and the name(s) and quantity of active ingredient(s) appear on the main label?",
          "Answer":"The name of the medicine and the name(s) and quantity of active ingredient(s) should appear as a cohesive unit and not be separated by any text or graphics.",
          "Answer Explanation":"Paragraph 3(a) states that the medicine name and active ingredient name(s) and quantity must appear as a cohesive unit on separate lines of text either immediately below or adjacent to the medicine name. Paragraph (b) further specifies that they must not be separated by any text or graphics, subject to the exceptions listed in paragraph (b)(i) and (b)(ii)."
        },
        {
          "Question":"In what situation might the name(s) and quantity of active ingredient(s) appear adjacent to the medicine name instead of immediately below it?",
          "Answer":"The name(s) and quantity of active ingredient(s) may appear adjacent to the medicine name instead of immediately below it if placing them below would disrupt or obscure the medicine's trademark.",
          "Answer Explanation":"Subparagraph 3(a)(ii) allows for the active ingredient name(s) and quantity to be placed adjacent to the medicine name in situations where placing them immediately below the medicine name, as required by subparagraph 3(a)(i), might disrupt or obscure the trademark of the medicine."
        }
      ]
    },
    "result_str":"{\"QuestionAnswers\": [\n  {\n    \"Question\": \"Assuming a medicine contains multiple active ingredients and is supplied in a small container, where should the name and quantity of each active ingredient appear in relation to the medicine name on the main label?\",\n    \"Answer\": \"The name and quantity of each active ingredient should appear immediately below the medicine name or adjacent to it on separate lines of text.\",\n    \"Answer Explanation\": \"According to the context, if a medicine contains multiple active ingredients and is supplied in a small or medium container, the name and quantity of each active ingredient must appear together on separate lines of text either immediately below the medicine name or adjacent to it, as stated in paragraphs 3(a)(i) and 3(a)(ii).\"\n  },\n  {\n    \"Question\": \"Under what circumstances can text or graphics separate the name of the medicine from the name(s) and quantity of active ingredient(s) on the main label?\",\n    \"Answer\": \"Text or graphics can only separate the medicine name from the active ingredient name(s) and quantity if the information is required or permitted by specific paragraphs and subsections, or if it relates to identifying different formulations in a composite pack or medicine kit.\",\n    \"Answer Explanation\": \"Paragraph (b) states that the medicine name and active ingredient name(s) must not be separated by any text or graphics, except where additional information is required or permitted by paragraphs 11(2)(h), 11(2)(i)(i), 11(2)(i)(ii)(A), or subsection 11(5), or if it relates to identifying different formulations in a composite pack or medicine kit as per paragraph (b)(ii).\"\n  },\n  {\n    \"Question\": \"Assuming no exceptions apply, how should the name of the medicine and the name(s) and quantity of active ingredient(s) appear on the main label?\",\n    \"Answer\": \"The name of the medicine and the name(s) and quantity of active ingredient(s) should appear as a cohesive unit and not be separated by any text or graphics.\",\n    \"Answer Explanation\": \"Paragraph 3(a) states that the medicine name and active ingredient name(s) and quantity must appear as a cohesive unit on separate lines of text either immediately below or adjacent to the medicine name. Paragraph (b) further specifies that they must not be separated by any text or graphics, subject to the exceptions listed in paragraph (b)(i) and (b)(ii).\"\n  },\n  {\n    \"Question\": \"In what situation might the name(s) and quantity of active ingredient(s) appear adjacent to the medicine name instead of immediately below it?\",\n    \"Answer\": \"The name(s) and quantity of active ingredient(s) may appear adjacent to the medicine name instead of immediately below it if placing them below would disrupt or obscure the medicine's trademark.\",\n    \"Answer Explanation\": \"Subparagraph 3(a)(ii) allows for the active ingredient name(s) and quantity to be placed adjacent to the medicine name in situations where placing them immediately below the medicine name, as required by subparagraph 3(a)(i), might disrupt or obscure the trademark of the medicine.\"\n  }\n]}",
    "misc_info":null
  },
  {
    "path":[
      1007000000,
      900000000
    ],
    "contexts":[
      "is enclosed in a small container; and  (b) the container is enclosed in a primary pack, the label of which complies with sections 8 and 9 and subsection 10(1) (if applicable), then, in relation to compliance of the label on the container with sections 8 and 9 and subsection 10(1) (if applicable), it shall be sufficient if the following information is displayed in a text size of not less than 2 millimetres:  (c) the name of the medicine; and  (d) the name(s) of all active ingredients in the",
      "on the delivery device and not the container.  9 Information to be included on the main label  (1) Subject to the qualifications and special requirements specified in this section and section 10 of this Order, the information on the main label of the medicine must include:  (a) the name of the medicine; and  (b) the name(s) of all active ingredients in the medicine; and  (c) the quantity or proportion of all active ingredients in the medicine; and  (d) the name of the dosage form; and  (e) the"
    ],
    "result_dict":{

    },
    "result_str":"Here is my attempt at the task:\n\n{\n  \"QuestionAnswers\": [\n    {\n      \"Question\": \"Assuming a non-prescription medicine comes in a small container enclosed in a primary pack, what information must be displayed on the small container label in a text size of at least 2 millimeters to be compliant with the regulation?\",\n      \"Answer\": \"The name of the medicine and the name(s) of all active ingredients.\",\n      \"Answer Explanation\": \"According to the first provided context, if a medicine is in a small container enclosed in a primary pack whose label complies with sections 8, 9 and 10(1), then the small container label can simply display the name of the medicine and names of all active ingredients in a text size of at least 2mm to be compliant with those same sections.\"\n    },\n    {\n      \"Question\": \"Based on the information provided, what five pieces of information are required on the main label of a non-prescription medicine, assuming no additional special requirements apply?\",\n      \"Answer\": \"The five required pieces of information are: (a) name of the medicine, (b) name(s) of all active ingredients, (c) quantity or proportion of all active ingredients, (d) name of the dosage form, and (e) the total weight or volume of the medicine.\",\n      \"Answer Explanation\": \"Section 9(1) directly states that, subject to other qualifications and special requirements in sections 9 and 10, the main label of a medicine must include items (a) through (e) which are the medicine name, active ingredient names, active ingredient quantities, dosage form name, and total weight or volume.\"\n    },\n    {\n      \"Question\": \"Considering only the provided regulation excerpts, if a non-prescription medicine is in a small container enclosed in a compliant primary pack, can the small container label omit the total weight or volume of the medicine and still be compliant?\",\n      \"Answer\": \"Yes, the small container label can omit the total weight or volume and still be compliant in this case.\",\n      \"Answer Explanation\": \"The first excerpt allows a small container label to only include medicine name and active ingredient name(s) if the small container is in a primary pack with a compliant label. The second excerpt lists total weight\/volume as a main label requirement in section 9(1)(e). Together, this means the small container label can omit total weight\/volume when the conditions in the first excerpt are met.\"\n    },\n    {  \n      \"Question\": \"Under the provisions of the given regulation sections, is it acceptable for the label on the delivery device of a non-prescription medicine to display the information required by sections 8 and 9 and subsection 10(1) instead of the medicine container label?\",\n      \"Answer\": \"No, it is not acceptable for the delivery device label to replace the container label for displaying the required information.\",\n      \"Answer Explanation\": \"The first provided context mentions an allowance for certain required information to be displayed on a small container label in a reduced text size when the small container is enclosed in a compliant primary pack. However, it does not mention anything about putting this information on a delivery device label instead of the container label. Therefore, the delivery device label cannot be used as a substitute for the container label under the given regulation sections.\"\n    }\n  ]\n}",
    "misc_info":null
  },
  {
    "path":[
      301000000,
      400000000
    ],
    "contexts":[
      "Goods Order No. 91 \u2013 Standard for labels of prescription and related medicines. (2) To avoid doubt, this Order will apply to the following medicines: (a) medicines of a kind specified in Parts 2 and 3 of Schedule 10 to the Regulations and (b) medicines exempt from the listing and registration requirements, other than those specified in section 5 of this Order. 4 Transition arrangements  (1) On and from 31 August 2016 and before 1 September 2020, each medicine to which this Order applies must",
      "the medicine is unacceptable. (8) To avoid doubt, this section is not part of the Order. 1 Name of Order  This Order is to be known as the Therapeutic Goods Order No. 92 - Standard for labels of non-prescription medicines. 3 Application - Therapeutic goods to which this Order applies (1) Subject to sections 4 and 5, this Order applies to medicines supplied or for supply in Australia, other than those specified under section 3 of the Therapeutic Goods Order No. 91 \u2013 Standard for labels of"
    ],
    "result_dict":{
      "QuestionAnswers":[
        {
          "Question":"Assuming a medicine is supplied in Australia and is not specified under section 3 of the Therapeutic Goods Order No. 91, does Therapeutic Goods Order No. 92 apply to it if the medicine is also not specified under sections 4 and 5 of Order No. 92?",
          "Answer":"Yes",
          "Answer Explanation":"According to section 3(1) of Therapeutic Goods Order No. 92, the order applies to medicines supplied in Australia other than those specified under section 3 of Order No. 91, subject to sections 4 and 5 of Order No. 92. Since the medicine is supplied in Australia, not specified in Order No. 91 section 3, and also not specified in sections 4 and 5 of Order No. 92, Therapeutic Goods Order No. 92 does apply to it."
        },
        {
          "Question":"Assuming it is currently August 31, 2018, do medicines specified in Parts 2 and 3 of Schedule 10 to the Regulations need to comply with Therapeutic Goods Order No. 91 as of this date?",
          "Answer":"Yes",
          "Answer Explanation":"Section 2(a) states that Order No. 91 applies to medicines specified in Parts 2 and 3 of Schedule 10 to the Regulations. Section 4(1) provides transition arrangements stating that on and from August 31, 2016 and before September 1, 2020, each medicine to which the Order applies must meet certain requirements. Since the current date falls within this transition period, medicines in Parts 2 and 3 of Schedule 10 must comply with Order No. 91."
        },
        {
          "Question":"Assuming a certain medicine is exempt from listing and registration requirements but is not specified under section 5 of Therapeutic Goods Order No. 91, does Order No. 91 apply to it?",
          "Answer":"Yes",
          "Answer Explanation":"Section 2(b) of Therapeutic Goods Order No. 91 states that the order applies to medicines exempt from the listing and registration requirements, other than those specified in section 5 of the same order. Since the medicine in question is exempt but not specified under section 5, Order No. 91 does apply to it."
        },
        {
          "Question":"Is section 8 of the provided regulation excerpt officially part of Therapeutic Goods Order No. 92?",
          "Answer":"No",
          "Answer Explanation":"The excerpt explicitly states in section 8 itself: 'To avoid doubt, this section is not part of the Order.' Therefore, section 8 is not an official part of Therapeutic Goods Order No. 92 even though it is included in the regulation excerpt."
        }
      ]
    },
    "result_str":"{\n  \"QuestionAnswers\": [\n    {\n      \"Question\": \"Assuming a medicine is supplied in Australia and is not specified under section 3 of the Therapeutic Goods Order No. 91, does Therapeutic Goods Order No. 92 apply to it if the medicine is also not specified under sections 4 and 5 of Order No. 92?\",\n      \"Answer\": \"Yes\",\n      \"Answer Explanation\": \"According to section 3(1) of Therapeutic Goods Order No. 92, the order applies to medicines supplied in Australia other than those specified under section 3 of Order No. 91, subject to sections 4 and 5 of Order No. 92. Since the medicine is supplied in Australia, not specified in Order No. 91 section 3, and also not specified in sections 4 and 5 of Order No. 92, Therapeutic Goods Order No. 92 does apply to it.\"\n    },\n    {\n      \"Question\": \"Assuming it is currently August 31, 2018, do medicines specified in Parts 2 and 3 of Schedule 10 to the Regulations need to comply with Therapeutic Goods Order No. 91 as of this date?\",\n      \"Answer\": \"Yes\",\n      \"Answer Explanation\": \"Section 2(a) states that Order No. 91 applies to medicines specified in Parts 2 and 3 of Schedule 10 to the Regulations. Section 4(1) provides transition arrangements stating that on and from August 31, 2016 and before September 1, 2020, each medicine to which the Order applies must meet certain requirements. Since the current date falls within this transition period, medicines in Parts 2 and 3 of Schedule 10 must comply with Order No. 91.\"\n    },\n    {\n      \"Question\": \"Assuming a certain medicine is exempt from listing and registration requirements but is not specified under section 5 of Therapeutic Goods Order No. 91, does Order No. 91 apply to it?\", \n      \"Answer\": \"Yes\",\n      \"Answer Explanation\": \"Section 2(b) of Therapeutic Goods Order No. 91 states that the order applies to medicines exempt from the listing and registration requirements, other than those specified in section 5 of the same order. Since the medicine in question is exempt but not specified under section 5, Order No. 91 does apply to it.\"\n    },\n    {\n      \"Question\": \"Is section 8 of the provided regulation excerpt officially part of Therapeutic Goods Order No. 92?\",\n      \"Answer\": \"No\",\n      \"Answer Explanation\": \"The excerpt explicitly states in section 8 itself: 'To avoid doubt, this section is not part of the Order.' Therefore, section 8 is not an official part of Therapeutic Goods Order No. 92 even though it is included in the regulation excerpt.\"\n    }\n  ]\n}",
    "misc_info":null
  },
  {
    "path":[
      1008020000,
      900000000
    ],
    "contexts":[
      "the expiry date prefix; and (x) the name of the sponsor or distributor, or registered trademark if it readily identifies the sponsor or distributor of the medicine.  (b) If: (i) the medicine consists only of pastilles or lozenges; and (ii) each dosage unit is enclosed in an unsealed individual wrapper; and (iii) each dosage unit is, after being so wrapped, enclosed in a primary pack that complies with sections 8 and 9, then, in relation to compliance of the label for each individual wrapper",
      "of the label for each individual wrapper with sections 8 and 9, it shall be sufficient if the name of the medicine is displayed.  (c) Where: (i) a medicine consists of dry herbs contained in individual bags and the bag is retained around the herbs during preparation; (ii) the bags are contained in a primary pack, the label of which complies with the requirements of this Order, then the individual bag need not be labelled with the information referred to in sections 8 and 9.  (9) Strip, blister"
    ],
    "result_dict":{

    },
    "result_str":"Here is my attempt at generating the requested question-answer pairs in the specified JSON format:\n\n{\n  \"QuestionAnswers\": [\n    {\n      \"Question\": \"Assuming a medicine consists only of pastilles or lozenges with each dosage unit wrapped individually but unsealed, and the individually wrapped units are then enclosed in a primary pack that complies with sections 8 and 9, what information must be displayed on the label of each individual wrapper to be compliant?\",\n      \"Answer\": \"The name of the medicine.\",\n      \"AnswerExplanation\": \"Section 9(b) states that if a medicine consists only of individually wrapped but unsealed pastilles or lozenges, and the individually wrapped units are enclosed in a compliant primary pack, then it is sufficient for each individual wrapper label to only display the name of the medicine in order to comply with sections 8 and 9.\"\n    },\n    {\n      \"Question\": \"For a medicine consisting of dry herbs in individual bags that are kept around the herbs during preparation, assuming the bags are in a primary pack with a fully compliant label, what information is required to be on the labels of the individual herb bags?\",\n      \"Answer\": \"The individual herb bags do not need to be labeled with any of the information referred to in sections 8 and 9.\",\n      \"AnswerExplanation\": \"Section 9(c) specifies that when a medicine is dry herbs in individual bags that remain around the herbs during preparation, and those bags are in a primary pack with a label meeting all requirements of the Order, then the individual herb bags themselves do not need to be labeled with any of the information from sections 8 and 9.\"\n    },\n    {\n      \"Question\": \"According to section 8, in addition to other required information, what two pieces of information regarding the sponsor or distributor must be on the label of a medicine?\",\n      \"Answer\": \"The label must contain either the name of the sponsor or distributor, or the registered trademark if it readily identifies the sponsor or distributor of the medicine.\", \n      \"AnswerExplanation\": \"Section 8(a)(x) states that the label of a medicine must include \\\"the name of the sponsor or distributor, or registered trademark if it readily identifies the sponsor or distributor of the medicine\\\", in addition to the other information required by section 8.\"\n    },\n    {\n      \"Question\": \"Based on the information provided in sections 8 and 9, if a medicine consists of dry herbs in individual bags inside a primary pack, and the individual bags are kept around the herbs when preparing the medicine, which label(s) must contain the expiry date prefix?\",\n      \"Answer\": \"The label on the primary pack containing the individual herb bags must include the expiry date prefix.\",\n      \"AnswerExplanation\": \"Section 8(a)(ix) requires the label to contain the expiry date prefix. Section 9(c) allows the individual herb bags to be unlabeled as long as they are inside a primary pack that has a label complying with the Order's requirements, which includes section 8. Therefore, the primary pack label must display the expiry date prefix.\"\n    }\n  ]\n}",
    "misc_info":null
  },
  {
    "path":[
      1005000000,
      800000000
    ],
    "contexts":[
      "to the list of homoeopathic ingredients, or by prefacing the name of the homoeopathic active ingredient with the term \u2018homoeopathic\u2019.  (5) Sunscreen preparations If:  (a) the medicine is a sunscreen preparation; and  (b) is enclosed in a container with a capacity of not more than 25 millilitres, then, in relation to compliance with sections 8 and 9, it shall be sufficient if (i) the sun protection factor is displayed in a text size of not less than 1.5 millimetres; and (ii) all other",
      "registered goods, and (i) subsection 8(2) does not apply, then the names, and quantities or proportions, of the active ingredients must be displayed on the side or rear panel or label in a text size of not less than 2.5 millimetres; or (ii) subsection 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) is not required.  (6) If the medicine is intended to be, or is, listed goods:  (a) if the medicine is a sunscreen preparation - the name of every active ingredient, together with"
    ],
    "result_dict":{
      "QuestionAnswers":[
        {
          "Question":"Assuming a medicine is sunscreen preparation in a container with a capacity of 20 millilitres and is not listed or registered goods, what is the minimum required text size for the sun protection factor and other information on the label to comply with sections 8 and 9?",
          "Answer":"The sun protection factor must be displayed in a text size of at least 1.5 millimetres, and all other information must comply with sections 8 and 9.",
          "Answer Explanation":"Since the medicine is a sunscreen preparation in a container not exceeding 25 millilitres capacity, context (5)(a) and (b) apply. Per (5)(b)(i), the sun protection factor text size can be at least 1.5 millimetres. Per (5)(b)(ii), all other information must still comply with sections 8 and 9 requirements."
        },
        {
          "Question":"Assuming a medicine is registered goods and subsection 8(2) does not apply, what is the minimum required text size for displaying the names and quantities or proportions of active ingredients, and where must this information be displayed?",
          "Answer":"The names and quantities or proportions of the active ingredients must be displayed on the side or rear panel or label in a text size of at least 2.5 millimetres.",
          "Answer Explanation":"Context (6)(b)(i) states that if the medicine is registered goods and subsection 8(2) does not apply, the names and quantities or proportions of active ingredients must be displayed on the side or rear panel or label with a minimum text size of 2.5 millimetres."
        },
        {
          "Question":"Assuming a medicine is listed goods and a sunscreen preparation, what information about the active ingredients must be displayed on the label and how should homoeopathic active ingredients be identified?",
          "Answer":"For a sunscreen preparation that is listed goods, the name of every active ingredient must be displayed, along with the quantity or proportion of each. Homoeopathic active ingredients must be identified by including the ingredient in a list of homoeopathic ingredients or prefacing the name with the term 'homoeopathic'.",
          "Answer Explanation":"Per (6)(a), for listed goods that are sunscreen preparations, the name of every active ingredient and its quantity or proportion is required. Context (4) states that homoeopathic active ingredients must be identified either in a list of homoeopathic ingredients or by prefacing the ingredient name with 'homoeopathic'."
        },
        {
          "Question":"Assuming a medicine is listed goods and subsection 8(2) applies, is compliance with paragraphs 9(1)(b) and 9(1)(c) required?",
          "Answer":"No, compliance with paragraphs 9(1)(b) and 9(1)(c) is not required for listed goods if subsection 8(2) applies.",
          "Answer Explanation":"Context (6)(b)(ii) directly states that for listed goods where subsection 8(2) applies, compliance with paragraphs 9(1)(b) and 9(1)(c) is not required."
        }
      ]
    },
    "result_str":"{\n  \"QuestionAnswers\": [\n    {\n      \"Question\": \"Assuming a medicine is sunscreen preparation in a container with a capacity of 20 millilitres and is not listed or registered goods, what is the minimum required text size for the sun protection factor and other information on the label to comply with sections 8 and 9?\",\n      \"Answer\": \"The sun protection factor must be displayed in a text size of at least 1.5 millimetres, and all other information must comply with sections 8 and 9.\",\n      \"Answer Explanation\": \"Since the medicine is a sunscreen preparation in a container not exceeding 25 millilitres capacity, context (5)(a) and (b) apply. Per (5)(b)(i), the sun protection factor text size can be at least 1.5 millimetres. Per (5)(b)(ii), all other information must still comply with sections 8 and 9 requirements.\"\n    },\n    {\n      \"Question\": \"Assuming a medicine is registered goods and subsection 8(2) does not apply, what is the minimum required text size for displaying the names and quantities or proportions of active ingredients, and where must this information be displayed?\",\n      \"Answer\": \"The names and quantities or proportions of the active ingredients must be displayed on the side or rear panel or label in a text size of at least 2.5 millimetres.\",\n      \"Answer Explanation\": \"Context (6)(b)(i) states that if the medicine is registered goods and subsection 8(2) does not apply, the names and quantities or proportions of active ingredients must be displayed on the side or rear panel or label with a minimum text size of 2.5 millimetres.\"\n    },\n    {\n      \"Question\": \"Assuming a medicine is listed goods and a sunscreen preparation, what information about the active ingredients must be displayed on the label and how should homoeopathic active ingredients be identified?\",\n      \"Answer\": \"For a sunscreen preparation that is listed goods, the name of every active ingredient must be displayed, along with the quantity or proportion of each. Homoeopathic active ingredients must be identified by including the ingredient in a list of homoeopathic ingredients or prefacing the name with the term 'homoeopathic'.\",\n      \"Answer Explanation\": \"Per (6)(a), for listed goods that are sunscreen preparations, the name of every active ingredient and its quantity or proportion is required. Context (4) states that homoeopathic active ingredients must be identified either in a list of homoeopathic ingredients or by prefacing the ingredient name with 'homoeopathic'.\"\n    },\n    {  \n      \"Question\": \"Assuming a medicine is listed goods and subsection 8(2) applies, is compliance with paragraphs 9(1)(b) and 9(1)(c) required?\",\n      \"Answer\": \"No, compliance with paragraphs 9(1)(b) and 9(1)(c) is not required for listed goods if subsection 8(2) applies.\",\n      \"Answer Explanation\": \"Context (6)(b)(ii) directly states that for listed goods where subsection 8(2) applies, compliance with paragraphs 9(1)(b) and 9(1)(c) is not required.\"\n    }\n  ]\n}",
    "misc_info":null
  },
  {
    "path":[
      601150000,
      801020000
    ],
    "contexts":[
      "information\" means information required under paragraphs 8(1)(b), (c), (j), (k), (l) and (n) of this Order, that is critical for safe use of medicines that are self-selected by a consumer; \"delivered dose\" means, in relation to: (a) metered dose preparations - the dose delivered to the patient in a single actuation or delivery; and (b) powders for inhalation - the dose delivered from the inhaler in a single delivery; \"dial dispenser pack\" means a container that has the following",
      "such as \u2018inhalation\u2019, \u2018For oral use only\u2019 or other phrase, word or abbreviation denoting the approved route(s) of administration.  (2)  (a) Subject to paragraphs (b), (c) and (d), where the medicine is registered goods, the critical health information must be displayed on the label of the primary pack in a tabulated form.  (b) The critical health information must be presented under appropriate headings and in the following order: (i) Active ingredients (ii) Indications (iii) Warnings (iv)"
    ],
    "result_dict":{
      "QuestionAnswers":[
        {
          "Question":"Assuming all the information required is present on the label, in what format must the critical health information such as active ingredients, indications, and warnings be displayed on the primary pack of registered medicine goods?",
          "Answer":"The critical health information must be displayed in a tabulated form.",
          "Answer Explanation":"According to paragraph (2)(a), subject to some exceptions, where the medicine is registered goods, the critical health information must be displayed on the label of the primary pack in a tabulated form. Paragraph (2)(b) further specifies that this critical health information includes active ingredients, indications, and warnings, and must be presented under appropriate headings and in a specific order."
        },
        {
          "Question":"Assuming no other information is available, what is meant by the term 'information' in the context of these regulations?",
          "Answer":"'Information' refers to the information required under paragraphs 8(1)(b), (c), (j), (k), (l) and (n) of this Order, that is critical for safe use of medicines that are self-selected by a consumer.",
          "Answer Explanation":"The definition of 'information' is directly provided in the context. It states that 'information' means information required under specific paragraphs of section 8(1) of this Order, and that this information is critical for the safe use of medicines that are self-selected by a consumer."
        },
        {
          "Question":"For a powder inhaler product that is registered medicine goods, assuming the primary pack is a dial dispenser pack, what information must be displayed on the label and in what format?",
          "Answer":"The critical health information, including active ingredients, indications, and warnings, must be displayed on the label of the primary dial dispenser pack in a tabulated form.",
          "Answer Explanation":"Based on the definitions provided, a 'delivered dose' for powders for inhalation is the dose delivered from the inhaler in a single delivery. Paragraph (2)(a) states that for registered medicine goods, the critical health information must be displayed on the label of the primary pack in a tabulated form, subject to some exceptions. Paragraph (2)(b) specifies that this critical health information includes active ingredients, indications, and warnings. The context also defines 'dial dispenser pack' as a type of container."
        },
        {
          "Question":"Assuming a non-prescription medicine product is in a metered dose preparation form and is not registered goods, what information, if any, must be displayed on the label regarding the route of administration?",
          "Answer":"The label must display the approved route(s) of administration using a phrase, word or abbreviation such as 'inhalation' or 'For oral use only'.",
          "Answer Explanation":"Paragraph (1)(d) states that the label of the primary pack must include the approved route(s) of administration represented by a phrase, word or abbreviation such as 'inhalation', 'For oral use only' or other. This requirement applies generally and is not limited to registered goods. The definition of 'delivered dose' indicates that metered dose preparations are a type of dosage form, but this is not directly relevant to the labeling requirement for route of administration."
        }
      ]
    },
    "result_str":"{\"QuestionAnswers\": [{\"Question\": \"Assuming all the information required is present on the label, in what format must the critical health information such as active ingredients, indications, and warnings be displayed on the primary pack of registered medicine goods?\", \"Answer\": \"The critical health information must be displayed in a tabulated form.\", \"Answer Explanation\": \"According to paragraph (2)(a), subject to some exceptions, where the medicine is registered goods, the critical health information must be displayed on the label of the primary pack in a tabulated form. Paragraph (2)(b) further specifies that this critical health information includes active ingredients, indications, and warnings, and must be presented under appropriate headings and in a specific order.\"}, {\"Question\": \"Assuming no other information is available, what is meant by the term 'information' in the context of these regulations?\", \"Answer\": \"'Information' refers to the information required under paragraphs 8(1)(b), (c), (j), (k), (l) and (n) of this Order, that is critical for safe use of medicines that are self-selected by a consumer.\", \"Answer Explanation\": \"The definition of 'information' is directly provided in the context. It states that 'information' means information required under specific paragraphs of section 8(1) of this Order, and that this information is critical for the safe use of medicines that are self-selected by a consumer.\"}, {\"Question\": \"For a powder inhaler product that is registered medicine goods, assuming the primary pack is a dial dispenser pack, what information must be displayed on the label and in what format?\", \"Answer\": \"The critical health information, including active ingredients, indications, and warnings, must be displayed on the label of the primary dial dispenser pack in a tabulated form.\", \"Answer Explanation\": \"Based on the definitions provided, a 'delivered dose' for powders for inhalation is the dose delivered from the inhaler in a single delivery. Paragraph (2)(a) states that for registered medicine goods, the critical health information must be displayed on the label of the primary pack in a tabulated form, subject to some exceptions. Paragraph (2)(b) specifies that this critical health information includes active ingredients, indications, and warnings. The context also defines 'dial dispenser pack' as a type of container.\"}, {\"Question\": \"Assuming a non-prescription medicine product is in a metered dose preparation form and is not registered goods, what information, if any, must be displayed on the label regarding the route of administration?\", \"Answer\": \"The label must display the approved route(s) of administration using a phrase, word or abbreviation such as 'inhalation' or 'For oral use only'.\", \"Answer Explanation\": \"Paragraph (1)(d) states that the label of the primary pack must include the approved route(s) of administration represented by a phrase, word or abbreviation such as 'inhalation', 'For oral use only' or other. This requirement applies generally and is not limited to registered goods. The definition of 'delivered dose' indicates that metered dose preparations are a type of dosage form, but this is not directly relevant to the labeling requirement for route of administration.\"}]}",
    "misc_info":null
  },
  {
    "path":[
      903030000,
      903010000
    ],
    "contexts":[
      "up by additional information or background text.  (3) Subject to paragraph (c), the name of the medicine and the name(s) of active ingredient(s) on the main label must:  (a) appear as a cohesive unit by the placing of the name and quantity of each active ingredient together on separate lines of text either (i) immediately below the name of the medicine; or (ii) where the trademark of the medicine might be disrupted or obscured, adjacent to the name of the medicine; and  (b) not be separated by",
      "(ii) contains multiple active ingredients then, in relation to compliance of the label with paragraph 9(3)(a), the names of the multiple active ingredients and their quantities may be presented together on a continuous line, or lines, of text.  (4) All text required by this Order to be on the main label must be oriented in the same direction.  (5) If the medicine contains:  (a) two or more active ingredients; and  (b) at least two of those active ingredients belong to any of the following"
    ],
    "result_dict":{
      "QuestionAnswers":[
        {
          "Question":"Assuming a medicine contains three active ingredients belonging to the same pharmacological class, does the label need to separate the name of the medicine from the names and quantities of the active ingredients? If so, how should they be presented on the label?",
          "Answer":"No, the names and quantities of the active ingredients do not need to be separated from the name of the medicine.",
          "Answer Explanation":"According to paragraph 9(3)(a), the name of the medicine and the names and quantities of active ingredients must appear as a cohesive unit, either with the active ingredients immediately below the medicine name or adjacent to it. However, paragraph 9(3)(c)(ii) states that if a medicine contains multiple active ingredients, the names and quantities may be presented together on a continuous line or lines of text, in relation to compliance with paragraph 9(3)(a). Since the medicine in question contains three active ingredients of the same pharmacological class, their names and quantities can be presented together on the same line(s), adjacent to the medicine name, without separation."
        },
        {
          "Question":"Assuming a medicine label is compliant with all other requirements, is it acceptable for some text on the main label to be oriented vertically while other text is oriented horizontally?",
          "Answer":"No, it is not acceptable for text on the main label to have different orientations.",
          "Answer Explanation":"Paragraph 9(4) clearly states that all text required by this Order to be on the main label must be oriented in the same direction. Therefore, it is not permissible to have some text oriented vertically while other text is oriented horizontally on the main label, even if the label is compliant with all other requirements."
        },
        {
          "Question":"Assuming a medicine contains two active ingredients belonging to different pharmacological classes, can the name of the medicine be separated from the names and quantities of the active ingredients by additional information or background text on the main label?",
          "Answer":"No, the name of the medicine cannot be separated from the names and quantities of the active ingredients by additional information or background text.",
          "Answer Explanation":"Paragraph 9(3)(b) states that the name of the medicine and the names and quantities of active ingredients must not be separated by additional information or background text. This applies regardless of whether the active ingredients belong to the same or different pharmacological classes, as mentioned in paragraph 9(5). Therefore, even if the medicine contains two active ingredients from different classes, the main label cannot have any additional information or background text separating the medicine name from the active ingredient names and quantities."
        },
        {
          "Question":"Assuming a medicine contains four active ingredients, with two belonging to one pharmacological class and the other two belonging to another class, how should the names and quantities of the active ingredients be presented on the main label in relation to the medicine name?",
          "Answer":"The names and quantities of the active ingredients should be presented together on a continuous line or lines of text, either immediately below or adjacent to the medicine name.",
          "Answer Explanation":"Paragraph 9(5) states that if a medicine contains two or more active ingredients, with at least two belonging to the same pharmacological class, paragraph 9(3)(c) applies. Paragraph 9(3)(c)(ii) specifies that for a medicine with multiple active ingredients, the names and quantities of the active ingredients may be presented together on a continuous line or lines of text, in relation to compliance with paragraph 9(3)(a). Paragraph 9(3)(a) requires the active ingredient names and quantities to appear as a cohesive unit with the medicine name, either immediately below or adjacent to it. Therefore, the four active ingredients' names and quantities should be grouped together on continuous lines, positioned either below or next to the medicine name on the main label."
        }
      ]
    },
    "result_str":"{\"QuestionAnswers\": [{\"Question\": \"Assuming a medicine contains three active ingredients belonging to the same pharmacological class, does the label need to separate the name of the medicine from the names and quantities of the active ingredients? If so, how should they be presented on the label?\", \"Answer\": \"No, the names and quantities of the active ingredients do not need to be separated from the name of the medicine.\", \"Answer Explanation\": \"According to paragraph 9(3)(a), the name of the medicine and the names and quantities of active ingredients must appear as a cohesive unit, either with the active ingredients immediately below the medicine name or adjacent to it. However, paragraph 9(3)(c)(ii) states that if a medicine contains multiple active ingredients, the names and quantities may be presented together on a continuous line or lines of text, in relation to compliance with paragraph 9(3)(a). Since the medicine in question contains three active ingredients of the same pharmacological class, their names and quantities can be presented together on the same line(s), adjacent to the medicine name, without separation.\"}, {\"Question\": \"Assuming a medicine label is compliant with all other requirements, is it acceptable for some text on the main label to be oriented vertically while other text is oriented horizontally?\", \"Answer\": \"No, it is not acceptable for text on the main label to have different orientations.\", \"Answer Explanation\": \"Paragraph 9(4) clearly states that all text required by this Order to be on the main label must be oriented in the same direction. Therefore, it is not permissible to have some text oriented vertically while other text is oriented horizontally on the main label, even if the label is compliant with all other requirements.\"}, {\"Question\": \"Assuming a medicine contains two active ingredients belonging to different pharmacological classes, can the name of the medicine be separated from the names and quantities of the active ingredients by additional information or background text on the main label?\", \"Answer\": \"No, the name of the medicine cannot be separated from the names and quantities of the active ingredients by additional information or background text.\", \"Answer Explanation\": \"Paragraph 9(3)(b) states that the name of the medicine and the names and quantities of active ingredients must not be separated by additional information or background text. This applies regardless of whether the active ingredients belong to the same or different pharmacological classes, as mentioned in paragraph 9(5). Therefore, even if the medicine contains two active ingredients from different classes, the main label cannot have any additional information or background text separating the medicine name from the active ingredient names and quantities.\"}, {\"Question\": \"Assuming a medicine contains four active ingredients, with two belonging to one pharmacological class and the other two belonging to another class, how should the names and quantities of the active ingredients be presented on the main label in relation to the medicine name?\", \"Answer\": \"The names and quantities of the active ingredients should be presented together on a continuous line or lines of text, either immediately below or adjacent to the medicine name.\", \"Answer Explanation\": \"Paragraph 9(5) states that if a medicine contains two or more active ingredients, with at least two belonging to the same pharmacological class, paragraph 9(3)(c) applies. Paragraph 9(3)(c)(ii) specifies that for a medicine with multiple active ingredients, the names and quantities of the active ingredients may be presented together on a continuous line or lines of text, in relation to compliance with paragraph 9(3)(a). Paragraph 9(3)(a) requires the active ingredient names and quantities to appear as a cohesive unit with the medicine name, either immediately below or adjacent to it. Therefore, the four active ingredients' names and quantities should be grouped together on continuous lines, positioned either below or next to the medicine name on the main label.\"}]}",
    "misc_info":null
  },
  {
    "path":[
      1103030000,
      1103010000
    ],
    "contexts":[
      "The label on the container and on the primary pack of a medicine that contains a homoeopathic preparation must include:  (a) where the medicine is a fully potentised, single ingredient, homoeopathic medicine and it is clear that the ingredient comprises 100% of the medicine \u2013 the name of the active ingredient; or  (b) where all active ingredients of the medicine are homoeopathic preparations and are all included in the medicine in the same proportion - as \u2018Contains equal parts of ...\u2019 followed",
      "or semi-solid and includes an active ingredient which is a liquid - as the appropriate amount of the active ingredient, either by weight or volume, in a stated weight of the medicine; (v) where the medicine is a solid or semi-solid and includes an active ingredient which is a solid - as the weight of the active ingredient in a stated weight of the medicine.  (3) Expression of quantity or proportion of active ingredients for homoeopathic preparations The label on the container and on the primary"
    ],
    "result_dict":{
      "QuestionAnswers":[
        {
          "Question":"Assuming a homoeopathic medicine contains only a single fully potentised active ingredient that makes up 100% of the medicine, what must the medicine label include regarding the active ingredient?",
          "Answer":"The name of the active ingredient",
          "Answer Explanation":"According to the regulation section (a), where the homoeopathic medicine is a fully potentised, single ingredient medicine and it is clear that the ingredient comprises 100% of the medicine, the label must include the name of the active ingredient."
        },
        {
          "Question":"In the case where a homoeopathic medicine contains multiple active ingredients in equal proportions, how should the label express the ingredients according to the regulation?",
          "Answer":"The label should state 'Contains equal parts of ...' followed by the names of the active ingredients",
          "Answer Explanation":"The regulation section (b) specifies that where all active ingredients of the homoeopathic medicine are included in the same proportion, the label must state 'Contains equal parts of ...' followed presumably by the names of those active ingredients, though the regulation cuts off at that point."
        },
        {
          "Question":"When a homoeopathic medicine is in a solid or semi-solid form and contains a liquid active ingredient, how should the quantity of the active ingredient be expressed on the label?",
          "Answer":"As the appropriate amount of the active ingredient, either by weight or volume, in a stated weight of the medicine",
          "Answer Explanation":"Section (3)(iv) of the regulation states that for a solid or semi-solid homoeopathic medicine that includes a liquid active ingredient, the label must express the quantity as the appropriate amount of the active ingredient, either by weight or volume, in a stated weight of the overall medicine."
        },
        {
          "Question":"According to the regulation excerpt provided, if a solid or semi-solid homoeopathic medicine contains a solid active ingredient, how should the label express the quantity of that active ingredient?",
          "Answer":"As the weight of the active ingredient in a stated weight of the medicine",
          "Answer Explanation":"For a homoeopathic medicine that is a solid or semi-solid and includes a solid active ingredient, section (3)(v) requires the label to express the quantity as the weight of the active ingredient in a stated weight of the overall medicine formulation."
        }
      ]
    },
    "result_str":"{\"QuestionAnswers\": [\n  {\n    \"Question\": \"Assuming a homoeopathic medicine contains only a single fully potentised active ingredient that makes up 100% of the medicine, what must the medicine label include regarding the active ingredient?\",\n    \"Answer\": \"The name of the active ingredient\",\n    \"Answer Explanation\": \"According to the regulation section (a), where the homoeopathic medicine is a fully potentised, single ingredient medicine and it is clear that the ingredient comprises 100% of the medicine, the label must include the name of the active ingredient.\"\n  },\n  {\n    \"Question\": \"In the case where a homoeopathic medicine contains multiple active ingredients in equal proportions, how should the label express the ingredients according to the regulation?\",\n    \"Answer\": \"The label should state 'Contains equal parts of ...' followed by the names of the active ingredients\", \n    \"Answer Explanation\": \"The regulation section (b) specifies that where all active ingredients of the homoeopathic medicine are included in the same proportion, the label must state 'Contains equal parts of ...' followed presumably by the names of those active ingredients, though the regulation cuts off at that point.\"\n  },\n  {\n    \"Question\": \"When a homoeopathic medicine is in a solid or semi-solid form and contains a liquid active ingredient, how should the quantity of the active ingredient be expressed on the label?\",\n    \"Answer\": \"As the appropriate amount of the active ingredient, either by weight or volume, in a stated weight of the medicine\",\n    \"Answer Explanation\": \"Section (3)(iv) of the regulation states that for a solid or semi-solid homoeopathic medicine that includes a liquid active ingredient, the label must express the quantity as the appropriate amount of the active ingredient, either by weight or volume, in a stated weight of the overall medicine.\"\n  },\n  {\n    \"Question\": \"According to the regulation excerpt provided, if a solid or semi-solid homoeopathic medicine contains a solid active ingredient, how should the label express the quantity of that active ingredient?\",\n    \"Answer\": \"As the weight of the active ingredient in a stated weight of the medicine\",\n    \"Answer Explanation\": \"For a homoeopathic medicine that is a solid or semi-solid and includes a solid active ingredient, section (3)(v) requires the label to express the quantity as the weight of the active ingredient in a stated weight of the overall medicine formulation.\"\n  }\n]}",
    "misc_info":null
  },
  {
    "path":[
      601150000,
      801120000
    ],
    "contexts":[
      "information\" means information required under paragraphs 8(1)(b), (c), (j), (k), (l) and (n) of this Order, that is critical for safe use of medicines that are self-selected by a consumer; \"delivered dose\" means, in relation to: (a) metered dose preparations - the dose delivered to the patient in a single actuation or delivery; and (b) powders for inhalation - the dose delivered from the inhaler in a single delivery; \"dial dispenser pack\" means a container that has the following",
      "such as \u2018inhalation\u2019, \u2018For oral use only\u2019 or other phrase, word or abbreviation denoting the approved route(s) of administration.  (2)  (a) Subject to paragraphs (b), (c) and (d), where the medicine is registered goods, the critical health information must be displayed on the label of the primary pack in a tabulated form.  (b) The critical health information must be presented under appropriate headings and in the following order: (i) Active ingredients (ii) Indications (iii) Warnings (iv)"
    ],
    "result_dict":{
      "QuestionAnswers":[
        {
          "Question":"Assuming all the information required for safe use of medicines is considered 'critical health information', what form should this information take on the label of the primary pack of registered goods, and in what order should the information be presented?",
          "Answer":"The critical health information must be displayed in a tabulated form, under appropriate headings and in the following order: (i) Active ingredients (ii) Indications (iii) Warnings (iv) Directions for use.",
          "Answer Explanation":"According to the definition in the first context, 'critical health information' means information required for safe use of self-selected medicines. The second context, specifically paragraph (2)(a), states that for registered goods, this critical health information must be displayed on the primary pack label in tabulated form. Paragraph (2)(b) then specifies the order in which this information must be presented under appropriate headings."
        },
        {
          "Question":"What is the definition of 'delivered dose' for metered dose preparations and powders for inhalation respectively, and where on the label should the approved route(s) of administration, such as 'For oral use only', be specified?",
          "Answer":"For metered dose preparations, the delivered dose is the dose delivered to the patient in a single actuation or delivery. For powders for inhalation, it is the dose delivered from the inhaler in a single delivery. The approved route(s) of administration must be on the label of the primary pack.",
          "Answer Explanation":"The first context provides the definition of 'delivered dose' for both metered dose preparations and powders for inhalation. The second context, specifically the last sentence before paragraph (2), states that the approved route(s) of administration, with examples like 'For oral use only', must be on the label of the primary pack."
        },
        {
          "Question":"Assuming a non-prescription medicine is registered goods, what information is considered 'critical health information' that must be displayed on the primary pack label, and what are the exceptions to the requirement for this information to be in tabulated form?",
          "Answer":"The critical health information for registered non-prescription medicines includes active ingredients, indications, warnings, and directions for use, as per paragraphs 8(1)(b), (c), (j), (k), (l) and (n) referenced in the definition. This information must usually be in tabulated form on the primary pack label, with exceptions outlined in paragraphs (2)(b), (c) and (d).",
          "Answer Explanation":"The first context defines 'critical health information' by referencing specific paragraphs that list the required information for safe use. The second context states this information must be tabulated on the primary pack label for registered goods, with paragraph (2)(a) noting the exceptions in the subsequent paragraphs (b), (c) and (d)."
        },
        {
          "Question":"What physical characteristics define a 'dial dispenser pack', and what requirements are stated for the display of critical health information on the primary pack label of registered non-prescription medicines?",
          "Answer":"The first context defines a 'dial dispenser pack' as a container with specific physical characteristics, but the details are cutoff. The second context requires critical health information to be displayed on the primary pack label of registered non-prescription medicines in tabulated form, with some exceptions per paragraphs (2)(b), (c) and (d).",
          "Answer Explanation":"The definition of 'dial dispenser pack' is incomplete due to the context being cutoff. However, the second context covers the requirements for displaying critical health information on the primary pack label comprehensively in paragraphs (2)(a)-(d), with (a) stating the general requirement and noting the exceptions in the subsequent paragraphs."
        }
      ]
    },
    "result_str":"{\n  \"QuestionAnswers\": [\n    {\n      \"Question\": \"Assuming all the information required for safe use of medicines is considered 'critical health information', what form should this information take on the label of the primary pack of registered goods, and in what order should the information be presented?\",\n      \"Answer\": \"The critical health information must be displayed in a tabulated form, under appropriate headings and in the following order: (i) Active ingredients (ii) Indications (iii) Warnings (iv) Directions for use.\",\n      \"Answer Explanation\": \"According to the definition in the first context, 'critical health information' means information required for safe use of self-selected medicines. The second context, specifically paragraph (2)(a), states that for registered goods, this critical health information must be displayed on the primary pack label in tabulated form. Paragraph (2)(b) then specifies the order in which this information must be presented under appropriate headings.\"\n    },\n    {\n      \"Question\": \"What is the definition of 'delivered dose' for metered dose preparations and powders for inhalation respectively, and where on the label should the approved route(s) of administration, such as 'For oral use only', be specified?\",\n      \"Answer\": \"For metered dose preparations, the delivered dose is the dose delivered to the patient in a single actuation or delivery. For powders for inhalation, it is the dose delivered from the inhaler in a single delivery. The approved route(s) of administration must be on the label of the primary pack.\",\n      \"Answer Explanation\": \"The first context provides the definition of 'delivered dose' for both metered dose preparations and powders for inhalation. The second context, specifically the last sentence before paragraph (2), states that the approved route(s) of administration, with examples like 'For oral use only', must be on the label of the primary pack.\"\n    },\n    {\n      \"Question\": \"Assuming a non-prescription medicine is registered goods, what information is considered 'critical health information' that must be displayed on the primary pack label, and what are the exceptions to the requirement for this information to be in tabulated form?\",\n      \"Answer\": \"The critical health information for registered non-prescription medicines includes active ingredients, indications, warnings, and directions for use, as per paragraphs 8(1)(b), (c), (j), (k), (l) and (n) referenced in the definition. This information must usually be in tabulated form on the primary pack label, with exceptions outlined in paragraphs (2)(b), (c) and (d).\",\n      \"Answer Explanation\": \"The first context defines 'critical health information' by referencing specific paragraphs that list the required information for safe use. The second context states this information must be tabulated on the primary pack label for registered goods, with paragraph (2)(a) noting the exceptions in the subsequent paragraphs (b), (c) and (d).\"\n    },\n    {\n      \"Question\": \"What physical characteristics define a 'dial dispenser pack', and what requirements are stated for the display of critical health information on the primary pack label of registered non-prescription medicines?\",\n      \"Answer\": \"The first context defines a 'dial dispenser pack' as a container with specific physical characteristics, but the details are cutoff. The second context requires critical health information to be displayed on the primary pack label of registered non-prescription medicines in tabulated form, with some exceptions per paragraphs (2)(b), (c) and (d).\",\n      \"Answer Explanation\": \"The definition of 'dial dispenser pack' is incomplete due to the context being cutoff. However, the second context covers the requirements for displaying critical health information on the primary pack label comprehensively in paragraphs (2)(a)-(d), with (a) stating the general requirement and noting the exceptions in the subsequent paragraphs.\"\n    }\n  ]\n}",
    "misc_info":null
  },
  {
    "path":[
      802050000,
      802020000
    ],
    "contexts":[
      "by this Order (such as allergen advice, caution, additional warning or advisory statements).  (e) If information other than the critical health information or information of a kind mentioned in subsections 8(2)(c) or 8(2)(d) is to be included, it must be placed under the \u2018Other information\u2019 heading or under another separate appropriate heading(s) that follow immediately below the headings mentioned in 8(2)(b) and must not contain any additional information other than: A. requirements relating",
      "such as \u2018inhalation\u2019, \u2018For oral use only\u2019 or other phrase, word or abbreviation denoting the approved route(s) of administration.  (2)  (a) Subject to paragraphs (b), (c) and (d), where the medicine is registered goods, the critical health information must be displayed on the label of the primary pack in a tabulated form.  (b) The critical health information must be presented under appropriate headings and in the following order: (i) Active ingredients (ii) Indications (iii) Warnings (iv)"
    ],
    "result_dict":{
      "QuestionAnswers":[
        {
          "Question":"Assuming a non-prescription medicine is registered goods and no information other than critical health information is included on the label, what format and order must the critical health information be presented in on the primary pack label?",
          "Answer":"The critical health information must be displayed in a tabulated form, under appropriate headings, and in the following order: (i) Active ingredients (ii) Indications (iii) Warnings (iv) Directions for use.",
          "Answer Explanation":"This is specified in section 8(2)(a) and 8(2)(b). 8(2)(a) states that for registered goods, the critical health information must be in tabulated form on the primary pack label, subject to some exceptions. 8(2)(b) then specifies the required order of Active ingredients, Indications, Warnings and Directions for use under appropriate headings."
        },
        {
          "Question":"If information beyond the critical health information and specific other allowed types needs to be included on a medicine label, under what heading must it be placed and what restrictions apply to this additional information?",
          "Answer":"Any information beyond the critical health information and that allowed under 8(2)(c) and 8(2)(d) must be placed under the 'Other information' heading or another separate appropriate heading following immediately below the headings mentioned in 8(2)(b). This additional information is restricted to only regulatory requirements relating to this Order, such as allergen advice, cautions, additional warnings or advisory statements.",
          "Answer Explanation":"Section 8(2)(e) specifies that any other information beyond critical health information and 8(2)(c)\/(d) must go under 'Other information' or another appropriate heading below the 8(2)(b) headings. It also restricts this to only regulatory requirements from this Order like allergen advice, cautions, warnings or advisory statements."
        },
        {
          "Question":"Assuming no other information is included, what text is allowed to be on a medicine label to indicate the approved route(s) of administration?",
          "Answer":"The label may include text such as 'inhalation', 'For oral use only', or another phrase, word or abbreviation to denote the approved route(s) of administration, if no other information is included.",
          "Answer Explanation":"This is directly stated in section 8(1). It allows the inclusion of text to indicate approved administration route(s) in phrases like 'For oral use only' or 'inhalation', words, or abbreviations, as long as no other information is included on the label."
        },
        {
          "Question":"If a non-prescription medicine label includes the critical health information required by 8(2)(a)-(b) and the 'Other information' allowed by 8(2)(e), can it also include the approved route of administration text permitted by 8(1)?",
          "Answer":"No, a label cannot include text indicating the approved route of administration under 8(1) if it already has both the critical health information required by 8(2)(a)-(b) and the 'Other information' allowed by 8(2)(e).",
          "Answer Explanation":"Section 8(1) only allows including the approved administration route if no other information is included on the label. Sections 8(2)(a)-(b) require certain critical health information on the label, while 8(2)(e) optionally allows including 'Other information' like allergen advice. If a label has both the 8(2)(a)-(b) required and 8(2)(e) optional information, then it cannot also have the 8(1) route of administration, since 8(1) requires no other information be present."
        }
      ]
    },
    "result_str":"{\"QuestionAnswers\": [\n  {\n    \"Question\": \"Assuming a non-prescription medicine is registered goods and no information other than critical health information is included on the label, what format and order must the critical health information be presented in on the primary pack label?\",\n    \"Answer\": \"The critical health information must be displayed in a tabulated form, under appropriate headings, and in the following order: (i) Active ingredients (ii) Indications (iii) Warnings (iv) Directions for use.\",\n    \"Answer Explanation\": \"This is specified in section 8(2)(a) and 8(2)(b). 8(2)(a) states that for registered goods, the critical health information must be in tabulated form on the primary pack label, subject to some exceptions. 8(2)(b) then specifies the required order of Active ingredients, Indications, Warnings and Directions for use under appropriate headings.\"\n  },\n  {\n    \"Question\": \"If information beyond the critical health information and specific other allowed types needs to be included on a medicine label, under what heading must it be placed and what restrictions apply to this additional information?\",\n    \"Answer\": \"Any information beyond the critical health information and that allowed under 8(2)(c) and 8(2)(d) must be placed under the 'Other information' heading or another separate appropriate heading following immediately below the headings mentioned in 8(2)(b). This additional information is restricted to only regulatory requirements relating to this Order, such as allergen advice, cautions, additional warnings or advisory statements.\", \n    \"Answer Explanation\": \"Section 8(2)(e) specifies that any other information beyond critical health information and 8(2)(c)\/(d) must go under 'Other information' or another appropriate heading below the 8(2)(b) headings. It also restricts this to only regulatory requirements from this Order like allergen advice, cautions, warnings or advisory statements.\"\n  },\n  {\n    \"Question\": \"Assuming no other information is included, what text is allowed to be on a medicine label to indicate the approved route(s) of administration?\",\n    \"Answer\": \"The label may include text such as 'inhalation', 'For oral use only', or another phrase, word or abbreviation to denote the approved route(s) of administration, if no other information is included.\",\n    \"Answer Explanation\": \"This is directly stated in section 8(1). It allows the inclusion of text to indicate approved administration route(s) in phrases like 'For oral use only' or 'inhalation', words, or abbreviations, as long as no other information is included on the label.\"\n  },\n  {\n    \"Question\": \"If a non-prescription medicine label includes the critical health information required by 8(2)(a)-(b) and the 'Other information' allowed by 8(2)(e), can it also include the approved route of administration text permitted by 8(1)?\",\n    \"Answer\": \"No, a label cannot include text indicating the approved route of administration under 8(1) if it already has both the critical health information required by 8(2)(a)-(b) and the 'Other information' allowed by 8(2)(e).\",\n    \"Answer Explanation\": \"Section 8(1) only allows including the approved administration route if no other information is included on the label. Sections 8(2)(a)-(b) require certain critical health information on the label, while 8(2)(e) optionally allows including 'Other information' like allergen advice. If a label has both the 8(2)(a)-(b) required and 8(2)(e) optional information, then it cannot also have the 8(1) route of administration, since 8(1) requires no other information be present.\"\n  }\n]}",
    "misc_info":null
  },
  {
    "path":[
      908040000,
      907000000
    ],
    "contexts":[
      "the composite pack or medicine kit; and  (d) the information required under either paragraph 9(6)(b) or subsection 9(7) must be provided separately in relation to each formulation of medicine in the composite pack or medicine kit.  (9) If the medicine is intended to be, or is, registered goods, and the name of an active ingredient included in the medicine comprises an ingredient name specified in Schedule 2 to this Order, either alone or in combination with any other descriptors, then the names",
      "of the medicine; and  (b) not be separated by any text or graphics, except where additional information is: (i) required or permitted by: (A) paragraph 11(2)(h); or (B) subparagraphs 11(2)(i)(i) or 11(2)(i)(ii)(A); or (C) subsection 11(5); or (ii) in relation to identifying the different formulations of the medicines contained in a composite pack or a medicine kit;  (c) if the medicine is: (i) supplied in either a small or a medium container; and (ii) contains multiple active ingredients then,"
    ],
    "result_dict":{
      "QuestionAnswers":[
        {
          "Question":"Assuming a medicine containing multiple active ingredients is supplied in a small container and is intended to be registered goods, and one of the active ingredients has a name specified in Schedule 2 to this Order, what are the requirements for the names of the medicine?",
          "Answer":"The names must appear together, adjacent to each other, and not be separated by any text or graphics, with limited exceptions.",
          "Answer Explanation":"According to paragraph 11(2)(b), the names must not be separated by any text or graphics, with exceptions listed in subparagraphs 11(2)(i) and 11(2)(ii). Subsection 11(5)(c) states that if a medicine with multiple active ingredients is supplied in a small container, the names must appear together and adjacent to each other."
        },
        {
          "Question":"Consider a composite pack containing different formulations of medicines. What information must be provided separately for each formulation, and where should this information be located?",
          "Answer":"The information required under paragraph 9(6)(b) or subsection 9(7) must be provided separately for each formulation of medicine in the composite pack, and this information must be provided separately from the names of the medicine.",
          "Answer Explanation":"Paragraph 9(6)(d) states that for a composite pack, the information required under paragraph 9(6)(b) or subsection 9(7) must be provided separately for each formulation of medicine. Subparagraph 11(2)(b)(ii) allows the names to be separated by additional information relating to identifying the different formulations in a composite pack."
        },
        {
          "Question":"Assuming a medicine kit contains multiple formulations of medicines, one of which is intended to be registered goods and has an active ingredient with a name specified in Schedule 2 to this Order, what requirements apply to the names of that particular formulation?",
          "Answer":"The names of the active ingredient(s) in that formulation must appear together, adjacent to each other, and not be separated by any text or graphics, with limited exceptions. The information required under paragraph 9(6)(b) or subsection 9(7) must be provided separately for that formulation.",
          "Answer Explanation":"Paragraph 9(6)(d) requires the information under 9(6)(b) or 9(7) to be provided separately for each formulation in a medicine kit. Subsection 9(9) states that if a medicine is intended to be registered goods and has an active ingredient name specified in Schedule 2, the names must meet the requirements. Paragraph 11(2)(b) states the names must not be separated, with exceptions in 11(2)(i) and 11(2)(ii)."
        },
        {
          "Question":"For a composite pack containing different formulations of medicines, one of which is supplied in a small container and contains multiple active ingredients, what are the requirements for the names of the active ingredients in that particular formulation?",
          "Answer":"The names of the active ingredients in that formulation must appear together, adjacent to each other, and not be separated by any text or graphics, with limited exceptions. Additional information relating to identifying the different formulations in the composite pack may separate the names.",
          "Answer Explanation":"Subsection 11(5)(c) states that for a medicine with multiple active ingredients supplied in a small container, the names must appear together and adjacent to each other. Paragraph 11(2)(b) requires the names to not be separated, with exceptions in 11(2)(i) and 11(2)(ii). Subparagraph 11(2)(b)(ii) specifically allows separating the names with information relating to identifying different formulations in a composite pack."
        }
      ]
    },
    "result_str":"{\"QuestionAnswers\": [{\"Question\": \"Assuming a medicine containing multiple active ingredients is supplied in a small container and is intended to be registered goods, and one of the active ingredients has a name specified in Schedule 2 to this Order, what are the requirements for the names of the medicine?\", \"Answer\": \"The names must appear together, adjacent to each other, and not be separated by any text or graphics, with limited exceptions.\", \"Answer Explanation\": \"According to paragraph 11(2)(b), the names must not be separated by any text or graphics, with exceptions listed in subparagraphs 11(2)(i) and 11(2)(ii). Subsection 11(5)(c) states that if a medicine with multiple active ingredients is supplied in a small container, the names must appear together and adjacent to each other.\"}, {\"Question\": \"Consider a composite pack containing different formulations of medicines. What information must be provided separately for each formulation, and where should this information be located?\", \"Answer\": \"The information required under paragraph 9(6)(b) or subsection 9(7) must be provided separately for each formulation of medicine in the composite pack, and this information must be provided separately from the names of the medicine.\", \"Answer Explanation\": \"Paragraph 9(6)(d) states that for a composite pack, the information required under paragraph 9(6)(b) or subsection 9(7) must be provided separately for each formulation of medicine. Subparagraph 11(2)(b)(ii) allows the names to be separated by additional information relating to identifying the different formulations in a composite pack.\"}, {\"Question\": \"Assuming a medicine kit contains multiple formulations of medicines, one of which is intended to be registered goods and has an active ingredient with a name specified in Schedule 2 to this Order, what requirements apply to the names of that particular formulation?\", \"Answer\": \"The names of the active ingredient(s) in that formulation must appear together, adjacent to each other, and not be separated by any text or graphics, with limited exceptions. The information required under paragraph 9(6)(b) or subsection 9(7) must be provided separately for that formulation.\", \"Answer Explanation\": \"Paragraph 9(6)(d) requires the information under 9(6)(b) or 9(7) to be provided separately for each formulation in a medicine kit. Subsection 9(9) states that if a medicine is intended to be registered goods and has an active ingredient name specified in Schedule 2, the names must meet the requirements. Paragraph 11(2)(b) states the names must not be separated, with exceptions in 11(2)(i) and 11(2)(ii).\"}, {\"Question\": \"For a composite pack containing different formulations of medicines, one of which is supplied in a small container and contains multiple active ingredients, what are the requirements for the names of the active ingredients in that particular formulation?\", \"Answer\": \"The names of the active ingredients in that formulation must appear together, adjacent to each other, and not be separated by any text or graphics, with limited exceptions. Additional information relating to identifying the different formulations in the composite pack may separate the names.\", \"Answer Explanation\": \"Subsection 11(5)(c) states that for a medicine with multiple active ingredients supplied in a small container, the names must appear together and adjacent to each other. Paragraph 11(2)(b) requires the names to not be separated, with exceptions in 11(2)(i) and 11(2)(ii). Subparagraph 11(2)(b)(ii) specifically allows separating the names with information relating to identifying different formulations in a composite pack.\"}]}",
    "misc_info":null
  }
]